-DOCSTART- -X- N

Between NNP None
March NNP None
2008 CD None
and CC None
February NNP None
2011,157 CD Size
patients NNS None
who WP None
had VBD None
tubal JJ Condition
EP NNP Condition
diagnosed VBN None
by IN None
a DT None
non-laparoscopic JJ None
approach NN None
and CC None
were VBD None
hemodynamically RB None
stable JJ None
were VBD None
enrolled VBN None
in IN None
a DT None
prospective JJ None
study NN None
in IN None
Qassim NNP None
, , None
Saudi NNP None
Arabia NNP None
. . None
-DOCSTART- -X- N

acute JJ Condition
seasonal JJ Condition
allergic JJ Condition
conjunctivitis NN Condition
. . Condition
Eighteen JJ None
subjects NNS None
( ( None
mean JJ None
age NN None
, , None
29.5?11.0 CD None
years NNS None
) ) None
allergic VBP None
to TO None
grass VB None
pollen NN None
. . None
of IN None
allergic JJ None
conjunctivitis NN None
. . None
A DT None
CC NNP None
enhanced VBD None
Signs NNP None
of IN None
allergic JJ None
conjunctivitis NN None
generally RB None
were VBD None
-DOCSTART- -X- N

advanced JJ None
chronic JJ None
venous JJ None
insufficiency NN None
( ( None
CVI NNP None
) ) None
832 CD None
patients NNS None
stratified VBN None
by IN None
CEAP NNP None
classification NN None
. . None
300 CD None
patients NNS None
with IN None
C4 NNP None
CVI NNP None
, , None
119 CD None
patients NNS None
with IN None
C5 NNP None
CVI NNP None
, , None
and CC None
413 CD None
patients NNS None
with IN None
C6 NNP None
CVI NNP None
. . None
92 CD None
patients NNS None
with IN None
C4 NNP None
disease NN None
92 CD None
randomized VBD None
patients NNS None
with IN None
C4 NNP None
disease NN None
832 CD None
patients NNS None
-DOCSTART- -X- N

low-birth-weight JJ Condition
infants NNS Age
. . None
appropriate-for-gestational JJ Age
age NN Age
, , None
low-birth-weight JJ Condition
infants NNS Age
-DOCSTART- -X- N

myocardial JJ Condition
infarction NN Condition
acute JJ Condition
myocardial JJ Condition
infarction NN Condition
( ( Condition
MI NNP Condition
) ) Condition
patients NNS None
on IN None
thrombolytic JJ None
therapy NN None
( ( None
TLT NNP None
) ) None
106 CD Size
males NNS Sex
with IN None
Q-MI NNP Condition
entered VBD None
the DT None
study NN None
-DOCSTART- -X- N

healthy JJ Condition
subjects NNS Condition
. . None
10 CD None
healthy JJ None
men NNS None
-DOCSTART- -X- N

animals NNS None
and CC None
healthy JJ None
humans NNS None
. . None
Twenty-nine JJ Size
patients NNS None
( ( None
6 CD Size
type NN None
1 CD None
and CC None
23 CD Size
type NN None
2 CD None
) ) None
with IN None
gastroparesis NN Condition
at IN None
baseline NN None
and CC None
after IN None
treatment NN None
with IN None
KC NNP None
11458 CD None
in IN None
a DT None
dose NN None
of IN None
8 CD None
mg NNS None
t.d.s. NN None
or CC None
placebo NN None
for IN None
8 CD None
days NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
squamous JJ None
cell NN None
carcinoma NN None
of IN None
the DT None
head NN None
and CC None
neck NN None
. . None
Eighty-three JJ None
patients NNS None
with IN None
advanced JJ None
disease NN None
were VBD None
entered VBN None
into IN None
the DT None
first JJ None
study NN None
( ( None
43/chemotherapy CD None
; : None
40/control CD None
) ) None
, , None
and CC None
60 CD None
into IN None
the DT None
second JJ None
Patient JJ None
randomization NN None
was VBD None
stratified VBN None
by IN None
stage NN None
( ( None
III/IV NNP None
) ) None
and CC None
site NN None
-DOCSTART- -X- N

Forty NNP None
human JJ None
third JJ None
molars NNS None
-DOCSTART- -X- N

plantar NN Condition
fasciitis NN Condition
. . None
One CD Size
hundred VBD Size
three CD Size
subjects NNS None
were VBD None
randomly RB None
assigned VBN None
to TO None
one CD None
of IN None
three CD None
treatment NN None
categories NNS None
: : None
anti-inflammatory NN None
, , None
accommodative JJ None
, , None
or CC None
mechanical JJ None
. . None
Subjects NNS None
85 CD Size
patients NNS None
who WP None
completed VBD None
the DT None
study NN None
-DOCSTART- -X- N

female JJ Sex
undergraduate JJ Sex
students NNS Sex
( ( Sex
n=342 NN Sex
) ) Sex
. . Sex
women NNS Sex
's POS Sex
-DOCSTART- -X- N

48 CD Condition
healthy JJ Condition
volunteers NNS None
( ( None
24 CD Condition
men NNS Sex
and CC None
24 CD Condition
women NNS Sex
) ) None
. . None
-DOCSTART- -X- N

subcutaneous JJ None
heparin NN None
injection NN None
on IN None
bruising NN None
and CC None
pain NN None
. . None
50 CD Size
patients NNS None
to TO None
whom WP None
subcutaneous JJ Condition
heparin NN Condition
was VBD None
administered VBN None
. . None
-DOCSTART- -X- N

outpatient JJ None
epidural JJ None
anesthesia NN None
. . None
84 CD None
outpatients NNS None
undergoing JJ None
surgery NN None
( ( None
extracorporeal JJ None
shock NN None
wave NN None
lithotripsy NN None
( ( None
ESWL NNP None
] NNP None
. . None
-DOCSTART- -X- N

non-ST JJ Condition
elevation NN Condition
acute NN Condition
coronary JJ Condition
syndromes NNS Condition
. . Condition
non-ST-segment JJ None
elevation NN None
acute NN None
coronary JJ None
syndromes NNS None
. . None
240 CD None
patients NNS None
with IN None
either DT None
unstable JJ None
angina NN None
or CC None
non-ST-elevation JJ None
myocardial JJ None
infarction NN None
in IN None
the DT None
previous JJ None
2 CD None
weeks NNS None
-DOCSTART- -X- N

new JJ None
non-urgent JJ None
rheumatology NN None
out-patient JJ None
referrals NNS None
. . None
patients NNS None
referred VBN None
for IN None
a DT None
non-urgent JJ None
rheumatology NN None
opinion NN None
. . None
a DT None
'fast JJ None
track NN None
' POS None
appointment NN None
with IN None
a DT None
6-week JJ None
target NN None
waiting VBG None
time NN None
against IN None
an DT None
'ordinary JJ None
' POS None
appointment NN None
in IN None
the DT None
main JJ None
city NN None
out-patient JJ None
clinic NN None
of IN None
the DT None
rheumatology NN None
service NN None
for IN None
the DT None
Lothian JJ None
and CC None
Borders NNPS None
region NN None
( ( None
population NN None
approximately RB None
1 CD None
million CD None
) ) None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ None
heart NN None
failure NN None
patients NNS None
with IN None
chronic JJ None
heart NN None
failure NN None
( ( None
CHF NNP None
) ) None
patients NNS None
with IN None
CHF NNP None
. . None
Patients NNPS None
with IN None
stable JJ None
CHF NNP None
( ( None
NYHA NNP None
II/III NNP None
; : None
59 CD None
( ( None
11 CD None
) ) None
years NNS None
) ) None
-DOCSTART- -X- N

patients NNS None
with IN None
atrial JJ Condition
fibrillation NN Condition
. . None
after IN Condition
conversion NN Condition
to TO Condition
sinus VB Condition
rhythm NN Condition
. . None
patients NNS None
with IN None
atrial JJ Condition
fibrillation NN Condition
Patients NNPS None
who WP None
had VBD None
symptomatic JJ Condition
atrial JJ Condition
fibrillation NN Condition
for IN None
> $ None
48 CD None
hours NNS None
but CC None
< $ None
6 CD None
months NNS None
were VBD None
eligible JJ None
Patients NNS None
were VBD None
admitted VBN None
to TO None
a DT None
hospital NN None
randomly RB None
assigned VBN None
to TO None
receive VB None
either DT None
azimilide JJ None
125 CD None
mg NN None
or CC None
a DT None
matched JJ None
placebo NN None
twice RB None
daily RB None
for IN None
3 CD None
days NNS None
and CC None
then RB None
once RB None
daily JJ None
. . None
Patients NNS None
who WP None
were VBD None
in IN None
sinus NN None
rhythm NN None
spontaneously RB None
or CC None
had VBD None
sinus VBN None
rhythm NNS None
restored VBN None
by IN None
electric JJ None
cardioversion NN None
on IN None
day NN None
4 CD None
were VBD None
discharged VBN None
from IN None
the DT None
hospital NN None
. . None
patients NNS None
with IN None
structural JJ Condition
heart NN Condition
disease NN Condition
. . None
446 CD Size
patients NNS None
were VBD None
randomized VBN None
in IN None
the DT None
study NN None
; : None
314 CD Size
were VBD None
in IN None
the DT None
subgroup NN None
with IN None
structural JJ Condition
heart NN Condition
disease NN Condition
. . None
patients NNS None
with IN None
structural JJ Condition
heart NN Condition
disease NN Condition
who WP None
were VBD None
in IN None
atrial JJ Condition
fibrillation NN Condition
and CC None
converted VBD Condition
to TO Condition
sinus VB Condition
rhythm NN Condition
. . None
-DOCSTART- -X- N

diabetes NNS Condition
. . None
60 CD Size
individuals NNS None
with IN None
diabetes NNS Condition
-DOCSTART- -X- N

progressive JJ Condition
IgA NNP Condition
nephropathy NN Condition
. . None
38 CD Size
patients NNS None
with IN None
progressive JJ Condition
IgA NNP Condition
nephropathy NN Condition
and CC None
controlled VBN None
hypertension NN Condition
Proteinuria NNP Condition
, , None
present NN None
in IN None
all DT None
patients NNS None
at IN None
the DT None
time NN None
of IN None
entry NN None
into IN None
the DT None
trial NN None
Patients NNS None
selected VBN None
for IN None
moderately RB Condition
progressive JJ Condition
IgA NNP Condition
nephropathy JJ Condition
-DOCSTART- -X- N

patients NNS None
with IN None
migraine NN None
. . None
Forty-one CD None
migraine JJ None
subjects NNS None
( ( None
26 CD None
males NNS None
, , None
15 CD None
females NNS None
) ) None
, , None
mean JJ None
age NN None
36 CD None
+/- JJ None
2 CD None
years NNS None
( ( None
range VB None
36-39 CD None
years NNS None
) ) None
, , None
and CC None
20 CD None
healthy JJ None
control NN None
subjects NNS None
( ( None
14 CD None
males NNS None
, , None
six CD None
females NNS None
) ) None
, , None
mean JJ None
age NN None
36 CD None
+/- JJ None
2 CD None
years NNS None
( ( None
range VB None
36-39 CD None
years NNS None
) ) None
patients NNS None
without IN None
hypertension NN None
and CC None
other JJ None
cardiovascular JJ None
disease NN None
. . None
-DOCSTART- -X- N

during IN None
starvation NN None
in IN None
humans NNS None
. . None
starving VBG Condition
subjects NNS Condition
. . None
28 CD None
normal JJ Condition
men NNS None
( ( None
age NN None
27-35 CD None
years NNS None
) ) None
within IN None
10 CD None
% NN None
of IN None
their PRP$ None
ideal NN None
body NN None
weight NN None
. . None
They PRP None
were VBD None
randomly RB None
divided VBN None
into IN None
4 CD None
groups NNS None
of IN None
7 CD None
. . None
-DOCSTART- -X- N

atrial JJ Condition
fibrillation NN Condition
: : None
patients NNS None
with IN None
AF NNP None
. . None
Patients NNS None
with IN None
persistent JJ Condition
AF NNP Condition
or CC None
AF NNP Condition
induced VBD Condition
during IN None
a DT None
routine JJ None
electrophysiology NN Condition
study NN Condition
( ( None
EPS NNP None
) ) None
patients NNS None
with IN None
induced JJ None
AF NNP None
AF NNP None
in IN None
patients NNS None
-DOCSTART- -X- N

age-related JJ None
macular JJ None
degeneration NN None
( ( None
AMD NNP None
) ) None
. . None
patients NNS None
comprised VBD None
some DT None
randomized VBN None
to TO None
0 CD None
vs NNS None
10 CD None
vs NNS None
36 CD None
Gy NNP None
of IN None
radiation NN None
and CC None
( ( None
after IN None
a DT None
change NN None
of IN None
the DT None
study NN None
protocol NN None
became VBD None
necessary JJ None
) ) None
others NNS None
who WP None
participated VBD None
in IN None
a DT None
prospective JJ None
, , None
controlled VBD None
non-randomized JJ None
pilot NN None
study NN None
. . None
eyes NNS None
with IN None
visual JJ None
acuity NN None
of IN None
> NN None
or CC None
= VB None
0.1 CD None
and CC None
< NNP None
or CC None
= $ None
0.6 CD None
revealing VBG None
a DT None
juxta-subfoveal JJ None
CNV NNP None
either NN None
of IN None
the DT None
occult NN None
type NN None
( ( None
type JJ None
1 CD None
) ) None
or CC None
the DT None
classic JJ None
type NN None
( ( None
isolated JJ None
or CC None
as IN None
part NN None
of IN None
a DT None
predominantly RB None
occult JJ None
lesion NN None
) ) None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
severe JJ Condition
acute NN Condition
pancreatitis NN Condition
. . None
patients NNS None
with IN None
severe JJ Condition
acute NN Condition
pancreatitis NN Condition
( ( Condition
SAP NNP Condition
) ) Condition
. . None
71 CD Condition
patients NNS Condition
with IN None
confirmed VBN None
severe JJ Condition
acute NN Condition
pancreatitis NN Condition
from IN None
March NNP None
2009 CD None
to TO None
September NNP None
2011 CD None
in IN None
the DT None
Department NNP None
of IN None
Critical NNP None
Care NNP None
Medicine NNP None
of IN None
Huizhou NNP None
Municipal NNP None
Central NNP None
Hospital NNP None
, , None
Guangdong NNP None
, , None
China NNP None
patients NNS None
with IN None
severe JJ Condition
acute NN Condition
pancreatitis NN Condition
. . None
-DOCSTART- -X- N

irritable JJ None
bowel NN None
syndrome NN None
. . None
patients NNS None
with IN None
irritable JJ None
bowel NN None
syndrome NN None
( ( None
IBS NNP None
) ) None
IBS NNP None
patients NNS None
. . None
Patients NNPS None
with IN None
IBS NNP None
according VBG None
to TO None
the DT None
Rome NNP None
II NNP None
criteria NNS None
-DOCSTART- -X- N

able-bodied JJ None
participants NNS None
. . None
Participants NNS None
( ( None
n=14 CC None
) ) None
and CC None
a DT None
control NN None
group NN None
( ( None
n=7 RB None
) ) None
. . None
able-bodied JJ None
participants NNS None
. . None
-DOCSTART- -X- N

A DT None
total NN None
of IN None
119 CD Size
patients NNS Condition
, , None
aged VBN None
61-86 CD Age
years NNS Age
, , None
underwent JJ None
cataract NN Condition
surgery NN Condition
with IN None
phacoemulsification NN None
performed VBN None
by IN None
a DT None
single JJ None
surgeon NN None
. . None
-DOCSTART- -X- N

families NNS None
in IN None
challenging VBG None
contexts NN None
: : None
France NNP None
children NNS None
being VBG None
referred VBN None
for IN None
mental JJ None
health NN None
problems NNS None
. . None
families NNS None
living VBG None
in IN None
vulnerable JJ None
contexts NN None
. . None
440 CD None
women NNS None
and CC None
their PRP$ None
families NNS None
, , None
took VBD None
place NN None
in IN None
Paris NNP None
and CC None
its PRP$ None
inner JJ None
suburbs NNS None
from IN None
2006 CD None
to TO None
2011 CD None
. . None
To TO None
be VB None
eligible JJ None
for IN None
inclusion NN None
, , None
women NNS None
had VBD None
to TO None
be VB None
( ( None
i NN None
) ) None
under IN None
26 CD None
years NNS None
old JJ None
, , None
( ( None
ii NN None
) ) None
less JJR None
that IN None
27 CD None
weeks NNS None
pregnant JJ None
, , None
( ( None
iii NN None
) ) None
sufficiently RB None
fluent VBN None
in IN None
French JJ None
to TO None
give VB None
truly NN None
informed JJ None
consent NN None
to TO None
participate VB None
in IN None
the DT None
study NN None
and CC None
benefit NN None
from IN None
the DT None
intervention NN None
and CC None
( ( None
iv NN None
) ) None
presenting VBG None
with IN None
one CD None
or CC None
more JJR None
of IN None
the DT None
following JJ None
social JJ None
vulnerability NN None
factors NNS None
: : None
low JJ None
income NN None
, , None
low JJ None
educational JJ None
level NN None
, , None
and/or RB None
intending VBG None
to TO None
bring VB None
up RP None
the DT None
child NN None
without IN None
the DT None
child NN None
's POS None
father NN None
. . None
-DOCSTART- -X- N

asthma NN Condition
. . None
231 CD Size
patients NNS None
with IN None
chronic JJ Condition
reversible JJ Condition
obstructive JJ Condition
airway NN Condition
disease NN Condition
half NN Size
preferred VBD None
using VBG None
the DT None
powder NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
subclinical JJ Condition
hypothyroidism NN Condition
. . None
subclinical JJ Condition
hypothyroidism NN Condition
( ( None
SH NNP None
) ) None
SH NNP Condition
patients NNS None
. . None
42 CD Condition
patients NNS Condition
( ( None
29 CD Condition
women NNS Condition
and CC None
13 CD Condition
men NNS Condition
; : None
mean JJ None
age NN None
53.2+/-14.2 JJ Age
years NNS None
; : None
body NN None
surface JJ None
area NN None
1.76+/-0.14 JJ None
m2 NN None
) ) None
with IN None
SH NNP Condition
, , None
as IN None
judged VBN None
by IN None
elevated JJ None
serum NN None
TSH NNP None
levels NNS None
( ( None
> $ None
3.6 CD None
mIU/l NN None
; : None
range NN None
, , None
3.8-12.0 JJ None
) ) None
and CC None
normal JJ None
free JJ None
thyroid NN None
hormones NNS None
( ( None
FT4 NNP None
and CC None
FT3 NNP None
) ) None
and CC None
30 CD None
euthyroid JJ None
volunteer NN None
. . None
Subjects NNS None
with IN None
cardiac NN Condition
, , Condition
metabolic NN Condition
, , Condition
neurological JJ Condition
disease NN Condition
or CC None
any DT None
other JJ None
systemic JJ Condition
disease NN Condition
that WDT None
could MD None
affect VB None
autonomic JJ None
activity NN None
were VBD None
excluded VBN None
from IN None
the DT None
study NN None
. . None
Patients NNS None
with IN None
SH NNP Condition
Patients NNPS None
with IN None
SH NNP Condition
SH NNP Condition
patients NNS None
-DOCSTART- -X- N

Persistent JJ Condition
phenothiazine NN Condition
dyskinesia NN Condition
Six CD Size
patients NNS None
with IN None
persistent JJ Condition
phenothiazine NN Condition
dyskinesia NN Condition
-DOCSTART- -X- N

Helicobacter NNP Condition
pylori JJ Condition
infection NN Condition
in IN None
India NNP None
. . None
at IN None
Lokmanya NNP None
Tilak NNP None
Municipal NNP None
General NNP None
Hospital NNP None
, , None
Mumbai NNP None
. . None
Two CD None
hundred CD None
and CC None
thirty-one JJ None
patients NNS None
with IN None
dyspepsia NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
congestive JJ None
heart NN None
failure NN None
. . None
patients NNS None
with IN None
congestive JJ None
heart NN None
failure NN None
. . None
patients NNS None
with IN None
congestive JJ None
heart NN None
failure NN None
. . None
13 CD None
patients NNS None
with IN None
congestive JJ None
heart NN None
failure NN None
long-term JJ None
treatment NN None
of IN None
patients NNS None
having VBG None
congestive JJ None
heart NN None
failure NN None
patients NNS None
with IN None
ischemic JJ None
heart NN None
disease NN None
patients NNS None
with IN None
congestive JJ None
heart NN None
failure NN None
. . None
-DOCSTART- -X- N

allergic JJ Condition
rhinitis NN Condition
and CC None
urticaria NN Condition
. . None
Eight CD Size
volunteers NNS None
were VBD None
enrolled VBN None
-DOCSTART- -X- N

cetuximab-associated JJ Condition
acnelike JJ Condition
eruption NN Condition
. . None
cetuximab-related JJ Condition
facial JJ Condition
rash NN Condition
. . Condition
In IN None
all DT None
, , None
24 CD Size
patients NNS None
with IN None
metastatic JJ Condition
colorectal JJ Condition
cancer NN Condition
with IN Condition
cetuximab JJ Condition
facial JJ Condition
rash NN Condition
patients NNS None
with IN None
cetuximab-related JJ Condition
facial JJ Condition
rash NN Condition
. . None
-DOCSTART- -X- N

Abstinence NN None
or CC None
controlled VBN None
drinking NN None
excessive JJ None
drinkers NNS None
46 CD Size
clients NNS None
of IN None
a DT None
clinical JJ None
psychology NN None
alcohol NN None
problems NNS None
service NN None
( ( None
30 CD Size
men NNS Size
, , None
16 CD Size
women NNS Size
) ) None
Those DT None
with IN None
dependence NN None
indicators NNS None
for IN None
abstinence NN None
-DOCSTART- -X- N

patients NNS None
treated VBN None
for IN None
Helicobacter NNP Condition
pylori JJ Condition
infection NN Condition
. . None
795 CD Size
adults NNS Age
with IN None
preneoplastic JJ Condition
gastric JJ Condition
lesions NNS Condition
was VBD None
randomised VBN None
to TO None
receive VB None
anti-H JJ None
pylori NN None
treatment NN None
Ninety NNP None
seven CD None
per IN None
cent NN None
of IN None
subjects NNS None
were VBD None
H NNP None
pylori JJ None
positive JJ None
at IN None
baseline NN None
, , None
and CC None
53 CD None
% NN None
were VBD None
positive JJ None
at IN None
12 CD None
years NNS None
. . None
patients NNS None
with IN None
preneoplastic JJ Condition
gastric JJ Condition
lesions NNS Condition
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
solid JJ Condition
tumors NNS Condition
. . Condition
fasted JJ None
patients NNS None
Twenty-five JJ None
patients NNS None
-DOCSTART- -X- N

Belarus NNP Condition
. . None
The DT None
Promotion NN None
of IN None
Breastfeeding NNP Condition
Intervention NNP None
Trial NNP None
( ( None
PROBIT NNP None
) ) None
is VBZ None
a DT None
cluster-randomized JJ None
trial NN None
of IN None
a DT None
breast-feeding JJ None
promotion NN None
intervention NN None
17,046 CD Size
healthy JJ None
breast-fed JJ None
infants NNS None
were VBD None
enrolled VBN None
from IN None
31 CD None
Belarussian JJ None
maternity NN None
hospitals NNS None
and CC None
affiliated JJ None
clinics NNS None
13,889 CD Size
( ( None
81.5 CD None
% NN None
) ) None
were VBD None
followed VBN None
up RP None
at IN None
6.5 CD None
y NN None
-DOCSTART- -X- N

alcohol NN Condition
withdrawal NN Condition
syndrome NN Condition
in IN None
a DT None
medical JJ None
intensive JJ None
care NN None
unit NN None
: : None
alcohol NN Condition
withdrawal NN Condition
syndrome NN Condition
( ( None
AWS NNP Condition
) ) None
. . None
Twenty-six NNP Size
alcoholic JJ None
patients NNS None
with IN None
severe JJ None
AWS NNP None
and CC None
concomitant JJ None
medical JJ None
diseases NNS None
were VBD None
randomally RB None
enrolled VBN None
in IN None
the DT None
study NN None
. . None
-DOCSTART- -X- N

finasteride-treated JJ None
subjects NNS None
and CC None
male JJ None
pseudohermaphrodites NNS Condition
with IN None
inherited JJ Condition
5 CD Condition
alpha-reductase JJ Condition
deficiency NN Condition
. . None
Male JJ Condition
pseudohermaphrodites NNS Condition
( ( Condition
MPHs NNP Condition
) ) Condition
with IN Condition
inherited JJ Condition
5 CD Condition
alpha-reductase JJ Condition
deficiency NN Condition
and CC Condition
decreased VBD Condition
dihydrotestosterone NN Condition
production NN Condition
The DT None
5 CD None
alpha-steroid JJ None
metabolite NN None
profile NN None
in IN None
the DT None
MPHs NNP None
was VBD None
compared VBN None
with IN None
that DT None
of IN None
men NNS Condition
with IN Condition
benign JJ Condition
prostatic JJ Condition
hyperplasia NN Condition
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ Condition
obstructive JJ Condition
pulmonary JJ Condition
disease NN Condition
. . None
patients NNS None
with IN None
chronic JJ Condition
obstructive JJ Condition
pulmonary JJ Condition
disease NN Condition
( ( Condition
COPD NNP Condition
) ) Condition
. . None
patients NNS None
with IN None
COPD NNP Condition
. . None
204 CD Size
patients NNS None
patients NNS None
with IN None
COPD NNP Condition
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ Condition
obstructive JJ Condition
pulmonary JJ Condition
disease NN Condition
: : None
435 CD Size
adults NNS Age
with IN None
stable JJ Condition
, , Condition
symptomatic JJ Condition
, , Condition
smoking-related JJ Condition
COPD NNP Condition
were VBD None
randomized VBN None
79 CD Size
patients NNS None
with IN None
serious JJ Condition
adverse JJ Condition
events NNS Condition
( ( None
SAEs NNP Condition
) ) None
, , None
43 CD Size
( ( None
14.8 CD None
% NN None
) ) None
in IN None
the DT None
sibenadet NN Condition
pMDI NN Condition
group NN None
and CC None
36 CD Size
( ( None
24.8 CD None
% NN None
) ) None
in IN None
the DT None
placebo NN Condition
group NN None
. . None
-DOCSTART- -X- N

total JJ Condition
hip NN Condition
arthroplasty NN Condition
: : None
Minimally NNP None
invasive JJ None
total NN None
hip NN None
arthroplasty NN None
Twenty NNP Size
randomized VBD None
patients NNS None
who WP None
underwent VBP None
a DT None
primary JJ Condition
total JJ Condition
hip NN Condition
replacement NN Condition
with IN None
use NN None
of IN None
a DT None
minimally RB None
invasive JJ None
modified VBN None
Watson-Jones JJ None
approach NN None
( ( None
minimally RB None
invasive JJ None
group NN None
) ) None
were VBD None
compared VBN None
with IN None
a DT None
group NN None
of IN None
twenty NN Size
patients NNS None
who WP None
underwent VBD None
a DT None
total JJ None
hip NN None
arthroplasty NN None
with IN None
use NN None
of IN None
a DT None
standard JJ None
transgluteal NN None
Hardinge NNP None
approach NN None
( ( None
standard JJ None
group NN None
) ) None
. . None
patients NNS None
who WP None
underwent VBD None
a DT None
total JJ Condition
hip NN Condition
arthroplasty NN Condition
through IN None
a DT None
minimally RB None
invasive JJ None
Watson-Jones NNS None
approach NN None
standard JJ Condition
transgluteal NN Condition
approach NN Condition
. . None
-DOCSTART- -X- N

infants NNS None
at IN None
risk NN None
of IN None
allergic JJ None
disease NN None
. . None
Sixty-one JJ None
mother-infant JJ None
pairs NNS None
were VBD None
included VBN None
, , None
special JJ None
emphasis NN None
being VBG None
placed VBN None
on IN None
the DT None
maternal JJ None
allergic NN None
status NN None
. . None
infants NNS None
of IN None
allergic NN None
, , None
atopic NN None
mothers NNS None
Allergic NNP None
mothers NNS None
-DOCSTART- -X- N

critically RB Condition
ill JJ Condition
children NNS None
. . None
Twenty-five JJ None
percent NN None
of IN None
the DT None
children NNS None
with IN None
IIT NNP None
experienced VBD None
hypoglycemia NN Condition
We PRP None
studied VBD None
369 CD Size
patients NNS None
who WP None
stayed VBD None
in IN None
PICU NNP None
for IN None
at IN None
least JJS None
3 CD None
d NN None
( ( None
study VB None
1 CD None
) ) None
and CC None
126 CD Size
patients NNS None
in IN None
a DT None
nested JJ None
case-control NN None
study NN None
( ( None
study VB None
2 CD None
) ) None
. . None
-DOCSTART- -X- N

poisoning NN Condition
with IN Condition
acetaminophen NN Condition
: : None
Ten NNP Size
healthy JJ None
adult NN Age
volunteers NNS Age
victims NNS None
of IN None
acetaminophen NN Condition
overdose NN Condition
. . None
-DOCSTART- -X- N

patients NNS None
undergoing JJ None
noncardiac JJ None
surgery NN None
. . None
patients NNS None
undergoing JJ None
noncardiac JJ None
surgery NN None
patients NNS None
who WP None
are VBP None
already RB None
on IN None
an DT None
aspirin JJ None
regimen NNS None
and CC None
among IN None
those DT None
who WP None
are VBP None
not RB None
. . None
10,010 CD None
patients NNS None
who WP None
were VBD None
preparing VBG None
to TO None
undergo VB None
noncardiac JJ None
surgery NN None
and CC None
were VBD None
at IN None
risk NN None
for IN None
vascular JJ None
complications NNS None
-DOCSTART- -X- N

autistic JJ None
children NNS None
and CC None
adolescents NNS None
. . None
autistic JJ None
children NNS None
and CC None
adolescents VBZ None
10 CD None
autistic JJ None
subjects NNS None
10 CD None
autistic JJ None
subjects NNS None
20 CD None
subjects NNS None
autistic JJ None
children NNS None
. . None
-DOCSTART- -X- N

asthmatics NNS Condition
. . None
13 CD Size
asthmatic JJ Condition
patients NNS None
after IN None
single JJ None
and CC None
multiple JJ None
oral JJ None
dosage NN None
of IN None
a DT None
microcrystalline JJ None
theophylline NN None
tablet NN None
( ( None
Nuelin NNP None
) ) None
and CC None
a DT None
sustained-release JJ None
preparation NN None
( ( None
Nuelin NNP None
Retard NNP None
) ) None
-DOCSTART- -X- N

patients NNS None
with IN None
prostate JJ Condition
cancer NN Condition
. . Condition
men NNS None
with IN None
prostate NN Condition
cancer NN Condition
-DOCSTART- -X- N

Parenting VBG Condition
stress NN Condition
in IN None
the DT None
infant JJ None
aphakia NN None
treatment NN None
parenting VBG Condition
stress NN Condition
following VBG None
infants NNS Age
' POS None
cataract NN None
extraction NN None
surgery NN None
Caregivers NNPS None
caregiver NN None
stress NN None
during IN None
infancy NN Age
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
overactive JJ Condition
bladder NN Condition
. . Condition
patients NNS None
with IN None
overactive JJ None
bladder NN None
( ( None
OAB NNP None
) ) None
symptoms NNS None
. . None
patients NNS None
with IN None
OAB NNP None
symptoms NNS None
. . None
Twenty-six JJ None
patients NNS None
The DT None
mean JJ None
age NN None
was VBD None
67 CD None
years NNS None
and CC None
mean JJ None
BMI NNP None
was VBD None
28.3 CD None
kg/m NN None
( ( None
2 CD None
) ) None
. . None
patients NNS None
with IN None
OAB NNP None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
severe JJ Condition
Raynaud NNP Condition
's POS Condition
syndrome NN Condition
: : Condition
Patients NNPS None
with IN None
Raynaud NNP None
's POS None
syndrome NN None
healthy JJ None
volunteers NNS None
and CC None
patients NNS None
with IN None
primary JJ None
Raynaud NNP None
's POS None
syndrome NN None
. . None
20 CD None
patients NNS None
with IN None
severe JJ None
Raynaud NNP None
's POS None
syndrome NN None
, , None
and CC None
ten RB None
healthy JJ None
volunteers NNS None
. . None
primary JJ None
Raynaud NNP None
's POS None
syndrome NN None
-DOCSTART- -X- N

older JJR Age
adults NNS Age
with IN None
insomnia NN Condition
. . None
Seventeen NNP None
sedentary JJ None
adults NNS None
aged VBN None
> JJ Age
or=55 CD Age
years NNS Age
with IN None
insomnia NN None
( ( None
mean JJ None
age NN None
61.6 CD None
[ NN None
SD?4.3 NNP None
] NNP None
years NNS None
; : None
16 CD None
female NN None
) ) None
participated VBD None
included VBD None
primary JJ None
insomnia NN None
for IN None
at IN None
least JJS None
3 CD None
months NNS None
, , None
habitual JJ None
sleep NN None
duration NN None
< POS None
6.5h CD None
and CC None
a DT None
Pittsburgh NNP None
Sleep NNP None
Quality NNP None
Index NNP None
( ( None
PSQI NNP None
) ) None
score VBD None
> JJ None
5 CD None
. . None
in IN None
older JJR Age
adults NNS Age
with IN None
chronic JJ None
insomnia NN None
. . None
-DOCSTART- -X- N

children NNS None
previously RB None
randomly RB None
assigned VBN None
to TO None
intrathecal JJ None
methotrexate NN None
childhood NN None
acute NN None
lymphoblastic JJ Condition
leukemia NN Condition
. . None
children NNS Age
with IN None
acute JJ Condition
lymphoblastic JJ Condition
leukemia NN Condition
( ( Condition
ALL NNP Condition
) ) Condition
, , None
CNS NNP None
prophylaxis NN None
consists VBZ None
of IN None
either DT None
intrathecal JJ None
( ( None
IT NNP None
) ) None
methotrexate NN None
or CC None
triple VB None
IT NNP None
therapy NN None
( ( None
ie JJ None
, , None
methotrexate NN None
with IN None
both DT None
cytarabine NN None
and CC None
hydrocortisone NN None
) ) None
. . None
171 CD Size
children NNS Age
with IN None
standard-risk JJ None
ALL NNP None
, , None
age NN Age
1 CD Age
to TO Age
9.99 CD Age
years NNS Age
at IN None
diagnosis NN None
, , None
previously RB None
randomly RB None
assigned VBN None
to TO None
IT NNP None
methotrexate NNP None
( ( None
n JJ None
= NNP None
82 CD None
) ) None
or CC None
to TO None
triple VB None
IT NNP None
therapy NN None
( ( None
n JJ None
= NNP None
89 CD None
) ) None
on IN None
CCG NNP None
1952 CD None
, , None
underwent JJ None
neurocognitive JJ None
evaluation NN None
by IN None
a DT None
licensed JJ None
psychologist NN None
at IN None
a DT None
mean NN None
of IN None
5.9 CD None
years NNS None
after IN None
random JJ None
assignment NN None
. . None
Patients NNPS None
who WP None
received VBD None
IT NNP None
methotrexate NNP None
19.5 CD None
% NN None
of IN None
children NNS None
in IN None
the DT None
IT NNP None
methotrexate NNP None
group NN None
sex NN None
or CC None
age NN None
at IN None
diagnosis NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
severe JJ None
injuries NNS None
. . None
patients NNS None
sustaining VBG None
severe JJ None
injury NN None
. . None
patients NNS None
with IN None
major JJ None
infection NN None
on IN None
day NN None
60 CD None
. . None
Nine JJ None
university-affiliated JJ None
level NN None
1 CD None
trauma NN None
centers NNS None
. . None
Four CD None
hundred JJ None
sixteen JJ None
patients NNS None
with IN None
severe JJ None
injuries NNS None
, , None
assessed VBN None
by IN None
Injury NNP None
Severity NNP None
Score NNP None
and CC None
degree NN None
of IN None
contamination NN None
. . None
patients NNS None
treated VBN None
with IN None
interferon NN None
gamma NN None
. . None
-DOCSTART- -X- N

20 CD Size
patients NNS None
, , None
ASA NNP None
I-II NNP None
, , None
aged VBD None
20-54 JJ Age
, , None
both DT Condition
sexes NNS Condition
, , None
scheduled VBN None
for IN None
abdominal JJ Condition
surgery NN Condition
. . None
-DOCSTART- -X- N

peripheral JJ None
stage NN None
IA NNP None
non-small NN None
cell NN None
lung NN None
cancer NN None
: : None
patients NNS None
with IN None
operable JJ None
stage NN None
IA NNP None
lung NN None
cancer NN None
. . None
a DT None
planning NN None
study NN None
was VBD None
performed VBN None
in IN None
26 CD None
stage NN None
I PRP None
patients NNS None
, , None
of IN None
which WDT None
22 CD None
were VBD None
stage NN None
1A CD None
-DOCSTART- -X- N

primary JJ None
biliary JJ None
cirrhosis NN None
: : None
Twenty-four JJ Size
patients NNS None
with IN None
primary JJ None
biliary JJ None
cirrhosis NN None
and CC None
17 CD None
healthy JJ None
subjects NNS None
were VBD None
studied VBN None
. . None
Primary JJ None
biliary JJ None
cirrhosis NN None
patients NNS None
primary JJ Condition
biliary JJ Condition
cirrhosis NN Condition
patients NNS None
healthy JJ None
subjects NNS None
-DOCSTART- -X- N

Chinese JJ None
patients NNS None
with IN None
essential JJ None
hypertension NN None
. . None
105 CD None
patients NNS None
with IN None
mild JJ None
or CC None
moderate JJ None
essential JJ None
hypertension NN None
Only RB None
those DT None
patients NNS None
who WP None
have VBP None
finished VBN None
8 CD None
weeks NNS None
of IN None
active JJ None
treatment NN None
in IN None
both DT None
groups NNS None
were VBD None
included VBN None
into IN None
the DT None
final JJ None
analysis NN None
. . None
One CD None
hundred VBD None
one CD None
patients NNS None
( ( None
51 CD None
in IN None
enalapril NN None
group NN None
and CC None
50 CD None
in IN None
indapamide JJ None
group NN None
) ) None
completed VBD None
the DT None
study NN None
. . None
-DOCSTART- -X- N

autistic JJ Condition
children NNS Condition
. . Condition
autistic JJ None
children NNS None
. . None
-DOCSTART- -X- N

advanced JJ None
upper JJ None
gastrointestinal JJ None
cancer NN None
: : None
advanced JJ None
carcinoma NN None
of IN None
the DT None
stomach NN None
and CC None
pancreas NNS None
. . None
-DOCSTART- -X- N

dental JJ Condition
pain NN Condition
. . None
120 CD Size
patients NNS None
suffering VBG None
from IN None
pain NN None
as IN None
a DT None
result NN None
of IN None
oral JJ None
surgery NN None
-DOCSTART- -X- N

surgical JJ None
trainees NNS None
learning VBG None
open JJ None
gastrectomy NN None
Thirty NNP None
residents NNS None
in IN None
general JJ None
surgery NN None
performed VBD None
2 CD None
open JJ None
partial JJ None
gastrectomy NN None
training VBG None
events NNS None
on IN None
a DT None
porcine JJ None
model NN None
. . None
-DOCSTART- -X- N

in IN None
normal JJ None
male JJ None
college NN None
students NNS None
. . None
-DOCSTART- -X- N

muscle NN Condition
fatigue NN Condition
. . None
Seven NNP Size
paraplegic JJ None
subjects NNS None
participated VBN None
-DOCSTART- -X- N

hydrochloride NN None
in IN None
children NNS None
Seventy-two JJ None
drug-free JJ None
children NNS None
, , None
aged VBD None
5 CD None
to TO None
14 CD None
years NNS None
, , None
with IN None
pervasive JJ None
developmental NN None
disorders NNS None
accompanied VBN None
by IN None
moderate JJ None
to TO None
severe JJ None
hyperactivity NN None
. . None
subjects NNS None
Subjects NNS None
who WP None
tolerated VBD None
the DT None
test NN None
dose NN None
Children NNP None
responding VBG None
to TO None
methylphenidate VB None
Thirty-five JJ None
( ( None
49 CD None
% NN None
) ) None
of IN None
72 CD None
enrolled JJ None
subjects NNS None
13 CD None
( ( None
18 CD None
% NN None
) ) None
of IN None
72 CD None
subjects NNS None
. . None
-DOCSTART- -X- N

trauma NN Condition
patients NNS None
] VBP None
50 CD Size
posttraumatic JJ Condition
intensive-care JJ Condition
patients NNS None
with IN None
medium NN None
grade NN None
lesions NNS Condition
( ( None
ISS NNP Condition
criteria NNS Condition
) ) None
, , None
the DT None
patients NNS None
who WP None
are VBP None
at IN None
particularly RB None
high JJ None
infection NN None
exposure NN None
risk NN None
, , None
e.g NN None
. . None
through IN None
reintervention NN None
surgery NN None
, , None
haemorrhage NN None
complications NNS None
or CC None
extensive JJ None
diagnostic JJ None
interventions NNS None
. . None
-DOCSTART- -X- N

overweight NN Condition
and CC Condition
obese JJ Condition
women NNS Sex
. . None
overweight JJ Condition
and CC None
obese JJ Condition
women NNS Sex
Eighty-eight NNP Size
overweight NN Condition
and CC None
obese JJ Condition
women NNS Sex
participated VBD None
in IN None
this DT None
study NN None
. . None
-DOCSTART- -X- N

patients NNS None
undergoing VBG None
coronary JJ None
artery NN None
bypass NN None
surgery NN None
. . None
patients NNS None
undergoing VBG None
coronary JJ None
artery NN None
bypass NN None
graft NN None
surgery NN None
( ( None
CABG NNP None
) ) None
. . None
Sixty JJ None
patients NNS None
( ( None
age NN None
40-73 CD None
yr NN None
, , None
56 CD None
male NN None
) ) None
were VBD None
assigned VBN None
randomly RB None
to TO None
receive VB None
alfentanil NN None
, , None
fentanyl NN None
or CC None
sufentanil NN None
and CC None
propofol NN None
patients NNS None
undergoing VBG None
CABG NNP None
-DOCSTART- -X- N

childhood NN None
acute NN None
lymphoblastic JJ None
leukemia NN None
: : None
boys NNS None
with IN None
occult NN None
TL NNP None
494 CD None
boys NNS None
entered VBD None
on IN None
study NN None
263 CD None
boys NNS None
were VBD None
eligible JJ None
for IN None
testicular JJ None
biopsy NN None
. . None
Elective JJ None
testicular JJ None
biopsy NN None
was VBD None
performed VBN None
on IN None
235 CD None
( ( None
89.4 CD None
% NN None
) ) None
boys VBZ None
. . None
-DOCSTART- -X- N

90 CD None
Brazilian JJ None
women NNS None
, , None
diagnosed VBD None
to TO None
CIN2 NNP None
and CC None
high-risk JJ None
human JJ None
papillomavirus NN None
infection NN None
, , None
were VBD None
randomized VBN None
into IN None
two CD None
groups NNS None
of IN None
equal JJ None
size NN None
: : None
45 CD None
women NNS None
whose WP$ None
lesions NNS None
were VBD None
excised VBN None
and CC None
45 CD None
women NNS None
subjected VBN None
to TO None
prospective JJ None
follow-up NN None
at IN None
3-month JJ None
intervals NNS None
at IN None
least JJS None
for IN None
1 CD None
year NN None
( ( None
mean JJ None
6.8 CD None
months NNS None
) ) None
. . None
45 CD None
women NNS None
-DOCSTART- -X- N

photo NN None
and CC None
age-damaged JJ None
skin NN None
: : None
photoaging NN None
of IN None
facial JJ None
skin NN None
. . None
Fifteen NNP None
female JJ None
volunteers NNS None
were VBD None
enrolled VBN None
; : None
skin NN None
photoaging NN None
. . None
-DOCSTART- -X- N

children NNS Age
receiving VBG None
combined JJ None
cancer NN Condition
chemotherapy NN Condition
. . None
adults NNS Age
and CC None
children NNS Age
receiving VBG None
cancer NN Condition
chemotherapy NN Condition
. . None
children NNS None
receiving VBG None
highly RB Condition
emetogenic JJ Condition
chemotherapy NN Condition
for IN None
various JJ None
malignancies NNS Condition
. . None
total NN None
of IN None
51 CD Size
children NNS None
( ( None
mean JJ None
age NN None
: : None
7.7 CD Age
+/- NN Age
4.8 CD Age
year NN Age
) ) None
were VBD None
studied VBN None
children NNS Age
receiving VBG None
highly RB Condition
emetogenic JJ Condition
chemotherapy NN Condition
. . None
-DOCSTART- -X- N

autism NN None
in IN None
children NNS None
. . None
Sixty NNP None
children NNS None
with IN None
autism NN None
or CC None
Asperger NNP None
syndrome VBP None
( ( None
3-11 CD None
years NNS None
old JJ None
) ) None
-DOCSTART- -X- N

after IN None
GnRH NNP None
agonist NN None
treatment NN None
. . None
hormone NN None
replacement NN None
therapy NN None
28 CD None
patients NNS None
treated VBD None
for IN None
6 CD None
months NNS None
with IN None
a DT None
GnRH NNP None
agonist NN None
. . None
postmenopausal JJ None
women NNS None
with IN None
high JJ None
bone NN None
turnover NN None
treated VBN None
with IN None
HRT NNP None
. . None
women NNS None
with IN None
ovarian JJ None
deficiency NN None
. . None
-DOCSTART- -X- N

patients NNS None
and CC None
their PRP$ None
partners NNS None
with IN None
bacterial JJ None
vaginosis NN None
. . None
male JJ None
partners NNS None
of IN None
women NNS None
with IN None
bacterial JJ None
vaginosis NN None
patients NNS None
with IN None
bacterial JJ None
vaginosis NN None
. . None
sexual JJ None
partner NN None
of IN None
women NNS None
with IN None
bacterial JJ None
vaginosis NN None
-DOCSTART- -X- N

superficial JJ None
bladder NN Condition
cancer NN Condition
. . None
in IN None
patients NNS None
with IN None
primary JJ None
or CC None
recurrent JJ None
superficial JJ None
bladder NN None
tumors NNS None
, , None
including VBG None
carcinoma NN None
in IN None
situ NN None
( ( None
CIS NNP None
) ) None
. . None
Reported VBN None
are VBP None
the DT None
incidence NN None
of IN None
side NN None
effects NNS None
in IN None
165 CD None
patients NNS None
and CC None
the DT None
recurrence NN None
rate NN None
of IN None
tumors NNS None
in IN None
308 CD None
patients NNS None
after IN None
a DT None
follow-up JJ None
period NN None
of IN None
twelve JJ None
months NNS None
. . None
-DOCSTART- -X- N

dentinal JJ Condition
cold JJ Condition
sensitivity NN Condition
. . None
Postoperative NNP Condition
cold VBD Condition
sensitivity NN Condition
after IN None
the DT None
cementation NN None
of IN None
indirect JJ None
restorations NNS None
with IN None
composite JJ None
cements NNS None
The DT None
hypersensitive JJ None
root NN None
surfaces NNS None
of IN None
selected VBN None
teeth NNS None
sample JJ Size
size NN Size
was VBD Size
22 CD Size
. . None
-DOCSTART- -X- N

humans NNS Condition
. . None
Twenty-four NNP Size
subjects NNS None
, , None
each DT None
requiring VBG None
a DT None
nonmolar JJ Condition
extraction NN Condition
and CC None
delayed JJ Condition
implant NN Condition
placement NN Condition
-DOCSTART- -X- N

chemotherapy-naive JJ None
patients NNS None
with IN None
colorectal JJ Condition
cancer NN Condition
. . None
Forty-eight NNP Size
patients NNS None
were VBD None
randomized VBN None
Forty-five JJ Size
patients NNS None
were VBD None
assessable JJ None
for IN None
response NN None
: : None
-DOCSTART- -X- N

healthy JJ None
unvaccinated JJ None
individuals NNS None
. . None
healthy JJ None
unvaccinated JJ None
individuals NNS None
. . None
healthy JJ None
unvaccinated JJ None
individuals NNS None
. . None
-DOCSTART- -X- N

coronary JJ Condition
artery NN Condition
dissections NNS Condition
523 CD Size
patients NNS None
undergoing JJ None
balloon NN Condition
angioplasty NN Condition
and CC Condition
sequential JJ Condition
intracoronary JJ Condition
Doppler NN Condition
measurements NNS Condition
After IN None
successful JJ None
balloon NN None
angioplasty NN None
Patients NNS None
with IN None
severe JJ None
dissections NNS None
( ( None
n JJ None
= NNP None
128 CD None
) ) None
or CC None
without IN None
available JJ None
reference NN None
vessel NN None
CFVR NNP None
( ( None
n JJ None
= NNP None
139 CD None
) ) None
were VBD None
excluded VBN None
. . None
remaining VBG None
256 CD Size
patients NNS Size
-DOCSTART- -X- N

oral JJ Condition
health NN Condition
improvement NN Condition
previous JJ None
users NNS None
of IN None
traditional JJ None
materials NNS None
in IN None
a DT None
rural JJ None
population NN None
in IN None
Andhra NNP None
Pradesh NNP None
, , None
India NNP None
. . None
oral JJ Condition
health NN Condition
of IN None
an DT None
economically RB None
disadvantaged JJ None
rural JJ None
population NN None
in IN None
Andhra NNP None
Pradesh NNP None
, , None
India NNP None
who WP None
were VBD None
primarily RB None
users NNS None
of IN None
traditional JJ None
materials NNS None
. . None
150 CD Size
of IN None
the DT None
original JJ None
study NN None
population NN None
. . None
-DOCSTART- -X- N

subjects NNS None
with IN None
mild-to-moderate JJ Condition
Alzheimer NNP Condition
disease NN Condition
: : None
in IN None
subjects NNS None
with IN None
mild-to-moderate JJ None
AD NNP None
. . None
-DOCSTART- -X- N

Oesophageal JJ Condition
intubation NN Condition
Forty NNP None
patients NNS None
had VBD None
both DT None
their PRP$ None
trachea NN None
and CC None
oesophagus NN None
intubated VBN None
anaesthetist NN Condition
's POS Condition
feeling NN None
when WRB None
he PRP None
squeezes VBZ None
the DT None
bag NN None
. . None
-DOCSTART- -X- N

56 CD Size
old JJ Age
subjects NNS None
randomized VBN None
into IN None
3 CD None
groups NNS None
. . None
-DOCSTART- -X- N

patients NNS None
who WP None
had VBD None
received VBN None
a DT None
hip NN Condition
replacement NN Condition
. . None
258 CD None
patients NNS None
were VBD None
evaluated VBN None
. . None
-DOCSTART- -X- N

symptomatic JJ None
myocardial JJ None
ischemia NN None
. . None
an DT None
open JJ None
study NN None
in IN None
patients NNS None
with IN None
symptomatic JJ None
myocardial JJ None
ischemia NN None
. . None
data NNS None
from IN None
78 CD None
patients NNS None
. . None
-DOCSTART- -X- N

human JJ None
oocytes NNS None
274 CD None
oocytes NNS None
obtained VBN None
from IN None
46 CD Size
couples NNS None
undergoing JJ None
infertility NN Condition
treatment NN None
. . None
-DOCSTART- -X- N

Hawaiian JJ None
youth NN None
and CC None
communities NNS None
. . None
communities NNS None
on IN None
Hawai'i NNP None
Island NNP None
university-based JJ None
research NN None
team NN None
school-based JJ None
substance NN None
use NN None
prevention NN None
curriculum NN None
students NNS None
and CC None
community NN None
-DOCSTART- -X- N

Nineteen JJ Size
ragweed-sensitive JJ Condition
patients NNS None
were VBD Condition
randomized VBN Condition
into IN Condition
2 CD Condition
groups NNS Condition
; : Condition
10 CD Size
received VBD None
the DT None
polymerized JJ None
form NN None
and CC Condition
9 CD Size
received VBD None
the DT None
monomeric JJ None
form NN None
. . Condition
-DOCSTART- -X- N

in IN None
naive JJ Condition
and CC Condition
pre-immunized JJ Condition
subjects NNS None
. . None
A DT None
total NN None
of IN None
86 CD Size
healthy JJ Condition
subjects NNS None
-DOCSTART- -X- N

volunteers NNS None
. . None
Single NNP None
university NN None
hospital NN None
. . None
Ten CD None
male NN None
volunteers NNS None
aged VBN None
18-28 JJ None
( ( None
mean JJ None
22 CD None
) ) None
years NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
stable JJ Condition
angina NN Condition
. . None
Eight-seven JJ Size
angina NNS None
pectoris JJ None
patients NNS None
, , None
mean JJ Age
age NN Age
of IN Age
57 CD Age
+/- JJ Age
9 CD Age
, , None
82 CD None
white JJ None
and CC None
79 CD Sex
male NN Sex
patients NNS None
with IN None
stable JJ None
angina NN None
. . None
-DOCSTART- -X- N

microdose JJ Condition
flare-up JJ Condition
cycles NNS Condition
in IN Condition
poor JJ Condition
responders NNS Condition
microdose JJ None
gonadotropin-releasing JJ None
hormone NN None
analog NN None
( ( None
GnRH-a NNP None
) ) None
flare NN None
cycles NNS None
in IN None
poor JJ None
responders NNS None
. . None
total NN None
of IN None
119 CD None
women NNS None
119 CD None
patients NNS None
-DOCSTART- -X- N

33 CD Size
patients NNS None
with IN None
pulmonary JJ Condition
hypertension NN Condition
. . None
33 CD Size
age- JJ None
and CC None
sex-matched JJ None
control NN None
subjects NNS None
. . None
-DOCSTART- -X- N

canine JJ None
Canine NNP Condition
parvoviral JJ Condition
enteritis NN Condition
dogs NNS None
parvoviral JJ Condition
enteritis NN Condition
in IN Condition
dogs NNS Condition
. . None
beagle NN None
pups NNS None
( ( Age
8-9 JJ Age
weeks NNS None
) ) None
; : None
Fourteen JJ Size
animals NNS None
were VBD None
inoculated VBN None
with IN None
virulent JJ None
canine NN None
parvovirus NN None
; : None
10 CD Size
animals NNS None
that WDT None
developed VBD None
clinical JJ None
signs NNS None
thereby RB None
meeting VBG None
the DT None
inclusion NN None
criteria NNS None
were VBD None
admitted VBN None
to TO None
the DT None
treatment NN None
phase NN None
dogs NNS None
with IN None
parvoviral JJ Condition
enteritis NN Condition
-DOCSTART- -X- N

melanoma NN Condition
families NNS None
families NNS None
families NNS None
affected VBN None
by IN None
melanoma NN Condition
three CD Size
family NN Size
members NNS Size
per IN Size
family NN Size
for IN None
assessment NN None
- : None
the DT None
melanoma NN None
case NN None
, , None
a DT None
first-degree JJ None
relative NN None
( ( None
FDR NNP None
) ) None
, , None
and CC None
a DT None
relative NN None
who WP None
is VBZ None
a DT None
parent NN None
of IN None
a DT None
child JJ None
age NN None
18 CD Age
or CC Age
younger JJR Age
. . None
1380 CD Size
families NNS None
approached VBD None
, , None
313 CD Size
were VBD None
enrolled VBN None
, , None
263 CD None
were VBD None
excluded VBN None
because IN None
we PRP None
could MD None
not RB None
find VB None
or CC None
contact VB None
a DT None
family NN None
member NN None
( ( None
FDR CD None
or CC None
parent NN None
) ) None
, , None
331 CD None
did VBD None
not RB None
have VB None
eligible JJ None
family NN None
members NNS None
, , None
and CC None
473 CD None
refused VBD None
. . None
-DOCSTART- -X- N

sensory JJ None
and CC None
self-regulation JJ None
problems NNS None
in IN None
young JJ Age
children NNS Age
with IN None
autism NN Condition
: : None
46 CD Size
children NNS Age
with IN None
autism NN Condition
< NNP None
age NN Age
6 CD Age
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
. . None
children NNS Age
with IN None
autism NN Condition
. . Condition
Sixty NNP Size
subjects VBZ None
with IN None
autism NN Condition
-DOCSTART- -X- N

type NN Condition
2 CD Condition
diabetic JJ Condition
subjects NNS None
: : None
type NN None
2 CD None
diabetic JJ None
individuals NNS None
. . None
Twenty-four JJ Size
participants NNS None
with IN None
type NN Condition
2 CD Condition
diabetes NNS Condition
( ( None
mean JJ Age
age NN Age
58 CD Age
years NNS Age
; : None
14 CD Size
women NNS Sex
and CC None
10 CD Size
men NNS Sex
) ) None
-DOCSTART- -X- N

exposure NN None
prevention NN None
intervention NN None
on IN None
hazardous JJ None
substance NN None
exposures NNS None
in IN None
manufacturing VBG None
work NN None
sites NNS None
an DT None
industrial JJ None
hygienist NN None
walk-through JJ None
inspection NN None
( ( None
N NNP None
= NNP None
131 CD None
manufacturing NN None
processes/areas NNS None
in IN None
17 CD None
large JJ None
work NN None
sites NNS None
) ) None
. . None
A DT None
second JJ None
hygienist NN None
-DOCSTART- -X- N

ADDITION-Cambridge NNP None
trial NN None
protocol NN None
: : None
type NN None
2 CD None
diabetes NNS None
and CC None
intensive JJ None
treatment NN None
for IN None
screen-detected JJ None
patients NNS None
. . None
people NNS None
with IN None
screen-detected JJ None
diabetes NNS None
in IN None
primary JJ None
care NN None
. . None
63 CD None
practices NNS None
in IN None
the DT None
East NNP None
Anglia NNP None
region NN None
participated VBD None
. . None
people NNS None
aged VBN None
40-69 JJ None
years NNS None
at IN None
high-risk NN None
of IN None
undiagnosed JJ None
diabetes NNS None
. . None
individuals NNS None
with IN None
clinically RB None
diagnosed VBN None
diabetes NNS None
-DOCSTART- -X- N

humans NNS None
human JJ None
subjects NNS None
-DOCSTART- -X- N

eleven RB None
healthy JJ None
volunteers NNS None
-DOCSTART- -X- N

Between NNP None
October NNP None
15 CD None
, , None
1996 CD None
, , None
and CC None
March NNP None
24 CD None
, , None
1999 CD None
, , None
104 CD Size
patients NNS None
at IN None
13 CD None
centers NNS None
were VBD None
prospectively RB None
randomized VBN None
cerebral JJ Condition
AVM NNP Condition
-DOCSTART- -X- N

injection NN None
comfort NN None
cohesive JJ None
hyaluronic JJ None
acid NN None
filler NN None
three CD None
centers NNS None
enrolled VBD None
60 CD Size
subjects NNS None
, , None
injected VBN None
with IN None
both DT None
products NNS None
, , None
randomly RB None
assigned VBN None
to TO None
left VBD None
or CC None
right JJ None
nasolabial JJ None
fold NN None
. . None
Subjects NNS None
used VBD None
a DT None
visual JJ None
analog NN None
scale NN None
( ( None
0-10 JJ None
) ) None
for IN None
pain NN None
assessment NN None
. . None
-DOCSTART- -X- N

4 CD None
groups NNS None
of IN None
cancer NN None
patients NNS None
receiving VBG None
bone NN None
marrow NN None
transplants NNS None
( ( None
BMT NNP None
) ) None
: : None
( ( None
1 CD None
) ) None
treatment NN None
as IN None
usual JJ None
control NN None
, , None
( ( None
2 CD None
) ) None
therapist NN None
support NN None
, , None
( ( None
3 CD None
) ) None
relaxation NN None
and CC None
imagery NN None
training NN None
, , None
and CC None
( ( None
4 CD None
) ) None
training NN None
in IN None
a DT None
package NN None
of IN None
cognitive-behavioral JJ None
coping NN None
skills NNS None
which WDT None
included VBD None
relaxation NN None
and CC None
imagery NN None
. . None
94 CD None
patients NNS None
completed VBD None
the DT None
study NN None
which WDT None
involved VBD None
two CD None
training NN None
sessions NNS None
prior RB None
to TO None
treatment NN None
and CC None
twice RB None
a DT None
week NN None
'booster POS None
' POS None
sessions NNS None
during IN None
the DT None
first JJ None
5 CD None
weeks NNS None
of IN None
treatment NN None
. . None
-DOCSTART- -X- N

healthy JJ None
subjects NNS None
. . None
Subjects NNS None
normal JJ None
subjects NNS None
-DOCSTART- -X- N

rheumatoid JJ None
arthritis NN None
with IN None
special JJ None
regard NN None
to TO None
morning NN None
stiffness NN None
and CC None
pain NN None
on IN None
awakening VBG None
. . None
8 CD None
centres NNS None
out-patients NNS None
with IN None
definite NN None
or CC None
classical JJ None
rheumatoid NN None
arthritis NN None
. . None
83 CD None
evaluable JJ None
patients NNS None
-DOCSTART- -X- N

childhood/adolescent JJ Age
pervasive JJ Condition
developmental NN Condition
disorder NN Condition
. . None
Eleven NNP Size
patients NNS None
with IN None
a DT None
diagnosis NN None
of IN None
either DT None
autism NN Condition
, , None
Asperger NNP Condition
's POS Condition
syndrome NN Condition
, , None
or CC None
PDD NNP Condition
not RB None
otherwise RB None
specified VBN None
( ( None
PDD-NOS NNP None
) ) None
and CC None
aged VBN None
6-14 CD Age
years NNS Age
-DOCSTART- -X- N

patients NNS None
with IN None
mild JJ Condition
obstructive JJ Condition
sleep NN Condition
apnea NN Condition
. . None
cardiovascular JJ Condition
diseases NNS Condition
in IN None
obstructive JJ Condition
sleep NN Condition
apnea NN Condition
( ( Condition
OSA NNP Condition
) ) Condition
overweight JJ Condition
patients NNS None
with IN None
mild JJ Condition
OSA NNP Condition
. . Condition
Patients NNPS None
were VBD None
randomized VBN None
to TO None
supervised VBN None
intensive JJ None
lifestyle JJ None
intervention NN None
group NN None
( ( None
N=28 NNP Size
) ) None
or CC None
to TO None
control VB None
group NN None
( ( None
N=31 NNP Size
) ) None
, , None
which WDT None
received VBD None
routine JJ None
lifestyle JJ None
advices NNS None
. . None
overweight JJ Condition
patients NNS None
with IN None
mild JJ Condition
OSA NNP Condition
OSA NNP Condition
patients NNS None
-DOCSTART- -X- N

exuding VBG None
wounds NNS None
. . None
exuding VBG None
wounds NNS None
greater JJR None
than IN None
2.5 CD None
x JJ None
2.5 CD None
cm NN None
. . None
target NN None
population NN None
was VBD None
300 CD None
control NN None
and CC None
300 CD None
test NN None
subjects NNS None
across IN None
three CD None
sites NNS None
in IN None
the DT None
UK NNP None
, , None
but CC None
recruitment JJ None
difficulties NNS None
resulted VBD None
in IN None
only RB None
125 CD None
patients NNS None
being VBG None
evaluable JJ None
. . None
-DOCSTART- -X- N

school-aged JJ None
children NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
: : None
children NNS None
with IN None
autism NN None
spectrum NN None
disorder NN None
( ( None
ASD NNP None
) ) None
. . None
participants NNS None
. . None
Six CD None
children NNS None
children NNS None
with IN None
ASD NNP None
. . None
-DOCSTART- -X- N

duodenal JJ Condition
ulcer NN Condition
duodenal JJ Condition
ulcer NN Condition
. . None
171 CD Size
patients NNS None
with IN None
endoscopically RB None
confirmed VBN None
duodenal JJ Condition
ulcers NNS Condition
. . None
two CD None
treatment NN None
groups NNS None
-DOCSTART- -X- N

patients NNS None
< JJ Age
65 CD Age
years NNS Age
with IN None
poor JJ None
prognosis NN None
histologically RB None
aggressive JJ None
NHL NNP Condition
. . None
457 CD Size
patients NNS None
patients NNS None
with IN None
poor JJ None
prognosis NN None
histologically RB None
aggressive JJ None
non-Hodgkin JJ Condition
lymphoma NN Condition
( ( None
NHL NNP None
) ) None
showing VBG None
a DT None
response NN None
to TO None
initial JJ None
CHOP NNP None
( ( None
cyclophosphamide NN None
-DOCSTART- -X- N

patients NNS None
with IN None
diabetes NNS Condition
mellitus NNS Condition
( ( None
DM NNP None
) ) None
type NN None
2 CD None
and CC None
chronic JJ Condition
CME NNP Condition
without IN None
evident JJ None
vitreomacular JJ None
traction NN None
. . None
Forty NNP Size
eyes NNS None
with IN None
attached JJ None
posterior JJ None
hyaloid NN None
patients NNS None
with IN None
DM NNP None
type NN None
2 CD None
and CC None
cystoid JJ None
diabetic JJ None
macular NN None
edema NN None
without IN None
evident JJ None
vitreoretinal JJ None
traction NN None
. . None
ILM NNP None
eyes NNS None
with IN None
preexisting VBG None
PVD NNP None
. . None
-DOCSTART- -X- N

chronic JJ Condition
hepatitis NN Condition
B NNP Condition
patients NNS None
] NNP None
chronic JJ Condition
hepatitis NN Condition
B NNP Condition
patients NNS None
with IN None
liver JJ Condition
fibrosis NN Condition
. . None
57 CD Size
chronic NN Condition
hepatitis NN Condition
B NNP Condition
patients NNS None
with IN None
liver JJ Condition
fibrosis NN Condition
liver JJ Condition
fibrosis NN Condition
in IN None
chronic JJ Condition
hepatitis NN Condition
B NNP Condition
patients NNS None
-DOCSTART- -X- N

web-based JJ None
tailored JJ None
smoking NN Condition
cessation NN Condition
advice NN None
reports NNS None
Participants NNS None
were VBD None
allocated VBN None
randomly RB None
to TO None
one CD None
of IN None
two CD None
groups NNS None
Participants NNS None
( ( None
n IN None
= NNP None
1758 CD None
) ) None
were VBD None
visitors NNS None
to TO None
the DT None
QUIT NNP None
website NN None
who WP None
were VBD None
based VBN None
in IN None
the DT None
United NNP None
Kingdom NNP None
, , None
aged VBD None
18 CD Age
years NNS Age
or CC Age
over RB Age
and CC None
who WP None
smoked VBD None
cigarettes NNS None
or CC None
hand-rolled JJ None
tobacco NN None
. . None
MEASUREMENTS NNP None
intervention NN None
group NN None
did VBD None
control NN None
group NN None
on IN None
. . None
Intervention NN None
participants NNS None
gave VBD None
more RBR None
materials NNS None
than IN None
control NN None
participants NNS None
. . None
CONCLUSIONS VB None
-DOCSTART- -X- N

open JJ Condition
heart NN Condition
surgery NN Condition
Fifty-two JJ None
patients NNS None
undergoing VBG None
coronary JJ None
artery NN None
bypass NN None
on IN None
cardiopulmonary JJ None
bypass NN None
-DOCSTART- -X- N

male JJ Sex
adolescents NNS Age
adolescents NNS None
18 CD Size
male NN Sex
adolescents NNS Age
-DOCSTART- -X- N

[ JJ None
Obstetrical NNP None
analgesia NN None
23 CD None
normal JJ None
deliveries NNS None
. . None
group NN None
of IN None
normal JJ None
deliveries NNS None
in IN None
which WDT None
analgesia NN None
was VBD None
achieved VBN None
with IN None
pethidine NN None
. . None
-DOCSTART- -X- N

greyhound VB None
dogs NNS None
wearing VBG None
leg NN None
casts NNS None
The DT None
animal NN None
used VBN None
for IN None
these DT None
studies NNS None
was VBD None
the DT None
greyhound NN None
, , None
which WDT None
has VBZ None
thin JJ None
skin NN None
, , None
angular JJ None
conformation NN None
, , None
limited JJ None
body NN None
fat JJ None
and CC None
is VBZ None
predisposed VBN None
to TO None
pressure VB None
ulcers NNS None
similar JJ None
to TO None
those DT None
occurring VBG None
in IN None
humans NNS None
. . None
-DOCSTART- -X- N

autistic JJ Condition
behavior NN Condition
. . Condition
Eight NNP Age
young JJ Age
adults NNS Age
who WP Age
were VBD Age
diagnosed VBN Age
with IN Age
autism NN Age
-DOCSTART- -X- N

selected VBN Condition
patients NNS Condition
following VBG Condition
aortocoronary JJ Condition
bypass NN Condition
operation NN Condition
] NNP None
Two CD None
groups NNS None
of IN None
9 CD Size
male JJ Sex
patients NNS None
( ( None
age NN Age
: : Age
59 CD Age
+/- JJ Age
4 CD Age
and CC Age
56 CD Age
+/- JJ Age
6 CD Age
years NNS Age
, , Age
resp NN Age
. . None
) ) None
each DT None
trained VBN None
on IN None
bicycle NN None
ergometer JJ None
start NN None
on IN None
post-operative JJ None
days NNS None
24 CD None
and CC None
26 CD None
, , None
resp NN None
. . None
-DOCSTART- -X- N

Naltrexone NN None
in IN None
autistic JJ Condition
children NNS Age
: : None
naltrexone NN None
in IN None
autistic JJ Condition
children NNS Age
Forty-one CD Size
children NNS Age
, , None
all DT None
inpatients NNS Condition
, , None
ages VBZ None
2.9 CD Age
to TO Age
7.8 CD Age
years NNS Age
, , None
completed VBD None
the DT None
study NN None
. . None
hyperactivity NN None
children NNS None
with IN None
moderate JJ Condition
to TO Condition
severe VB Condition
self-injurious JJ Condition
behavior NN Condition
. . None
-DOCSTART- -X- N

primary JJ Condition
open-angle JJ Condition
glaucoma NN Condition
-- : None
results NNS None
black JJ None
Jamaican JJ None
population NN None
. . None
48 CD None
eyes NNS None
of IN None
30 CD Size
black JJ None
Jamaican JJ None
patients NNS None
with IN None
primary JJ Condition
open-angle JJ Condition
glaucoma NN Condition
. . None
All DT None
eyes NNS None
had VBD None
uncontrolled VBN Condition
intra-ocular JJ Condition
pressures NNS Condition
( ( Condition
greater JJR Condition
than IN Condition
or CC Condition
equal JJ Condition
to TO Condition
22 CD Condition
mm NNS Condition
Hg NNP Condition
) ) Condition
despite IN None
medical JJ None
therapy NN None
. . None
Jamaican NNP None
glaucoma NN Condition
patients NNS None
. . None
-DOCSTART- -X- N

during IN None
transesophageal JJ Condition
echocardiography NN Condition
: : None
Patients NNS None
with IN None
ischemic JJ Condition
stroke NN Condition
or CC Condition
transient JJ Condition
ischemic JJ Condition
attack NN Condition
undergoing JJ None
TEE NNP None
because IN None
of IN None
presumed JJ None
cardioembolic JJ None
origin NN None
in IN None
a DT None
specialized JJ None
stroke NN None
unit NN None
of IN None
the DT None
Johann NNP None
Wolfgang NNP None
Goethe-University NNP None
, , None
Frankfurt/Main NNP None
, , None
Germany NNP None
. . None
Forty-one CD Size
( ( Size
41 CD Size
) ) Size
patients NNS None
were VBD None
studied VBN None
. . None
-DOCSTART- -X- N

unselected JJ None
hypertensive JJ Condition
population NN None
. . None
One CD Size
hundred VBD Size
nineteen JJ Size
patients NNS None
with IN None
essential JJ Condition
hypertension NN Condition
( ( None
96 CD Size
completing VBG None
six CD None
months NNS None
and CC None
92 CD Size
a DT None
one CD None
year NN None
study NN None
period NN None
) ) None
all DT None
groups NNS None
smallest JJS None
patients NNS None
-DOCSTART- -X- N

discoid JJ None
lupus NN None
erythematosus NN None
. . None
patients NNS None
with IN None
therapy-resistant JJ None
discoid NN None
lupus NN None
erythematosus NN None
( ( None
DLE NNP None
) ) None
. . None
Thirty-seven JJ None
patients NNS None
with IN None
at IN None
least JJS None
one CD None
newly RB None
developed VBN None
DLE NNP None
lesion NN None
-DOCSTART- -X- N

35 CD Condition
women NNS Condition
with IN Condition
axillary JJ Condition
hair NN Condition
-DOCSTART- -X- N

HIV-infected JJ Condition
patients NNS None
with IN None
painful JJ Condition
peripheral JJ Condition
neuropathy NN Condition
: : None
HIV-related NNP Condition
painful JJ Condition
peripheral JJ Condition
neuropathy NN Condition
( ( Condition
PPN NNP Condition
) ) None
22 CD Size
patients NNS None
19 CD Size
patients NNS None
who WP None
received VBD None
at IN None
least JJS None
2 CD None
weeks NNS None
of IN None
the DT None
drug NN None
, , None
16 CD Size
of IN None
whom WP None
were VBD None
crossed-over RB None
to TO None
receive VB None
the DT None
alternate NN None
agent NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
a DT None
history NN None
of IN None
seasonal JJ None
allergic JJ None
rhinitis NN None
. . None
susceptible JJ None
individuals NNS None
eight CD None
subjects NNS None
with IN None
a DT None
history NN None
of IN None
seasonal JJ None
allergic JJ None
rhinitis NN None
, , None
who WP None
were VBD None
tested VBN None
out IN None
of IN None
season NN None
Another DT None
group NN None
of IN None
eight CD None
subjects NNS None
with IN None
a DT None
history NN None
of IN None
seasonal JJ None
allergic JJ None
rhinitis NN None
-DOCSTART- -X- N

Thirty NN Size
patients NNS None
undergoing VBG None
elective JJ None
cholecystectomy NN Condition
were VBD None
allocated VBN None
patients NNS None
who WP None
received VBD None
the DT None
infusion NN None
of IN None
morphine NN None
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
or CC None
asthma NN Condition
and CC None
other JJ None
special JJ Condition
health NN Condition
care NN Condition
needs NNS Condition
: : None
parents NNS None
of IN None
children NNS Age
with IN None
autism NN Condition
compared VBN None
with IN None
parents NNS None
of IN None
children NNS Age
with IN None
asthma NN Condition
or CC None
other JJ None
special JJ Condition
health NN Condition
care NN Condition
needs VBZ Condition
Parents NNPS None
of IN None
495 CD Size
children NNS Age
with IN None
autism NN Condition
, , None
parents NNS None
of IN None
6716 CD Size
children NNS Age
with IN None
asthma NN Condition
, , None
and CC None
parents NNS None
of IN None
11,403 CD Size
children NNS None
with IN None
other JJ None
special JJ Condition
health NN Condition
care NN Condition
needs VBZ Condition
without IN None
asthma NN Condition
. . None
-DOCSTART- -X- N

youth NN Age
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
. . None
16 CD Size
male NN Sex
youth NN Age
aged VBD Age
12 CD Age
to TO Age
19 CD Age
who WP None
were VBD None
diagnosed VBN None
with IN None
Autistic NNP Condition
or CC Condition
Asperger NNP Condition
's POS Condition
Disorder NNP Condition
. . None
Participants NNS None
younger JJR Age
participants NNS None
aged VBD None
12 CD Age
to TO Age
15 CD Age
young JJ None
people NNS None
diagnosed VBN None
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
. . Condition
young JJ None
people NNS None
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
. . None
-DOCSTART- -X- N

mammography NN None
. . None
Participants NNS None
were VBD None
1908 CD None
women NNS None
aged VBD None
50 CD None
to TO None
75 CD None
years NNS None
continuously RB None
enrolled VBD None
in IN None
a DT None
large JJ None
group-model JJ None
HMO NNP None
during IN None
the DT None
study NN None
who WP None
underwent VBD None
a DT None
bilateral JJ None
mammogram NN None
during IN None
the DT None
first JJ None
quarter NN None
of IN None
1994 CD None
and CC None
no DT None
subsequent JJ None
mammogram NN None
during IN None
the DT None
next JJ None
18 CD None
to TO None
21 CD None
months NNS None
. . None
-DOCSTART- -X- N

patients NNS None
undergoing JJ None
total JJ None
mastectomy NN None
. . None
128 CD Size
women NNS None
undergoing VBG Condition
total JJ Condition
mastectomy NN Condition
. . None
patients NNS None
undergoing JJ Condition
total JJ Condition
mastectomy NN Condition
-DOCSTART- -X- N

in IN None
patients NNS None
with IN None
haematological JJ Condition
malignancies NNS Condition
. . None
Adults NNS Age
with IN None
haematological JJ None
malignancies NNS None
receiving VBG None
chemotherapy NN None
or CC None
bone NN None
marrow NN None
transplants NNS None
more RBR None
patients NNS None
receiving VBG None
flu NN None
required VBN None
amphotericin NN None
B NNP None
-DOCSTART- -X- N

Primary JJ None
capsulectomy NN None
, , None
anterior JJ None
vitrectomy NN None
, , None
lensectomy NN None
, , None
and CC None
posterior JJ None
chamber NN None
lens NNS None
implantation NN None
in IN None
children NNS Age
: : None
childhood NN Age
cataract NN Condition
. . None
45 CD None
eyes NNS None
38 CD None
eyes NNS None
were VBD None
included VBN None
All DT None
eyes NNS None
had VBD None
lensectomy NN None
and CC None
posterior JJ None
chamber NN None
intraocular JJ None
lens NNS None
( ( None
PC NNP None
IOL NNP None
) ) None
implantation NN None
. . None
children NNS Age
. . None
-DOCSTART- -X- N

population-based JJ None
screening NN None
study NN None
. . None
prostate NN Condition
cancer NN Condition
and CC Condition
benign JJ Condition
conditions NNS Condition
of IN Condition
the DT Condition
prostate NN Condition
( ( None
Rotterdam NNP None
section NN None
of IN None
the DT None
European NNP None
Randomized NNP None
Study NNP None
of IN None
Screening NNP None
for IN None
Prostate NNP None
Cancer NNP None
) ) None
10,865 CD Size
men NNS None
have VBP None
been VBN None
screened VBN None
biopsy NN None
results NNS None
of IN None
1202 CD Size
men NNS None
with IN None
PSA NNP Condition
levels NNS Condition
of IN Condition
4 CD Condition
ng/mL NNS Condition
or CC Condition
more JJR Condition
1202 CD Size
men NNS None
studied VBD None
, , None
361 CD Size
cases NNS None
of IN None
prostate NN None
cancer NN None
-DOCSTART- -X- N

postexercise NN Condition
hypotension NN Condition
in IN None
humans NNS None
. . None
blood NN None
pressure NN None
that WDT None
occurs VBZ None
after IN None
exercise NN None
in IN None
humans NNS None
. . None
Eight NNP Size
healthy JJ None
subjects NNS None
humans NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
locally RB Condition
advanced VBN Condition
resectable JJ Condition
rectal JJ Condition
cancer NN Condition
. . None
Patients NNPS None
with IN None
stage NN Condition
II/III NNP Condition
LARC NNP Condition
Thirty-seven JJ Size
patients NNS None
were VBD None
eligible JJ None
17 CD Size
patients NNS None
13 CD None
patients NNS None
6 CD None
patients NNS None
patients NNS None
with IN None
resectable JJ Condition
LARC NNP Condition
. . None
-DOCSTART- -X- N

attention-deficit/hyperactivity NN None
disorder NN None
symptoms NNS None
in IN None
children NNS None
with IN None
autism NN None
spectrum NN None
disorder NN None
. . None
attention-deficit/hyperactivity NN None
disorder NN None
( ( None
ADHD NNP None
) ) None
in IN None
patients NNS None
with IN None
autism NN None
spectrum NN None
disorder NN None
( ( None
ASD NNP None
) ) None
97 CD None
patients NNS None
aged VBD None
6 CD None
to TO None
17 CD None
years NNS None
with IN None
ADHD NNP None
and CC None
ASD NNP None
were VBD None
randomly RB None
assigned VBN None
ADHD NNP None
patients NNS None
without IN None
ASD NNP None
. . None
Children NNP None
with IN None
ASD NNP None
; : None
-DOCSTART- -X- N

nonresectable JJ Condition
rectal JJ Condition
cancer NN Condition
: : None
locally RB Condition
advanced JJ Condition
rectal JJ Condition
cancer NN Condition
Patients NNP None
( ( None
N NNP None
= NNP None
207 CD None
) ) None
with IN None
nonresectable JJ None
rectal JJ None
cancer NN None
were VBD None
randomized VBN None
to TO None
preoperative VB None
CRT NNP None
or CC None
RT NNP None
( ( None
2 CD None
Gy NNP None
? . None
25 CD None
? . None
5-fluorouracil/leucovorin JJ None
) ) None
. . None
the DT None
105 CD None
patients NNS None
alive JJ None
in IN None
Norway NNP None
and CC None
Sweden NNP None
after IN None
4 CD None
to TO None
12 CD None
years NNS None
of IN None
follow-up NN None
, , None
78 CD None
( ( None
74 CD None
% NN None
) ) None
responded VBD None
44 CD None
patients NNS None
in IN None
the DT None
CRT NNP None
group NN None
, , None
for IN None
locally RB None
advanced JJ None
rectal JJ None
cancer NN None
. . None
-DOCSTART- -X- N

premenopausal JJ Condition
women NNS Sex
women NNS None
36 CD Size
premenopausal JJ Sex
women NNS Sex
, , None
20 CD Size
of IN Size
whom WP Size
used VBD Size
OC NNP Size
premenopausal NN Size
OC NNP Size
non-OC JJ Size
users NNS Size
-DOCSTART- -X- N

psychotic JJ Condition
depression NN Condition
patients NNS None
with IN None
major JJ Condition
depression NN Condition
. . None
major JJ Condition
depression NN Condition
with IN None
psychotic JJ Condition
features NNS Condition
( ( Condition
MDpsy NNP Condition
) ) Condition
. . None
MDpsy NNP Condition
in IN None
patients NNS None
who WP None
participated VBD None
in IN None
the DT None
STOPD-PD NNP None
study NN None
, , None
a DT None
randomized VBN None
, , None
double-blind JJ None
, , None
clinical JJ None
trial NN None
comparing VBG None
a DT None
subjects NNS None
with IN None
a DT None
history NN None
of IN None
no DT None
prior JJ None
treatment NN None
or CC None
inadequate JJ None
treatment NN None
who WP None
were VBD None
treated VBN None
with IN None
a DT None
combination NN None
of IN None
olanzapine NN None
and CC None
sertraline NN None
. . None
subjects NNS None
who WP None
had VBD None
previously RB None
failed VBN None
to TO None
respond VB None
to TO None
an DT None
antidepressant JJ None
alone NN None
and CC None
who WP None
were VBD None
treated VBN None
with IN None
olanzapine JJ None
monotherapy NN None
. . None
subjects NNS None
who WP None
had VBD None
previously RB None
failed VBN None
to TO None
respond VB None
to TO None
a DT None
combination NN None
of IN None
an DT None
antipsychotic JJ None
and CC None
an DT None
antidepressant NN None
. . None
patients NNS None
with IN None
MDpsy NNP Condition
. . None
-DOCSTART- -X- N

obese JJ Condition
, , None
insulin JJ Condition
resistant NN Condition
, , None
normoglycemic JJ Condition
, , None
hypertensive JJ Condition
men NNS None
. . None
6 CD Size
obese JJ Condition
insulin NN Condition
resistant NN Condition
, , None
normoglycemic JJ Condition
hypertensive JJ Condition
men NNS None
were VBD None
investigated VBN None
( ( None
age NN None
49 CD Age
+/- JJ Age
2 CD Age
years NNS None
, , None
BMI NNP None
27.6 CD None
+/- JJ None
1.2 CD None
, , None
mean JJ None
+/- JJ None
SEM NNP None
) ) None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ Condition
obstructive JJ Condition
pulmonary JJ Condition
disease NN Condition
at IN None
the DT None
stable JJ None
phase NN None
] NNP None
. . None
patients NNS None
with IN None
chronic JJ None
obstructive JJ None
pulmonary JJ None
disease NN None
( ( None
COPD NNP Condition
) ) None
at IN None
the DT None
stable JJ Condition
phase NN Condition
. . None
Thirty-six JJ Size
patients NNS None
with IN None
COPD NNP Condition
patients NNS None
with IN None
COPD NNP None
in IN None
the DT None
stable JJ None
phase NN None
. . None
-DOCSTART- -X- N

We PRP None
used VBD None
data NNS None
from IN None
EORTC NNP None
22881-10882 JJ None
trial NN None
, , None
with IN None
median JJ None
follow-up NN None
of IN None
77.4 CD None
months NNS None
. . None
Patients NNS None
receiving VBG None
BCT NNP Condition
and CC Condition
50Gy CD Condition
whole JJ Condition
breast NN Condition
irradiation NN Condition
were VBD None
randomized VBN None
to TO None
no DT None
boost NN None
and CC None
16Gy CD None
boost NN None
younger JJR Age
patients NNS Age
8.4 CD None
% NN None
of IN None
the DT None
study NN None
population NN None
would MD None
receive VB None
67 CD None
% NN None
of IN None
the DT None
study NN None
population NN None
younger JJR None
patients NNS None
-DOCSTART- -X- N

healthy JJ Condition
young JJ Condition
subjects NNS Condition
Five NNP None
groups NNS None
of IN None
8 CD None
subjects NNS None
each DT None
-DOCSTART- -X- N

paclitaxel-induced JJ None
paclitaxel-induced JJ None
Thirty-two JJ Size
patients NNS None
undergoing VBG None
six CD None
courses NNS None
of IN None
paclitaxel-based JJ None
chemotherapy NN Condition
patients NNS None
with IN None
cancer NN Condition
-DOCSTART- -X- N

Thirteen NNP Size
emmetropic JJ Condition
subjects NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
previously RB None
untreated VBN None
metastatic JJ Condition
colorectal NN Condition
cancer NN Condition
. . None
previously RB None
untreated VBN None
metastatic JJ Condition
colorectal NN Condition
carcinoma NN Condition
( ( Condition
CRC NNP Condition
) ) Condition
patients NNS None
. . None
Between NNP None
May NNP None
1996 CD None
and CC None
July NNP None
1997 CD None
, , None
380 CD Size
patients NNS Size
320 CD None
events NNS None
-DOCSTART- -X- N

extended VBN None
wear NN None
rigid JJ None
gas NN None
permeable JJ None
contact NN None
lenses NNS None
. . None
single-center JJ None
, , None
controlled VBN None
, , None
double-masked JJ None
study NN None
of IN None
39 CD None
RGP NNP None
lens VBZ None
wearers NNS None
. . None
RGP NNP None
lenses VBZ None
-DOCSTART- -X- N

The DT None
Central NNP None
Medical NNP None
Unit NNP None
( ( None
CMU NNP None
) ) None
-- : None
a DT None
freestanding JJ None
primary NN None
care NN None
medical JJ None
clinic NN None
staffed VBN None
by IN None
physicians NNS None
and CC None
nurse JJ None
practitioners NNS None
. . None
Injection NNP None
drug NN None
users NNS None
( ( None
IDUs NNP None
) ) None
seeking VBG None
substance NN Condition
abuse NN Condition
treatment NN None
between IN None
the DT None
ages NNS None
of IN None
18 CD Age
and CC Age
50 CD Age
years NNS Age
who WP None
were VBD None
addicted VBN None
to TO None
opioids NNS None
( ( None
e.g. NN None
heroin NN None
) ) None
and CC None
not RB None
currently RB None
in IN None
drug NN None
treatment NN None
. . None
One CD Size
hundred VBD Size
forty JJ Size
opioid-addicted JJ None
IDUs NNP None
were VBD None
referred VBN None
to TO None
the DT None
medical JJ None
clinic NN None
for IN None
AOD NNP None
. . None
Among IN None
the DT None
125 CD Size
patients NNS None
who WP None
enrolled VBD None
in IN None
the DT None
study NN None
, , None
57 CD Size
selected VBN None
clonidine NN None
and CC None
68 CD Size
selected VBN None
clonidine/naltrexone NN None
. . None
IDUs NNP None
who WP None
are VBP None
addicted VBN Condition
to TO Condition
opioids NNS Condition
. . None
-DOCSTART- -X- N

endometrial JJ None
polyps NNS None
121 CD None
women NNS None
were VBD None
randomly RB None
allocated VBN None
to TO None
polyp VB None
removal NN None
-DOCSTART- -X- N

Dural NNP Condition
Arteriovenous NNP Condition
Fistula NNP Condition
. . Condition
dural JJ None
arteriovenous JJ None
fistula NN None
( ( None
DAVF NNP None
) ) None
in IN None
the DT None
transverse NN None
sinus NN None
. . None
Nine NNP None
patients NNS None
underwent JJ Condition
NCE NNP Condition
4D CD Condition
MRA NNP Condition
All DT None
patients NNS None
also RB None
underwent JJ None
digital JJ None
subtraction NN None
angiography NN None
( ( None
DSA NNP None
) ) None
Among IN None
seven CD None
patients NNS None
with IN None
patent NN None
DAVFs NNP None
, , None
of IN None
three CD None
patients NNS None
with IN None
CVR NNP None
. . None
-DOCSTART- -X- N

Twenty-six NNP Size
patients NNS None
with IN None
knee NN Condition
disorders NNS Condition
requiring VBG Condition
arthroscopy NN Condition
-DOCSTART- -X- N

posterior JJ Condition
uveitis NN Condition
noninfectious JJ Condition
posterior JJ Condition
uveitis NN Condition
. . None
0.59-mg JJ None
FA NNP None
intravitreous JJ None
implant NN None
in IN None
110 CD Size
patients NNS None
and CC None
the DT None
2.1-mg JJ None
FA NNP None
intravitreous JJ None
implant NN None
in IN None
168 CD Size
patients NNS None
. . None
subjects NNS None
with IN None
noninfectious JJ Condition
posterior JJ Condition
uveitis NN Condition
. . None
-DOCSTART- -X- N

Seventy-two JJ Size
oncology NN Condition
nurses NNS Condition
-DOCSTART- -X- N

neonatal JJ Condition
resuscitation NN Condition
protocol-helping JJ Condition
babies NNS Condition
breathe VBP Condition
at IN Condition
birth NN Condition
Nepal NNP None
low JJ None
and CC None
middle JJ None
income NN None
countries NNS None
tertiary JJ None
hospital NN None
in IN None
Nepal NNP None
. . None
skilled JJ None
birth NN None
attendants NNS None
tertiary JJ None
level NN None
maternity NN None
hospital NN None
in IN None
Nepal NNP None
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
cystic JJ Condition
fibrosis NN Condition
children NNS Age
with IN None
advanced JJ Condition
cystic JJ Condition
fibrosis NN Condition
hospitalized VBN Condition
with IN None
respiratory JJ Condition
exacerbations NNS Condition
. . None
Twenty-two JJ Size
children NNS Age
with IN None
severe JJ Condition
CF NNP Condition
and CC None
signs NNS None
of IN None
acute NN Condition
lower JJR Condition
respiratory NN Condition
infection NN Condition
Pseudomonas NNP None
aeruginosa NN None
was VBD None
the DT None
predominant JJ None
sputum NN None
pathogen NN None
in IN None
most JJS None
patients NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
early JJ None
breast NN None
cancer NN None
patients NNS None
with IN None
early JJ None
breast NN None
cancer NN None
-DOCSTART- -X- N

randomized VBN None
trial NN None
with IN None
32 CD Size
male JJ Sex
volunteers NNS None
. . None
-DOCSTART- -X- N

Lead-exposed JJ None
Children NNP None
( ( None
TLC NNP None
) ) None
toddlers NNS None
. . None
young JJ None
children NNS None
Lead-Exposed JJ None
Children NNP None
lead-exposed JJ None
children NNS None
Baltimore NNP None
, , None
Cincinnati NNP None
and CC None
Columbus NNP None
, , None
Newark NNP None
and CC None
Philadelphia NNP None
. . None
Children NNP None
were VBD None
eligible JJ None
for IN None
TLC NNP None
if IN None
they PRP None
were VBD None
between IN None
12 CD None
and CC None
33 CD None
months NNS None
of IN None
age NN None
, , None
had VBD None
a DT None
confirmed VBN None
blood NN None
lead NN None
concentration NN None
between IN None
20 CD None
and CC None
44 CD None
micrograms/dL NN None
and CC None
lived VBD None
in IN None
a DT None
residence NN None
suitable JJ None
for IN None
lead JJ None
dust NN None
reduction NN None
. . None
children NNS None
A DT None
total NN None
of IN None
1854 CD None
children NNS None
were VBD None
evaluated VBN None
and CC None
780 CD None
children NNS None
were VBD None
randomised VBN None
between IN None
August NNP None
1994 CD None
and CC None
January NNP None
1997 CD None
. . None
The DT None
mean JJ None
age NN None
of IN None
randomised JJ None
children NNS None
was VBD None
24 CD None
months NNS None
and CC None
mean VB None
blood NN None
lead JJ None
level NN None
26 CD None
micrograms/dL NN None
. . None
Three-quarters NNS None
were VBD None
African-American JJ None
. . None
Most JJS None
children NNS None
had VBD None
poor JJ None
, , None
single JJ None
mothers NNS None
who WP None
had VBD None
completed VBN None
12 CD None
or CC None
fewer JJR None
years NNS None
of IN None
school NN None
and CC None
who WP None
lived VBD None
in IN None
older JJR None
, , None
poorly RB None
maintained VBD None
residences NNS None
. . None
-DOCSTART- -X- N

autism NN Condition
spectrum NN Condition
disorders NNS Condition
. . None
subjects NNS None
diagnosed VBN None
with IN None
an DT None
autism NN Condition
spectrum NN Condition
disorder NN Condition
( ( Condition
ASD NNP Condition
) ) Condition
subjects NNS None
diagnosed VBN None
with IN None
an DT None
ASD NNP Condition
subjects NNS None
diagnosed VBN None
with IN None
an DT None
ASD NNP Condition
. . None
trial NN None
using VBG None
oral JJ None
lipoceutical JJ None
glutathione NN None
( ( None
n=13 JJ Size
) ) None
or CC None
transdermal JJ None
glutathione NN None
( ( None
n=13 JJ Size
) ) None
in IN None
children NNS Age
, , None
3-13 CD Age
years NNS None
of IN None
age NN None
, , None
with IN None
a DT None
diagnosis NN None
of IN None
an DT None
ASD NNP Condition
. . None
Subjects NNPS None
underwent JJ None
pre- JJ None
and CC None
post-treatment JJ None
lab NN None
testing VBG None
oral JJ None
and CC None
transdermal JJ None
treatment NN None
groups NNS None
subjects NNS None
diagnosed VBN None
with IN None
an DT None
ASD NNP Condition
-DOCSTART- -X- N

palatal-anterior JJ None
superior JJ None
alveolar JJ None
injection NN None
40 CD Size
subjects NNS None
-DOCSTART- -X- N

ventricular JJ Condition
arrhythmias NN Condition
. . None
German JJ None
speaking NN None
countries NNS None
. . None
20 CD Size
patients NNS None
with IN None
ventricular JJ Condition
arrhythmias NNS Condition
( ( None
VA NNP Condition
) ) None
of IN None
various JJ None
origin NN None
. . None
-DOCSTART- -X- N

after IN Condition
end-to-side JJ Condition
neurorrhaphy NN Condition
. . Condition
after IN None
end-to-side JJ None
neurorrhaphy NN None
Four CD None
groups NNS None
( ( None
n=4 JJ None
for IN None
each DT None
group NN None
) ) None
were VBD None
used VBN None
: : None
end-to-end JJ None
coaptation NN None
( ( None
six CD None
months NNS None
postoperatively RB None
) ) None
, , None
end-to-side JJ None
coaptation NN None
( ( None
four CD None
months NNS None
and CC None
six CD None
months NNS None
postoperatively RB None
) ) None
and CC None
normal JJ None
control NN None
. . None
-DOCSTART- -X- N

Half NN None
of IN None
the DT None
participants NNS None
were VBD None
randomly RB None
assigned VBN None
to TO None
the DT None
conscious-processing-condition NN None
( ( None
i.e. FW None
consciously RB None
thinking VBG None
about IN None
the DT None
information NN None
they PRP None
read VBP None
in IN None
the DT None
case NN None
description NN None
) ) None
, , None
the DT None
other JJ None
half NN None
to TO None
the DT None
unconscious-processing JJ None
condition NN None
( ( None
i.e. FW None
performing VBG None
an DT None
unrelated JJ None
distracter NN None
task NN None
) ) None
. . None
-DOCSTART- -X- N

biliary JJ None
and CC None
gastric JJ None
surgery NN None
. . None
80 CD Size
patients NNS None
undergoing JJ None
biliary JJ None
or CC None
gastric JJ None
surgery NN None
. . None
biliary JJ None
and CC None
gastric JJ None
surgery NN None
. . None
-DOCSTART- -X- N

acute JJ None
epicondylitis NN Condition
. . None
pain NN None
of IN None
medial NN None
or CC None
lateral JJ None
epicondylitis NN Condition
( ( None
tennis IN Condition
elbow NN Condition
) ) None
. . None
patients NNS None
with IN None
medial JJ None
or CC None
lateral JJ None
elbow NN None
epicondylitis NN Condition
. . None
199 CD None
patients NNS None
with IN None
elbow JJ None
epicondylitis NN Condition
-DOCSTART- -X- N

those DT None
with IN None
recent JJ None
ischemic JJ None
stroke NN None
: : None
50 CD None
patients NNS None
with IN None
acute JJ None
ischemic JJ None
stroke NN None
( ( None
17 CD None
, , None
17 CD None
, , None
and CC None
16 CD None
in IN None
the DT None
high JJ None
, , None
low JJ None
, , None
and CC None
placebo NN None
groups NNS None
, , None
respectively RB None
) ) None
Mean NNP None
( ( None
+/-SD NNP None
) ) None
age NN None
was VBD None
70 CD None
( ( None
+/-13 JJ None
) ) None
years NNS None
. . None
-DOCSTART- -X- N

241 CD Size
consecutive JJ None
patients NNS None
undergoing VBG None
elective JJ None
coronary JJ Condition
artery NN Condition
bypass NN Condition
grafting VBG None
were VBD None
randomly RB None
allocated VBN None
into IN None
three CD None
groups NNS None
. . None
Group1 NNP Size
( ( Size
n=77 NN Size
) ) Size
Group NNP Size
2 CD Size
( ( Size
n=72 NN Size
) ) Size
Group NNP Size
3 CD Size
( ( Size
n=92 NN Size
) ) Size
-DOCSTART- -X- N

patients NNS None
with IN None
Stage NNP None
IV NNP None
lung NN None
and CC None
colorectal JJ None
cancer NN None
: : None
patients NNS None
with IN None
cancer NN None
those DT None
with IN None
Stage NNP None
IV NNP None
disease NN None
Sixty-six JJ None
adults NNS None
with IN None
Stage NNP None
IV NNP None
lung NN None
or CC None
colorectal JJ None
cancer NN None
were VBD None
randomized VBN None
RESULTS NNP None
Three CD None
participants NNS None
dropped VBD None
out RP None
and CC None
seven CD None
died VBD None
of IN None
patients NNS None
with IN None
Stage NNP None
IV NNP None
lung NN None
and CC None
colorectal JJ None
cancer NN None
. . None
-DOCSTART- -X- N

intrahepatic JJ Condition
cholestasis NN Condition
. . Condition
multicenter NN None
cholestatic JJ None
patients NNS None
with IN None
chronic JJ None
liver NN None
disease NN None
. . None
220 CD None
inpatients NNS None
( ( None
26 CD None
% NN None
chronic JJ None
active JJ None
hepatitis NN None
, , None
68 CD None
% NN None
cirrhosis NN None
, , None
6 CD None
% NN None
primary JJ None
biliary JJ None
cirrhosis NN None
) ) None
with IN None
stable JJ None
( ( None
1 CD None
month NN None
or CC None
more JJR None
) ) None
at IN None
least JJS None
twofold JJ None
increases NNS None
in IN None
serum JJ None
total NN None
and CC None
conjugated VBD None
bilirubin NN None
and CC None
alkaline JJ None
phosphatase NN None
volunteered VBD None
for IN None
the DT None
trial NN None
. . None
-DOCSTART- -X- N

menopausal NN None
symptoms NNS None
in IN None
women NNS None
treated VBN None
with IN None
soy JJ None
isoflavones NNS None
. . None
women NNS None
who WP None
do VBP None
and CC None
who WP None
do VBP None
not RB None
produce VB None
equol NN None
96 CD None
healthy JJ None
menopausal NN None
women NNS None
. . None
-DOCSTART- -X- N

tutors NNS None
of IN None
children NNS Age
with IN None
autism NN Condition
. . None
trained JJ None
tutors NNS None
. . None
novice JJ None
tutors NNS None
of IN None
children NNS Age
with IN None
autism NN Condition
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
head NN None
and CC None
neck NN None
cancer NN None
: : None
124 CD None
patients NNS None
with IN None
histologically RB None
proven VBN None
locally RB None
advanced JJ None
non-nasopharyngeal JJ None
head NN None
and CC None
neck NN None
cancer NN None
( ( None
HNC NNP None
) ) None
patients NNS None
with IN None
locally RB None
advanced JJ None
HNC NNP None
-DOCSTART- -X- N

pregnant JJ Condition
Pakistani NNP Condition
women NNS Sex
in IN None
Oslo NNP None
. . None
pregnant JJ Condition
Pakistani NNP None
immigrant NN None
women NNS Sex
group NN None
of IN None
Norwegian JJ Condition
women NNS Sex
. . None
women NNS Sex
in IN None
the DT None
18th CD Condition
week NN Condition
of IN Condition
pregnancy NN Condition
. . None
Women NNP Sex
referred VBD None
to TO None
routine VB None
ultrasound JJ None
examination NN None
at IN None
Aker NNP None
and CC None
Ullev?l NNP None
Hospitals NNP None
in IN None
Norway NNP None
. . None
SUBJECTS NNP None
All NNP None
( ( None
58 CD None
) ) None
healthy JJ None
women NNS None
of IN None
Pakistani NNP None
origin NN None
referred VBD None
from IN None
October NNP None
of IN None
1991 CD None
to TO None
January NNP None
of IN None
1992 CD None
were VBD None
included VBN None
, , None
of IN None
whom WP None
38 CD None
( ( None
66 CD None
% NN None
) ) None
participated VBD None
. . None
Forty-five JJ None
Norwegian JJ None
women NNS None
were VBD None
randomly RB None
included VBN None
in IN None
the DT None
same JJ None
period NN None
and CC None
38 CD None
( ( None
84 CD None
% NN None
) ) None
of IN None
these DT None
women NNS None
participated VBD None
. . None
-DOCSTART- -X- N

nonvalvular JJ None
atrial JJ None
fibrillation NN None
. . None
patients NNS None
with IN None
atrial JJ None
fibrillation NN None
double-blind JJ None
trial NN None
, , None
we PRP None
randomly VBP None
assigned VBD None
14,264 CD None
patients NNS None
with IN None
nonvalvular JJ None
atrial JJ None
fibrillation NN None
who WP None
were VBD None
at IN None
increased VBN None
risk NN None
for IN None
stroke NN None
-DOCSTART- -X- N

asthmatic JJ None
children NNS None
: : None
asthmatic JJ None
children NNS None
. . None
paediatric JJ None
hospital NN None
located VBN None
on IN None
northeast NN None
of IN None
Brazil NNP None
with IN None
42 CD None
asthmatic JJ None
children NNS None
aged VBN None
? . None
36 CD None
months NNS None
. . None
The DT None
children NNS None
were VBD None
children NNS None
who WP None
received VBD None
the DT None
intervention NN None
proposed VBN None
-DOCSTART- -X- N

adolescents NNS Age
. . None
Two CD Size
hundred CD Size
and CC Size
thirty-seven JJ Size
students NNS None
, , None
drawn NN None
from IN None
six CD None
homeroom NN None
grade NN None
eight CD None
classes NNS None
-DOCSTART- -X- N

hypotensive JJ Condition
eye NN Condition
surgery NN Condition
. . None
Thirty NN Size
patients NNS None
undergoing VBG None
elective JJ Condition
eye NN Condition
surgery NN Condition
-DOCSTART- -X- N

boys NNS Sex
with IN None
fragile JJ Condition
x JJ Condition
syndrome NN Condition
: : None
boys NNS Sex
with IN None
fragile JJ Condition
X NNP Condition
syndrome NN Condition
. . None
Twenty NNP Size
boys VBZ Age
with IN None
fragile JJ Condition
X NNP Condition
syndrome NN Condition
-DOCSTART- -X- N

non-insulin JJ Condition
dependent NN Condition
diabetes VBZ Condition
mellitus NN Condition
30 CD None
non-insulin JJ None
dependent NN None
( ( None
Type NNP None
II NNP None
) ) None
diabetic JJ None
subjects NNS None
Type NNP None
II NNP None
diabetic JJ None
-DOCSTART- -X- N

skeletally RB Condition
matured VBN Condition
non-syndromal JJ Condition
patients NNS Condition
with IN Condition
transverse JJ Condition
maxillary JJ Condition
hypoplasia NN Condition
. . Condition
23 CD Size
bone-borne JJ None
and CC None
19 CD Size
tooth-borne JJ None
patients NNS None
were VBD None
analyzed VBN None
. . None
-DOCSTART- -X- N

chronic JJ Condition
tension-type JJ Condition
headache NN Condition
chronic JJ Condition
tension-type JJ Condition
headache NN Condition
( ( Condition
CTTH NNP Condition
) ) Condition
. . None
Two CD Size
hundred VBD Size
and CC Size
eighty-eight JJ Size
cases NNS Size
CTTH NNP Condition
-DOCSTART- -X- N

patients NNS None
with IN None
major JJ None
depressive JJ None
disorder NN None
( ( None
MDD NNP None
) ) None
. . None
15 CD None
MDD NNP None
patients NNS None
and CC None
14 CD None
age-matched JJ None
controls NNS None
. . None
MDD NNP None
patients NNS None
and CC None
age-matched JJ None
controls NNS None
MDD NNP None
patients NNS None
-DOCSTART- -X- N

schizophrenia NN None
: : None
in IN None
schizophrenia NN None
. . None
in IN None
schizophrenia NN None
patients NNS None
with IN None
negative JJ None
symptoms NNS None
who WP None
were VBD None
receiving VBG None
second JJ None
generation NN None
antipsychotics NNS None
. . None
Forty-three JJ None
subjects NNS None
-DOCSTART- -X- N

FIGO NNP Condition
stage NN Condition
I PRP Condition
endometrial JJ Condition
carcinoma NN Condition
with IN None
myometrial JJ Condition
invasion NN Condition
. . None
FIGO NNP Condition
stage NN Condition
I PRP Condition
endometrial JJ Condition
carcinoma NN Condition
with IN None
myometrial JJ Condition
invasion NN Condition
patients NNS None
62 CD Size
patients NNS None
who WP None
entered VBD None
the DT None
study NN None
Five CD None
patients NNS None
had VBD None
a DT None
relapse NN None
: : None
FIGO NNP Condition
stage NN Condition
I PRP Condition
endometrial JJ Condition
carcinoma NN Condition
with IN None
myometrial JJ Condition
invasion NN Condition
. . None
-DOCSTART- -X- N

periodontal JJ None
furcation NN None
pockets NNS None
46 CD None
upper JJ None
and CC None
lower JJR None
molars NNS None
with IN None
furcation NN None
grade NN None
II NNP None
involvement NN None
16 CD None
patients NNS None
with IN None
periodontal JJ None
disease NN None
-DOCSTART- -X- N

middle JJ Condition
ear NN Condition
surgery NN Condition
. . None
30 CD Size
patients NNS None
middle VB None
ear JJ None
surgery NN None
using VBG None
induced JJ None
hypotension NN Condition
to TO None
a DT None
mean JJ None
arterial JJ None
pressure NN None
of IN None
55 CD None
mm NN None
Hg NNP None
. . None
middle JJ None
ear NN None
surgery NN None
-DOCSTART- -X- N

rural JJ Condition
family NN Condition
medicine NN None
: : None
December NNP None
2008 CD None
and CC None
April NNP None
2011 CD None
to TO None
improve VB None
CRC NNP None
screening VBG None
in IN None
16 CD None
rural JJ None
family NN None
physician NN None
offices NNS None
. . None
Subjects NNS Condition
due JJ None
for IN None
CRC NNP Condition
screening VBG Condition
This DT None
study NN None
enrolled VBD None
743 CD Size
patients NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
inflammatory JJ Condition
bowel NN Condition
disease NN Condition
Fifty-six JJ Size
outpatients NNS None
Thirty-nine JJ Size
subjects NNS None
completed VBD None
the DT None
study NN None
IBD NNP None
patients NNS None
-DOCSTART- -X- N

Forty NNP Age
women NNS Age
, , Age
aged VBN Age
26-40 CD Age
years NNS Age
gastric JJ None
contents NNS None
and CC None
pH NN None
before IN None
general JJ None
anaesthesia NN None
. . None
-DOCSTART- -X- N

gastroesophageal NN Condition
reflux NN Condition
( ( Condition
GER NNP Condition
) ) Condition
patients NNS Condition
undergoing VBG Condition
thoracotomy NN Condition
in IN Condition
the DT Condition
lateral JJ Condition
position NN Condition
80 CD Size
adult NN None
patients NNS None
undergoing VBG None
thoracotomy NN None
. . None
Patients NNS None
at IN None
high JJ None
risk NN None
of IN None
GER NNP None
were VBD None
excluded VBN None
from IN None
the DT None
study NN None
. . None
Patients NNS None
undergoing JJ None
thoracotomy NNS None
-DOCSTART- -X- N

Children NNP None
younger JJR None
than IN None
16 CD None
years NNS None
and CC None
experiencing VBG None
moderate JJ None
to TO None
severe VB None
blunt NN None
head JJ None
injury NN None
group NN None
. . None
One CD None
hundred VBD None
two CD None
patients NNS None
were VBD None
enrolled VBN None
, , None
with IN None
a DT None
median JJ None
age NN None
of IN None
6.1 CD None
years NNS None
. . None
Sixty-eight JJ None
percent NN None
were VBD None
boys NNS None
. . None
2 CD None
treatment NN None
groups NNS None
3 CD None
( ( None
7 CD None
% NN None
) ) None
of IN None
46 CD Size
patients NNS None
3 CD None
( ( None
5 CD None
% NN None
) ) None
of IN None
56 CD Size
patients NNS None
groups NNS None
( ( None
seizure JJ None
rate NN None
increased VBN None
by IN None
1.5 CD None
% NN None
in IN None
the DT None
phenytoin NN None
group NN None
) ) None
children NNS None
may MD None
be VB None
much RB None
-DOCSTART- -X- N

sepsis-related JJ None
acute JJ None
kidney NN None
injury NN None
patients NNS None
. . None
sepsis-related JJ None
acute JJ None
kidney NN None
injury NN None
( ( None
AKI NNP None
) ) None
. . None
Twenty-eight JJ None
sepsis-related JJ None
AKI NNP None
patients NNS None
were VBD None
included VBN None
and CC None
randomized VBN None
into IN None
online JJ None
HDF NNP None
and CC None
high-flux JJ None
HD NNP None
. . None
state NN None
in IN None
sepsis-related JJ None
AKI NNP None
. . None
-DOCSTART- -X- N

individuals NNS None
with IN None
serious JJ Condition
mental JJ Condition
illness NN Condition
( ( None
SMI NNP Condition
) ) None
receiving VBG None
antipsychotic JJ None
drug NN None
therapy NN None
. . None
individuals NNS None
with IN None
SMI NNP None
over IN None
8 CD None
weeks NNS None
. . None
30 CD None
individuals NNS None
( ( None
BMI NNP None
? . None
28 CD None
kg/m NN None
( ( None
2 CD None
) ) None
) ) None
were VBD None
for IN None
individuals NNS None
with IN None
SMI NNP None
and CC None
patients NNS None
taking VBG None
antipsychotic JJ None
medications NNS None
; : None
financial JJ None
-DOCSTART- -X- N

retinopathy NN Condition
of IN Condition
prematurity NN Condition
( ( None
ROP NNP None
) ) None
40 CD Size
preterm JJ None
infants NNS Age
undergoing VBG None
ROP NNP Condition
screening NN None
. . None
neonatal JJ None
intensive JJ None
units NNS None
for IN None
infants NNS None
undergoing VBG None
routine JJ None
ROP NNP None
screening VBG None
exams NNS None
. . None
RESULT NNP None
Forty NNP None
preterm NN None
infants NNS None
were VBD None
included VBN None
in IN None
the DT None
study NN None
. . None
in IN None
preterm JJ None
infants NNS None
of IN None
-DOCSTART- -X- N

Fifteen NNP Size
atopic NN Condition
asthmatics NNS Condition
were VBD None
randomized VBN None
in IN None
double-blind NN None
, , None
cross-over JJ None
fashion NN None
to TO None
receive VB None
for IN None
1 CD None
week NN None
either CC None
levocetirizine JJ None
5 CD None
mg NN None
or CC None
placebo NN None
. . None
-DOCSTART- -X- N

disability NN None
: : None
vocational JJ None
rehabilitation NN None
( ( None
VR NNP None
) ) None
clients NNS None
. . None
people NNS None
with IN None
disabilities NNS None
. . None
A NNP None
total NN None
of IN None
297 CD None
VR NNP None
clients NNS None
participated VBD None
in IN None
a DT None
randomized JJ None
trial NN None
VR NNP None
clients NNS None
with IN None
higher JJR None
rates NNS None
of IN None
secondary JJ None
health NN None
conditions NNS None
-DOCSTART- -X- N

39 CD None
patients NNS None
being VBG None
treated VBN None
with IN None
high JJ None
flux JJ None
dialysis NN None
. . None
patients NNS None
being VBG None
maintained VBN None
on IN None
high JJ None
flux JJ None
dialysis NN None
. . None
-DOCSTART- -X- N

polyarteritis NN Condition
nodosa NN Condition
and CC None
Churg-Strauss JJ Condition
syndrome NN Condition
: : None
polyarteritis NN Condition
nodosa NN Condition
( ( None
PAN NNP Condition
) ) None
and CC None
Churg-Strauss JJ Condition
syndrome NN Condition
( ( None
CSS NNP Condition
) ) None
236 CD Size
patients NNS None
71 CD Size
patients NNS None
( ( None
1981-1983 JJ None
) ) None
compared VBN None
the DT None
association NN None
of IN None
CYC NNP None
with IN None
corticosteroids NNS None
( ( None
CS NNP None
) ) None
and CC None
PE NNP None
to TO None
CS NNP None
and CC None
PE NNP None
, , None
in IN None
order NN None
to TO None
evaluate VB None
the DT None
efficacy NN None
of IN None
CYC NNP None
given VBN None
as IN None
the DT None
first-line JJ None
treatment NN None
to TO None
control VB None
disease NN None
activity NN None
and CC None
subsequent JJ None
survival NN None
of IN None
PAN NNP None
and CC None
CSS NNP None
patients NNS None
. . None
December NNP None
1983 CD None
and CC None
December NNP None
1988 CD None
at IN None
patients NNS None
without IN Condition
HBV NNP Condition
markers NNS Condition
and CC None
the DT None
second JJ None
at IN None
patients NNS None
with IN Condition
HBV NNP Condition
markers NNS Condition
. . None
78 CD Size
patients NNS None
without IN Condition
HBV NNP Condition
markers NNS Condition
33 CD Size
patients NNS None
with IN None
PAN NNP Condition
related VBD None
to TO None
HBV NNP Condition
56 CD Size
patients NNS None
and CC None
addressed VBD None
to TO None
severe VB Condition
PAN NNP Condition
without IN Condition
HBV NNP Condition
markers NNS Condition
or CC None
CSS NNP None
PAN NNP Condition
related VBD None
to TO None
HBV NNP None
-DOCSTART- -X- N

persistent JJ Condition
corneal JJ Condition
epithelial JJ Condition
defects NNS Condition
. . Condition
persistent JJ Condition
corneal JJ Condition
epithelial JJ Condition
defects NNS Condition
. . Condition
60 CD None
eyes NNS None
of IN None
59 CD None
patients NNS None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
arterial JJ Condition
occlusive JJ Condition
disease NN Condition
of IN Condition
the DT Condition
lower JJR Condition
extremities NNS Condition
] VBP Condition
patients NNS None
with IN None
advanced JJ None
atherosclerosis NN None
manifested VBN None
by IN None
arterial JJ None
occlusion NN None
in IN None
the DT None
lower JJR None
extremities NNS None
without IN None
a DT None
baseline NN None
blood NN None
lipid JJ None
disorder NN None
statin NN None
treatment NN None
comparable JJ None
control NN None
group NN None
without IN None
statins VBZ None
patients NNS None
with IN None
arterial JJ None
occlusion NN None
of IN None
the DT None
lower JJR None
extremities NNS None
with IN None
baseline NN None
dyslipidaemia NN None
-DOCSTART- -X- N

patients NNS None
. . None
Emergency NNP None
Department NNP None
, , None
University NNP None
Hospital NNP None
of IN None
Wales NNP None
. . None
A DT None
total NN None
of IN None
302 CD None
patients NNS None
aged VBN None
over IN None
15 CD None
years NNS None
. . None
-DOCSTART- -X- N

Neurosurgical JJ None
unit NN None
and CC None
haematology NN None
ward NN None
of IN None
university NN None
hospital NN None
. . None
100 CD Size
neurosurgical JJ None
patients NNS None
and CC None
40 CD Size
patients NNS None
with IN None
leukaemia NNS Condition
who WP None
required VBD None
chemotherapy NN None
. . None
-DOCSTART- -X- N

advanced JJ None
infectious JJ None
keratitis NN None
with IN None
corneal JJ None
melting NN None
. . None
Forty NNP None
eyes NNS None
from IN None
40 CD Size
patients NNS None
with IN None
advanced JJ Condition
infectious JJ Condition
keratitis NN Condition
and CC Condition
coexisting VBG Condition
corneal NN Condition
melting NN Condition
. . None
Twenty-one CD Size
patients NNS Size
( ( None
21 CD None
eyes NNS None
) ) None
underwent JJ None
PACK-CXL JJ Condition
treatment NN Condition
in IN Condition
addition NN Condition
to TO Condition
antimicrobial JJ Condition
therapy NN Condition
. . None
The DT Size
control NN Size
group NN Size
consisted VBD Size
of IN Size
19 CD Size
patients NNS Size
( ( None
19 CD None
eyes NNS None
) ) None
-DOCSTART- -X- N

laryngeal JJ None
cancer NN None
. . None
120 CD None
newly RB None
identified VBN None
cases NNS None
of IN None
laryngeal JJ None
squamous JJ None
cell NN None
carcinoma NN None
who WP None
were VBD None
registered VBN None
at IN None
10 CD None
participating VBG None
institutions NNS None
between IN None
November NNP None
1984 CD None
and CC None
October NNP None
1989 CD None
. . None
Of IN None
the DT None
initial JJ None
120 CD None
cases NNS None
, , None
11 CD None
cases NNS None
were VBD None
disqualified VBN None
( ( None
3 CD None
cases NNS None
of IN None
double JJ None
cancer NN None
and CC None
8 CD None
of IN None
incomplete JJ None
primary JJ None
therapy NN None
) ) None
and CC None
the DT None
remaining VBG None
109 CD None
were VBD None
used VBN None
for IN None
evaluation NN None
. . None
-DOCSTART- -X- N

patients NNS None
requiring VBG None
mechanical JJ None
ventilation NN None
postacute NN None
care NN None
a DT None
mean JJ None
length NN None
of IN None
stay NN None
of IN None
25 CD None
days NNS None
or CC None
more JJR None
. . None
patients NNS None
requiring VBG None
mechanical JJ None
ventilation NN None
patient NN None
receiving VBG None
mechanical JJ None
ventilation NN None
hospital JJ None
discharge NN None
and CC None
billing NN None
data NNS None
from IN None
the DT None
2005 CD None
Nationwide NNP None
Inpatient NNP None
Sample NNP None
for IN None
54 CD None
686 CD None
Medicare NNP None
beneficiaries NNS None
admitted VBD None
to TO None
US NNP None
community NN None
hospitals NNS None
who WP None
met VBD None
the DT None
study NN None
's POS None
eligibility NN None
criteria NNS None
. . None
-DOCSTART- -X- N

acute JJ Condition
migraine NN Condition
attacks NNS Condition
. . None
multicenter NN None
296 CD Size
patients NNS None
fulfilling VBG None
the DT None
International NNP None
Headache NNP None
Society NNP None
diagnostic JJ None
criteria NNS None
for IN None
migraine NN Condition
were VBD None
enrolled VBN None
. . None
-DOCSTART- -X- N

young JJ Age
people NNS None
with IN None
familial JJ Condition
adenomatous JJ Condition
polyposis NN Condition
. . None
colorectal JJ Condition
cancer NN Condition
Familial NNP Condition
adenomatous JJ Condition
polyposis NN Condition
( ( None
FAP NNP Condition
) ) None
FAP NNP Condition
patients NNS None
from IN None
10 CD Age
to TO Age
21 CD Age
years NNS Age
of IN None
age NN None
. . None
total NN None
of IN None
206 CD None
randomized JJ None
FAP NNP None
patients NNS None
commenced VBD None
intervention NN None
, , None
of IN None
whom WP None
133 CD None
had VBD None
at IN None
least JJS None
one CD None
follow-up JJ None
endoscopy NN None
and CC None
were VBD None
therefore RB None
included VBN None
in IN None
the DT None
primary JJ None
analysis NN None
. . None
-DOCSTART- -X- N

pediatric JJ None
obesity NN Condition
. . None
Obese JJ Condition
children NNS None
-DOCSTART- -X- N

85 CD None
patients NNS None
with IN None
advanced JJ None
ovarian JJ None
carcinomas NN None
cases NNS None
of IN None
advanced JJ None
tumors NNS None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
advanced JJ Condition
cancer NN Condition
: : Condition
advanced JJ None
cancer NN None
. . None
Patients NNP None
with IN None
advanced JJ None
cancer NN None
with IN None
a DT None
fatigue NN None
score NN None
of IN None
? . None
4 CD None
out IN None
of IN None
10 CD None
on IN None
the DT None
Edmonton NNP None
Symptom NNP None
Assessment NNP None
Scale NNP None
( ( None
ESAS NNP None
) ) None
were VBD None
RESULTS VB None
One CD None
hundred JJ None
forty-one JJ None
patients NNS None
were VBD None
evaluable JJ None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
ocular JJ Condition
burns NNS Condition
] FW None
patients NNS None
with IN None
ocular JJ Condition
burns NNS Condition
. . None
Fifty-five JJ Size
cases NNS None
of IN None
patients NNS None
with IN None
ocular JJ Condition
burns NNS Condition
( ( None
in IN None
88 CD Size
eyes NNS None
) ) None
49 CD None
eyes NNS None
were VBD None
transplanted VBN None
patients NNS None
with IN None
ocular JJ Condition
burns NNS Condition
. . None
-DOCSTART- -X- N

healthy JJ None
volunteers NNS None
. . None
healthy JJ None
volunteers NNS None
. . None
A DT None
university NN None
medical JJ None
center NN None
. . None
Seven NNP Size
healthy JJ None
men NNS Sex
and CC None
women NNS Sex
. . None
Six NNP None
subjects NNS None
( ( None
86 CD None
% NN None
) ) None
completed VBD None
the DT None
study NN None
; : None
one CD None
was VBD None
removed VBN None
due JJ None
to TO None
the DT None
development NN None
of IN None
a DT None
rash NN None
. . None
-DOCSTART- -X- N

15 CD Condition
and CC Condition
19 CD Condition
healthy JJ Condition
women NNS Condition
, , Condition
respectively RB Condition
. . Condition
-DOCSTART- -X- N

hirsutism NN None
. . None
hirsutism NN None
. . None
Women NNP None
with IN None
hirsutism NN None
, , None
as IN None
defined VBN None
by IN None
a DT None
minimum JJ None
Ferriman-Gallwey JJ None
score NN None
of IN None
10 CD None
47 CD None
women NNS None
enrolled VBD None
hirsutism NN None
. . None
-DOCSTART- -X- N

junior JJ None
high JJ None
school NN None
students NNS None
. . None
Fifty-nine JJ Size
junior JJ None
high JJ None
school NN None
students NNS None
who WP None
volunteered VBD None
to TO None
participate VB None
in IN None
treatment NN None
for IN None
interpersonal JJ None
anxiety NN Condition
( ( None
RET NNP None
) ) None
, , None
rational-emotive JJ None
therapy NN None
with IN None
imagery NN None
( ( None
REI NNP None
) ) None
, , None
relationship-oriented JJ None
counseling NN None
( ( None
ROC NNP None
) ) None
, , None
and CC None
waiting-list JJ None
control NN None
( ( None
WLC NNP None
) ) None
groups NNS None
. . None
-DOCSTART- -X- N

children NNS None
with IN None
autism NN None
. . None
Children NNP None
with IN None
autism NN None
young JJ None
children NNS None
with IN None
autism NN None
21 CD None
young JJ None
children NNS None
with IN None
autism NN None
. . None
-DOCSTART- -X- N

cancer NN None
patients NNS None
. . None
cancer NN None
patients NNS None
with IN None
dysfunctional JJ None
fear NN None
of IN None
progression NN None
. . None
cancer NN None
patients NNS None
receiving VBG None
inpatient JJ None
rehabilitation NN None
. . None
A DT None
total NN None
of IN None
174 CD None
patients NNS None
were VBD None
included VBN None
in IN None
the DT None
economic JJ None
evaluation NN None
. . None
cancer NN None
patients NNS None
with IN None
high JJ None
levels NNS None
of IN None
anxiety NN None
. . None
-DOCSTART- -X- N

contemporary JJ Condition
coronary JJ Condition
stent NN Condition
trials NNS Condition
: : Condition
The DT None
Resolute NNP None
'All-Comers NNS None
' POS None
stent JJ None
trial NN None
. . None
after IN None
the DT None
assigned JJ None
percutaneous JJ None
coronary JJ None
intervention NN None
or CC None
at IN None
discharge NN None
. . None
2121/2292 CD None
patients NNS None
( ( None
92.5 CD None
% NN None
) ) None
had VBD None
an DT None
analysable JJ None
dataset NN None
for IN None
either DT None
biomarker NN None
. . None
890/2121 CD None
patients NNS None
267/890 CD None
patients NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
metabolic JJ None
syndrome JJ None
receiving VBG None
low-dose JJ None
aspirin NN None
. . None
Patients NNS None
who WP None
had VBD None
metabolic JJ None
syndrome NN None
-DOCSTART- -X- N

chronic JJ Condition
central JJ Condition
serous JJ Condition
chorioretinopathy NN Condition
: : Condition
Thirty-four JJ None
eyes NNS None
of IN None
32 CD None
patients NNS None
with IN None
chronic JJ None
CSC NNP None
with IN None
> NNP None
6 CD None
months NNS None
' POS None
duration NN None
of IN None
symptoms NNS None
or CC None
recurrent JJ None
CSC NNP None
were VBD None
randomly RB None
placed VBN None
into IN None
the DT None
low-fluence JJ None
PDT NNP None
group NN None
( ( None
n JJ None
= NNP None
18 CD None
) ) None
or CC None
the DT None
ranibizumab NN None
group NN None
( ( None
n JJ None
= NNP None
16 CD None
) ) None
. . None
16 CD None
eyes NNS None
2 CD None
eyes NNS None
-DOCSTART- -X- N

postmenopausal NN None
patients NNS None
with IN None
metastatic JJ Condition
breast NN Condition
carcinoma NN Condition
: : None
Breast NNP Condition
cancer NN Condition
patients NNS None
with IN Condition
prior JJ Condition
response NN Condition
to TO Condition
endocrine VB Condition
therapy NN Condition
post NN None
menopausal NN None
patients NNS None
who WP None
had VBD None
disease NN None
progression NN None
after IN None
receiving VBG None
antiestrogen NN None
therapy NN None
either DT None
for IN None
metastatic JJ None
disease NN None
or CC None
as IN None
adjuvant JJ None
therapy NN None
. . None
In IN None
2 CD None
multiinstitutional JJ None
prospective JJ None
trials NNS None
, , None
683 CD Size
postmenopausal NN None
patients NNS None
postmenopausal NN None
patients NNS None
with IN None
metastatic JJ None
breast NN None
carcinoma NN None
-DOCSTART- -X- N

patients NNS None
with IN None
rheumatoid JJ None
arthritis NN None
patients NNS None
with IN None
rheumatoid JJ None
arthritis NN None
( ( None
RA NNP None
) ) None
38 CD None
patients NNS None
with IN None
RA NNP None
and CC None
20 CD None
controls NNS None
-DOCSTART- -X- N

endometriosis-related JJ None
infertility NN None
patients NNS None
endometriosis NN None
( ( None
EMs NNP None
) ) None
-related VBD None
infertility NN None
patients NNS None
130 CD None
EMs-related JJ None
infertility NN None
patients NNS None
of IN None
blood NN None
stasis NN None
and CC None
toxin NN None
accumulation NN None
syndrome NN None
diagnosed VBD None
and CC None
treated VBN None
by IN None
laparoscopic NN None
surgery NN None
-DOCSTART- -X- N

acute JJ Condition
neck NN Condition
pain NN Condition
: : None
patients NNS None
with IN None
acute JJ Condition
NP NNP Condition
( ( None
n JJ None
= NNP None
72 CD Size
) ) None
were VBD None
treatment NN None
of IN None
acute JJ None
neck NN None
pain NN None
. . None
The DT None
neck NN None
pain NN None
and CC None
improved VBN None
-DOCSTART- -X- N

finishing VBG None
steers NNS None
. . None
A DT None
total NN None
of IN None
4,178 CD None
steers NNS None
( ( None
mean JJ None
initial JJ None
BW NNP None
= NN None
403.9 CD None
? . None
16.04 CD None
kg NN None
) ) None
were VBD None
used VBN None
to TO None
test VB None
-DOCSTART- -X- N

pre-core NN None
mutant NN None
chronic JJ None
hepatitis NN None
B NNP None
infection NN None
pre-core JJ None
mutant NN None
of IN None
hepatitis NN None
B NNP None
virus NN None
( ( None
HBV NNP None
) ) None
infection NN None
Mediterranean NNP None
Europe NNP None
and CC None
in IN None
Asia NNP None
. . None
pre-core JJ None
mutant NN None
HBV NNP None
patients NNS None
with IN None
this DT None
variant NN None
patients NNS Condition
with IN Condition
pre-core JJ Condition
mutant NN Condition
hepatitis NN Condition
B NNP Condition
. . None
patients NNS Condition
with IN Condition
chronic JJ Condition
hepatitis NN Condition
B NNP Condition
, , Condition
including VBG Condition
those DT Condition
with IN Condition
pre-core JJ Condition
mutant JJ Condition
HBV NNP Condition
infection NN Condition
. . None
-DOCSTART- -X- N

acute JJ Condition
myeloid NN Condition
leukemia NN Condition
. . None
Fifty-four CD Size
patients NNS None
treated VBN None
with IN None
daunorubicin NN Condition
, , None
cytosine JJ Condition
arabinoside NN Condition
and CC None
thioquanine NN Condition
for IN None
acute JJ Condition
myeloid NN Condition
leukemia NN Condition
patients NNS None
undergoing JJ None
remission NN Condition
induction NN Condition
therapy NN Condition
for IN None
acute JJ Condition
myeloid NN Condition
leukemia NN Condition
. . None
-DOCSTART- -X- N

vasculogenic JJ Condition
sexual JJ Condition
dysfunction NN Condition
men NNS None
with IN None
mild NN None
to TO None
moderate VB None
penile IN None
vascular JJ None
insufficiency NN None
. . None
Sexual JJ None
Dysfunction NNP None
Clinic NNP None
at IN None
VA NNP None
Medical NNP None
Center NNP None
, , None
Sepulveda NNP None
, , None
CA NNP None
. . None
Convenience NNP None
sample NN None
of IN None
couples NNS None
. . None
patient JJ None
partner NN None
impotent JJ None
men NNS None
men NNS None
with IN None
the DT None
pelvic JJ None
steal JJ None
syndrome NN None
; : None
erectile JJ None
dysfunction NN None
in IN None
patients NNS None
with IN None
mild JJ None
to TO None
moderate VB None
penile IN None
vascular JJ None
disease NN None
. . None
-DOCSTART- -X- N

third JJ Condition
stage NN Condition
of IN Condition
labor NN Condition
. . None
Three CD Size
hundred VBD Size
and CC Size
fifty-five JJ Size
women NNS Size
third JJ Condition
stage NN Condition
of IN Condition
labor NN Condition
-DOCSTART- -X- N

90 CD None
patients NNS None
( ( None
78 CD None
women NNS None
; : None
median JJ None
age NN None
, , None
52 CD None
yr NN None
; : None
range NN None
, , None
22-83 JJ None
) ) None
with IN None
a DT None
nontoxic JJ None
nodular JJ None
goiter NN None
( ( None
median JJ None
size NN None
, , None
63 CD None
ml NN None
; : None
range NN None
, , None
25-379 JJ None
ml NN None
) ) None
were VBD None
randomized VBN None
-DOCSTART- -X- N

great JJ Condition
saphenous JJ Condition
varicose NN Condition
veins NNS Condition
. . None
Consecutive JJ None
patients NNS None
with IN None
symptomatic JJ Condition
varicose NN Condition
veins NNS Condition
due JJ Condition
to TO Condition
isolated JJ Condition
great JJ Condition
saphenous JJ Condition
vein NN Condition
( ( Condition
GSV NNP Condition
) ) Condition
incompetence NN Condition
and CC None
suitable JJ None
for IN None
RFA NNP None
GSV NNP None
in IN None
all DT None
47 CD Condition
patients NNS None
. . None
patients NNS None
with IN None
great JJ Condition
saphenous JJ Condition
varicose NN Condition
veins NNS Condition
. . None
-DOCSTART- -X- N

recurrent NN None
chronic JJ None
hyperplastic JJ None
sinusitis NN None
with IN None
nasal JJ None
polyposis NN None
. . None
One CD None
hundred JJ None
seventy NN None
patients NNS None
with IN None
bilateral JJ None
obstructive CD None
or CC None
minimally RB None
obstructive JJ None
chronic JJ None
hyperplastic JJ None
sinusitis NN None
with IN None
nasal JJ None
polyposis NN None
. . None
All DT None
patients NNS None
were VBD None
surgically RB None
treated VBN None
in IN None
the DT None
ENT NNP None
Department NNP None
, , None
University NNP None
of IN None
Siena NNP None
Medical NNP None
School NNP None
. . None
One CD None
month NN None
after IN None
surgery NN None
1 CD None
patients NNS None
patients NNS None
treated VBN None
with IN None
furosemide NN None
or CC None
mometasone NN None
patients NNS None
who WP None
did VBD None
not RB None
receive VB None
any DT None
treatment NN None
chronic JJ None
hyperplastic JJ None
sinusitis NN None
with IN None
nasal JJ None
polyposis NN None
. . None
-DOCSTART- -X- N

pulmonary JJ Condition
vascular NN Condition
bed NN Condition
in IN None
man NN Sex
. . None
oedema NNS Condition
in IN None
patients NNS None
with IN None
hypoxic JJ Condition
cor NN Condition
pulmonale NN Condition
. . None
Eight NNP Size
normal JJ None
volunteers NNS None
were VBD None
studied VBN None
-DOCSTART- -X- N

pituitary JJ None
region NN None
lesions NNS None
Twelve CD None
patients NNS None
with IN None
known VBN None
or CC None
suspected VBN None
pituitary JJ None
lesions NNS None
Six CD None
of IN None
the DT None
patients NNS None
-DOCSTART- -X- N

child NN Condition
's POS Condition
autism NN Condition
] NN Condition
children NNS None
's POS None
autism NN None
. . None
Forty NNP None
autistic JJ None
children NNS None
receiving VBG None
rehabilitation NN None
training NN None
child NN Condition
's POS Condition
autism NN Condition
. . Condition
-DOCSTART- -X- N

patients NNS None
with IN None
advanced JJ Condition
gastric JJ Condition
cancer NN Condition
: : None
patients NNS None
with IN None
non-resectable JJ None
gastric JJ None
and CC None
gastro-oesophageal JJ Condition
adenocarcinoma NN Condition
. . None
Three CD Size
hundred VBD Size
and CC Size
sixty-nine JJ Size
patients NNS None
with IN None
histological JJ None
proof NN None
of IN None
adenocarcinoma NN Condition
, , None
who WP None
had VBD None
received VBN None
no RB None
more RBR None
than IN None
a DT None
single JJ None
regimen NN None
of IN None
5-fluorouracil-based JJ None
chemotherapy NN None
pre-defined JJ None
sub-group NN None
of IN None
123 CD Size
patients NNS None
who WP None
had VBD None
received VBN None
prior RB None
chemotherapy NN None
patients NNS None
who WP None
had VBD None
previously RB None
received VBN None
chemotherapy NN None
. . None
-DOCSTART- -X- N

shoulder NN None
arthroscopy NN None
] NNP None
Thirty-two JJ None
patients NNS None
with IN None
impingement JJ None
syndrome JJ None
underwent JJ None
subacromial JJ None
decompression NN None
in IN None
the DT None
course NN None
of IN None
arthroscopic JJ None
shoulder NN None
surgery NN None
. . None
-DOCSTART- -X- N

Three CD Size
individuals NNS None
with IN None
mental JJ Condition
retardation NN Condition
exhibited VBD None
stimulus JJ None
overselectivity NN None
in IN None
a DT None
delayed JJ None
matching-to-sample NN None
task NN None
-DOCSTART- -X- N

term NN None
neonates NNS Age
: : None
81 CD Size
full-term JJ None
neonates NNS None
, , None
up RB None
to TO None
4 CD Age
wk NN Age
of IN None
postnatal JJ None
age NN None
, , None
who WP None
needed VBD None
venepuncture NN None
for IN None
blood NN None
investigations NNS None
. . None
pain VB Condition
in IN None
term NN None
neonates NNS None
. . None
-DOCSTART- -X- N

advanced JJ Condition
nasopharyngeal JJ Condition
carcinoma NN Condition
Nasopharyngeal NNP Condition
carcinoma NN Condition
( ( Condition
NPC NNP Condition
) ) Condition
patients NNS None
with IN None
advanced JJ Condition
NPC NNP Condition
From NNP None
December NNP None
1993 CD None
to TO None
April NNP None
1999 CD None
, , None
284 CD Size
patients NNS None
with IN None
1992 CD None
American NNP None
Joint NNP None
Committee NNP None
on IN None
Cancer NNP Condition
stage NN Condition
III NNP Condition
to TO Condition
IV NNP Condition
( ( Condition
M0 NNP Condition
) ) Condition
NPC NNP Condition
patients NNS None
with IN None
advanced JJ Condition
NPC NNP Condition
-DOCSTART- -X- N

luminal NN Condition
A NNP Condition
breast NN Condition
cancer NN Condition
subgroup NN None
two CD None
primary JJ None
breast NN None
cancer NN None
cohorts NNS None
( ( None
n JJ None
= NN None
144 CD None
and CC None
n JJ None
= NNP None
564 CD None
) ) None
and CC None
mRNA JJ None
expression NN None
of IN None
YAP1 NNP None
was VBD None
evaluated VBN None
in IN None
a DT None
gene NN None
expression NN None
dataset NN None
( ( None
n JJ None
= NN None
1107 CD None
) ) None
ER+ NNP None
( ( None
Estrogen NNP None
Receptor NNP None
? . None
positive JJ None
) ) None
subgroup NN None
the DT None
ER- NNP None
( ( None
Estrogen NNP None
Receptor NNP None
? . None
negative JJ None
) ) None
subgroup NN None
YAP1 NNP None
aggressive JJ None
luminal NN None
A NNP None
breast NN None
cancer NN None
subgroup NN None
, , None
-DOCSTART- -X- N

patients NNS None
with IN None
pedunculated JJ Condition
and CC Condition
small JJ Condition
sessile NN Condition
tubular NN Condition
and CC Condition
tubulovillous JJ Condition
adenomas NN Condition
. . None
After IN None
initial JJ Condition
colonoscopic NN Condition
polypectomy NN Condition
patients NNS None
age NN None
above IN Age
60 CD Age
years NNS Age
and CC None
male JJ Sex
gender NN None
-DOCSTART- -X- N

males NNS Sex
with IN None
latent JJ Condition
myofascial JJ Condition
trigger NN Condition
points NNS Condition
. . None
Thirty NNP Size
physically RB Condition
active JJ Condition
males NNS None
with IN None
tight JJ Condition
hamstrings NNS Condition
and CC Condition
at IN Condition
least JJS Condition
one CD Condition
latent NN Condition
MTrP NNP Condition
on IN Condition
muscles NNS Condition
innervated VBN Condition
by IN Condition
the DT Condition
lumbosacral JJ Condition
, , Condition
sciatic JJ Condition
, , Condition
tibial JJ Condition
and CC Condition
common JJ Condition
peroneal JJ Condition
nerves NNS Condition
. . None
young JJ Age
and CC None
physically RB Condition
active JJ Condition
males NNS None
-DOCSTART- -X- N

feline JJ None
chlamydophilosis NN None
. . None
feline JJ None
chlamydophilosis NN None
cats NNS None
within IN None
an DT None
affected JJ None
group NN None
chlamydia NN None
( ( None
Chlamydophila NNP None
felis RB None
) ) None
infection NN None
in IN None
cats NNS None
. . None
five CD None
cats NNS None
treated VBN None
. . None
-DOCSTART- -X- N

obsessive-compulsive JJ None
disorder NN None
: : None
Twelve CD None
patients NNS None
were VBD None
given VBN None
fluoxetine NN None
( ( None
20 CD None
mg/d NN None
) ) None
plus CC None
zinc NN None
( ( None
440 CD None
mg/d NN None
) ) None
and CC None
11 CD None
patients NNS None
were VBD None
given VBN None
fluoxetine JJ None
plus CC None
placebo NN None
for IN None
8 CD None
wk NNS None
. . None
-DOCSTART- -X- N

junior JJ Age
high JJ Age
school NN Age
girls NNS Sex
' POS None
volleyball NN None
performance NN None
. . None
72 CD Size
seventh-grade JJ Age
girls NNS Sex
' POS None
-DOCSTART- -X- N

Eleven JJ None
patients NNS None
with IN None
12 CD None
traumatic JJ None
femur NN None
fractures NNS None
-DOCSTART- -X- N

ruptured JJ Condition
cerebral JJ Condition
aneurysms NNS Condition
. . None
acute NN Condition
( ( Condition
< JJ Condition
72 CD Condition
hours NNS Condition
) ) Condition
aneurysmal VBP Condition
subarachnoid JJ Condition
hemorrhage NN Condition
( ( Condition
SAH NNP Condition
) ) Condition
. . None
One CD Size
hundred VBD Size
nine CD Size
consecutive JJ Condition
patients NNS Condition
were VBD None
randomly RB Condition
assigned VBN Condition
One CD None
year NN None
postoperatively RB None
, , None
43/41 CD None
( ( None
surgical/endovascular JJ None
) ) None
patients NNS None
-DOCSTART- -X- N

patients NNS None
after IN Condition
myocardial JJ Condition
infarction NN Condition
male NN None
patients NNS None
after IN None
myocardial JJ None
infarction NN None
( ( None
MI NNP None
) ) None
aged VBD Age
between IN Age
38 CD Age
and CC Age
61 CD Age
. . None
the DT None
training NN Size
group NN Size
( ( Size
n JJ Size
= NNP Size
21 CD Size
) ) Size
, , None
staying VBG None
in IN None
Cardiac NNP None
Rehabilitation NNP None
Department NNP None
and CC None
the DT None
control NN Size
group NN Size
( ( Size
n JJ Size
= NNP Size
11 CD Size
) ) Size
The DT None
training NN None
group NN None
MI NNP None
patients NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
overactive JJ Condition
bladder NN Condition
associated VBN Condition
with IN Condition
benign JJ Condition
prostatic JJ Condition
hyperplasia NN Condition
: : None
total NN None
of IN None
100 CD Size
patients NNS None
with IN None
benign JJ Condition
prostatic JJ Condition
hyperplasia NN Condition
( ( Condition
BPH NNP Condition
) ) Condition
and CC Condition
overactive JJ Condition
bladder NN Condition
( ( Condition
OAB NNP Condition
) ) Condition
symptoms NNS None
( ( None
BPH/OAB NNP None
) ) None
, , None
enrolled VBN None
between IN None
June NNP None
2006 CD None
to TO None
March NNP None
2008 CD None
-DOCSTART- -X- N

middle-aged JJ None
and CC None
older JJR None
adults NNS None
. . None
decreased JJ Condition
central JJ Condition
arterial JJ Condition
compliance NN Condition
in IN None
young JJ None
men NNS None
. . None
older JJR None
adults NNS None
with IN None
reduced JJ Condition
baseline NN Condition
arterial JJ Condition
compliance NN Condition
. . None
middle-aged JJ None
and CC None
older JJR None
adults NNS None
. . None
37 CD Size
healthy JJ Condition
, , None
sedentary JJ Condition
men NNS Sex
and CC None
women NNS Sex
( ( None
52+/-2 JJ Age
years NNS Age
) ) None
performed VBD None
13 CD None
weeks NNS None
of IN None
ST NNP None
( ( None
n=13 NN None
) ) None
, , None
ST+aerobic NNP None
exercise NN None
( ( None
n=12 JJ None
) ) None
or CC None
stretching VBG None
exercises NNS None
Participants NNS None
were VBD None
rigorously RB None
screened VBN None
for IN None
cardiovascular JJ Condition
disease NN Condition
and CC None
underwent JJ None
pre-post JJ None
testing NN None
for IN None
carotid JJ Condition
arterial JJ Condition
compliance NN Condition
( ( None
via IN None
simultaneous JJ None
ultrasound NN None
and CC None
applanation NN None
tonometry NN None
) ) None
, , None
carotid-femoral JJ None
pulse NN None
wave NN None
velocity NN None
, , None
plasma JJ None
endothelin-1 NN None
and CC None
angiotensin NN None
II NNP None
concentrations NNS None
and CC None
carotid JJ None
artery NN None
vasoreactivity NN None
( ( None
cold JJ None
pressor NN None
test NN None
) ) None
middle-aged JJ None
and CC None
older JJR None
adults NNS None
. . None
-DOCSTART- -X- N

age-associated JJ Condition
memory NN Condition
impairment NN Condition
. . None
age-associated JJ None
memory NN None
impairment NN None
( ( None
AAMI NNP None
) ) None
patients NNS None
. . None
AAMI NNP None
patients NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
liver JJ None
metastases NNS None
from IN None
colorectal JJ None
cancer NN None
150 CD None
patients NNS None
will MD None
be VB None
included VBN None
and CC None
randomized VBN None
intraoperatively RB None
after IN None
surgical JJ None
exploration NN None
just RB None
prior RB None
to TO None
resection NN None
. . None
-DOCSTART- -X- N

patients NNS None
suffering VBG None
from IN None
severe JJ None
acute NN None
pancreatitis NN None
] NNP None
patients NNS None
with IN None
severe JJ None
acute NN None
pancreatitis NN None
( ( None
ASP NNP None
) ) None
. . None
Seventy NNP None
SAP NNP None
cases NNS None
admitted VBD None
from IN None
January NNP None
2005 CD None
to TO None
October NNP None
2012 CD None
were VBD None
randomly RB None
assigned VBN None
parenteral JJ None
nutrition NN None
( ( None
PN NNP None
) ) None
group NN None
( ( None
n=22 NN None
) ) None
, , None
EN NNP None
group NN None
( ( None
n=25 CC None
) ) None
and CC None
bifidobacterium NN None
added VBD None
EN NNP None
( ( None
P+EN NNP None
) ) None
group NN None
( ( None
n=23 RB None
) ) None
. . None
-DOCSTART- -X- N

recurrent NN None
gastric JJ Condition
carcinoma NN Condition
. . None
cancer NN Condition
patients NNS None
a DT None
group NN None
of IN None
patients NNS None
with IN None
recurrent JJ None
gastric JJ None
cancer NN None
1 CD None
) ) None
Intradermal NNP None
group NN None
( ( None
ID NNP None
Group NNP None
) ) None
, , None
42 CD Size
patients NNS None
given VBN None
an DT None
intradermal JJ None
injections NNS None
of IN None
OK-432 NNP None
. . None
2 CD None
) ) None
Intramuscular NNP None
group NN None
( ( None
IM NNP None
Group NNP None
) ) None
, , None
40 CD Size
patients NNS None
given VBN None
an DT None
intramuscular JJ None
injections NNS None
of IN None
OK-432 NNP None
. . None
3 CD None
) ) None
Control NNP None
group NN None
( ( None
C NNP None
Group NNP None
) ) None
, , None
39 CD Size
patients NNS None
not RB None
given VBN None
injections NNS None
. . None
-DOCSTART- -X- N

primary JJ None
and CC None
repeat VB None
lower JJR None
extremity NN None
amputation NN None
: : None
African JJ None
Americans NNPS None
Randomly NNP None
selected VBD None
medical JJ None
records NNS None
were VBD None
reviewed VBN None
for IN None
248 CD None
African JJ None
American NNP None
, , None
30 CD None
Hispanic NNP None
, , None
and CC None
235 CD None
white JJ None
or CC None
other-race JJ None
patients NNS None
undergoing VBG Condition
above- JJ Condition
or CC Condition
below-knee JJ Condition
amputation NN Condition
between IN None
1995 CD None
and CC None
2003 CD None
at IN None
three CD None
Chicago NNP None
teaching VBG None
hospitals NNS None
. . None
African JJ None
American JJ None
amputees NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
symptomatic JJ Condition
paroxysmal JJ Condition
atrial JJ Condition
fibrillation NN Condition
and/or NN Condition
flutter NN Condition
monitored VBD None
with IN None
trans-telephonic JJ None
electrocardiography NN None
: : None
patients NNS None
with IN None
paroxysmal JJ Condition
atrial JJ Condition
fibrillation NN Condition
or CC Condition
flutter NN Condition
( ( Condition
PAF/PAFL NNP Condition
) ) Condition
experiencing VBG None
2 CD None
or CC None
more JJR None
episodes NNS None
of IN None
symptomatic JJ Condition
PAF/PAFL NNP Condition
during IN None
a DT None
28-day JJ None
observation NN None
period NN None
to TO None
determine VB None
the DT None
dose-response JJ None
effect NN None
and CC None
safety NN None
of IN None
flecainide NN None
. . None
143 CD Size
patients NNS None
at IN None
30 CD None
centers NNS None
123 CD Size
patients NNS None
patients NNS None
with IN None
PAF/PAFL NNP Condition
. . None
-DOCSTART- -X- N

intestinal JJ None
absorption NN None
of IN None
fructose NN None
25 CD Size
healthy JJ None
controls NNS None
-DOCSTART- -X- N

sublingual JJ Condition
and CC Condition
vaginal JJ Condition
misoprostol NN Condition
in IN Condition
second JJ Condition
trimester NN Condition
termination NN Condition
of IN Condition
pregnancy NN Condition
. . Condition
second JJ None
trimester NN None
medical JJ None
abortion NN None
. . None
Tertiary JJ None
referral JJ None
unit NN None
and CC None
a DT None
teaching JJ None
hospital NN None
. . None
Two CD None
hundred VBD None
and CC None
twenty-four JJ None
women NNS None
at IN None
12 CD None
to TO None
20 CD None
weeks NNS None
of IN None
gestation NN None
. . None
-DOCSTART- -X- N

advanced JJ Condition
head NN Condition
and CC Condition
neck NN Condition
cancer NN Condition
patients NNS Condition
. . Condition
first-line JJ None
treatment NN None
of IN None
patients NNS None
with IN None
advanced JJ None
head NN None
and CC None
neck NN None
cancer NN None
. . None
successive JJ None
patients NNS None
with IN None
unresectable JJ None
grade NN None
I/II NNP None
head NN None
and CC None
neck NN None
cancer NN None
who WP None
were VBD None
not RB None
suitable JJ None
for IN None
irradiation NN None
treatment NN None
( ( None
T NNP None
any DT None
N3 NNP None
or CC None
T4 NNP None
N2C NNP None
) ) None
, , None
metastatic JJ None
or CC None
previously RB None
irradiated VBN None
. . None
A DT Condition
total NN Condition
of IN Condition
170 CD Condition
patients NNS Condition
were VBD Condition
included VBN Condition
in IN Condition
the DT Condition
study NN Condition
. . Condition
head NN None
and CC None
neck NN None
cancer NN None
patients NNS None
. . None
-DOCSTART- -X- N

type NN None
2 CD None
diabetic JJ None
patients NNS None
: : None
45 CD None
patients NNS None
with IN None
type JJ None
2 CD None
diabetes NNS None
mellitus FW None
( ( None
DM NNP None
) ) None
Forty-five JJ None
patients NNS None
with IN None
type JJ None
2 CD None
DM NNP None
initially RB None
were VBD None
compared VBN None
with IN None
15 CD None
healthy JJ None
controls NNS None
matched VBN None
for IN None
age NN None
and CC None
sex NN None
. . None
type JJ None
2 CD None
DM NNP None
healthy JJ None
individuals NNS None
-DOCSTART- -X- N

acute JJ Condition
ischaemic JJ Condition
stroke NN Condition
. . None
within IN None
the DT None
first JJ None
6 CD None
hours NNS None
of IN None
acute JJ Condition
ischaemic JJ Condition
stroke NN Condition
. . None
Patients NNS None
fulfilling VBG None
the DT None
selection NN None
criteria NNS None
Fourteen CD Size
patients NNS None
were VBD None
given VBN None
IVF NNP None
and CC None
13 CD Size
IAF NNP None
. . None
27 CD Size
patients NNS None
had VBD None
been VBN None
included VBN None
because IN None
of IN None
the DT None
mortality NN None
rate NN None
. . None
-DOCSTART- -X- N

beef NN None
heifers NNS None
fed VBP None
high- JJ None
or CC None
low-starch JJ None
diets NNS None
for IN None
different JJ None
periods NNS None
before IN None
breeding VBG None
. . None
Spring-born JJ None
Hereford NNP None
x NNP None
Angus NNP None
heifers NNS None
( ( None
n JJ None
= NNP None
206 CD None
) ) None
heifers NNS None
( ( None
205 CD None
+/- JJ None
5 CD None
kg NN None
; : None
n CC None
= VB None
68 CD None
) ) None
grazing NN None
dormant JJ None
native JJ None
pasture NN None
Heifers NNS None
HS NNP None
and CC None
LS NNP None
heifers NNS None
HS NNP None
and CC None
LS NNP None
heifers NNS None
HS NNP None
and CC None
LS NNP None
heifers NNS None
heifers NNS None
-DOCSTART- -X- N

minimally RB None
verbal JJ None
children NNS None
with IN None
autism NN None
: : None
3 CD None
to TO None
5 CD None
year NN None
old JJ None
, , None
minimally RB None
verbal JJ None
children NNS None
with IN None
autism NN None
who WP None
were VBD None
attending VBG None
a DT None
non-public JJ None
preschool NN None
. . None
deficits NNS None
in IN None
minimally RB None
verbal JJ None
children NNS None
with IN None
ASD NNP None
-DOCSTART- -X- N

smoking VBG Condition
cessation NN Condition
total NN None
of IN None
1,524 CD Size
smokers NNS None
( ( None
649 CD Size
men NNS Sex
and CC None
875 CD Size
women NNS Sex
) ) None
of IN None
average JJ Age
age NN Age
45.1 CD Age
years NNS Age
-DOCSTART- -X- N

progressive JJ None
, , None
metastatic JJ None
, , None
castration-resistant JJ None
prostate NN None
cancer NN None
. . None
metastatic JJ None
castration-resistant JJ None
prostate NN None
cancer NN None
( ( None
mCRPC NN None
) ) None
. . None
Men NNP None
with IN None
progressive JJ None
mCRPC NN None
after IN None
docetaxel-based JJ None
chemotherapy NN None
873 CD None
patients NNS None
were VBD None
randomly RB None
assigned VBN None
-DOCSTART- -X- N

persons NNS None
with IN None
osteoarthritis NN Condition
249 CD Size
adults NNS Age
from IN None
Washington NNP None
State NNP None
aged VBD Age
55 CD Age
to TO Age
75 CD Age
with IN None
a DT None
doctor-confirmed JJ None
diagnosis NN None
of IN None
osteoarthritis NN Condition
-DOCSTART- -X- N

patients NNS None
undergoing VBG None
elective JJ Condition
craniotomy NN Condition
for IN None
supratentorial JJ Condition
mass NN Condition
lesions NNS Condition
. . None
Ninety-one JJ Size
patients NNS None
-DOCSTART- -X- N

hepatocellular JJ Condition
carcinomas NN Condition
. . None
85 CD Size
HCC NNP None
patients NNS None
after IN None
transcatheter JJ None
arterial JJ None
chemoembolization NN None
and CC None
radiofrequency NN None
ablation NN None
therapy NN None
were VBD None
randomized VBN None
to TO None
immunotherapy VB None
group NN None
and CC None
no DT None
adjuvant JJ None
therapy NN None
group NN None
. . None
All DT None
patients NNS None
were VBD None
screened VBN None
by IN None
computed JJ None
tomography NN None
every DT None
2 CD None
months NNS None
to TO None
observe VB None
the DT None
tumor NN None
recurrent NN None
conditions NNS None
. . None
HCC NNP None
patients NNS None
-DOCSTART- -X- N

haemorrhoids NNS Condition
. . None
89 CD Size
consecutive JJ None
patients NNS None
with IN None
haemorrhoids NNS Condition
. . None
-DOCSTART- -X- N

stroke NN Condition
patients NNS None
16 CD Size
consecutive JJ None
patients NNS None
( ( None
median JJ None
age NN None
58.5 CD None
years NNS None
, , None
range VB None
40-83 JJ None
) ) None
Crying VBG Condition
history NN Condition
was VBD None
determined VBN None
from IN None
semistructured VBN None
interviews NNS None
and CC None
from IN None
diaries NNS None
kept VBN None
by IN None
the DT None
patients NNS None
. . None
13 CD Size
patients NNS None
in IN None
whom WP None
frequency NN None
of IN None
crying NN Condition
-DOCSTART- -X- N

patients NNS None
with IN None
multivessel JJ None
disease NN None
. . None
patients NNS None
with IN None
coronary JJ None
artery NN None
disease NN None
. . None
patients NNS None
with IN None
multivessel JJ None
disease NN None
suitable JJ None
for IN None
treatment NN None
with IN None
either DT None
procedure NN None
Patients NNPS None
with IN None
multivessel JJ None
disease NN None
were VBD None
randomly RB None
assigned VBN None
to TO None
an DT None
initial JJ None
treatment NN None
strategy NN None
of IN None
CABG NNP None
( ( None
n JJ None
= NNP None
914 CD None
) ) None
or CC None
PTCA NNP None
( ( None
n JJ None
= NNP None
915 CD None
) ) None
Among IN None
diabetic JJ None
patients NNS None
who WP None
were VBD None
being VBG None
treated VBN None
with IN None
insulin NN None
or CC None
oral JJ None
hypoglycemic JJ None
agents NNS None
at IN None
base NN None
line NN None
patients NNS None
with IN None
multivessel JJ None
disease NN None
treated JJ None
diabetics NNS None
-DOCSTART- -X- N

autistic JJ Condition
children NNS Condition
. . Condition
autistic JJ None
children NNS None
who WP None
underwent VBP None
intrathecal JJ None
transplantation NN None
of IN None
stem NN None
cells NNS None
by IN None
lumbar NN None
puncture NN None
. . None
Forty NNP None
autistic JJ None
children NNS None
aged VBN None
2-12 CD None
, , None
who WP None
were VBD None
scheduled VBN None
for IN None
stem NN None
cell NN None
transplantation NN None
via IN None
lumbar NN None
puncture NN None
under IN None
anesthesia NN None
autistic JJ None
children NNS None
. . None
-DOCSTART- -X- N

acute NN Condition
otitis NN Condition
media NNS Condition
in IN Condition
children NNS Condition
under IN Condition
2 CD Condition
years NNS Condition
of IN Condition
age NN Condition
. . Condition
children NNS None
younger JJR None
than IN None
2 CD None
years NNS None
of IN None
age NN None
with IN None
acute JJ None
otitis NN None
media NNS None
. . None
291 CD None
children NNS None
6 CD None
to TO None
23 CD None
months NNS None
of IN None
age NN None
, , None
with IN None
acute JJ None
otitis NN None
media NNS None
diagnosed VBN None
with IN None
the DT None
use NN None
of IN None
stringent NN None
criteria NNS None
children NNS None
6 CD None
to TO None
23 CD None
months NNS None
of IN None
age NN None
with IN None
acute JJ None
otitis NN None
media NNS None
-DOCSTART- -X- N

tuberculosis NN None
in IN None
an DT None
immigrant JJ None
population NN None
. . None
Immigrants NNS Condition
with IN None
LTBI NNP Condition
. . None
in IN None
Barcelona NNP None
, , None
Spain NNP None
, , None
from IN None
April NNP None
2001 CD None
to TO None
April NNP None
2005 CD None
. . None
590 CD Size
subjects NNS None
enrolled VBN None
-DOCSTART- -X- N

heart NN None
failure NN None
patients NNS None
. . None
heart NN None
failure NN None
patients NNS None
patients NNS None
surviving VBG None
myocardial JJ None
infarction NN None
. . None
humans NNS None
. . None
Patients NNPS None
with IN None
post-myocardial JJ None
infarction NN None
left VBD None
ventricular JJ None
dysfunction NN None
patients NNS None
with IN None
stable JJ None
congestive JJ None
heart NN None
failure NN None
. . None
-DOCSTART- -X- N

youth NN Age
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
: : None
youth NN Age
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
( ( Condition
ASD NNP Condition
) ) Condition
youth NN Age
with IN None
ASD NNP Condition
between IN None
the DT None
ages NNS None
of IN None
18-21 JJ Age
years NNS None
of IN None
age NN None
. . None
24 CD Size
( ( None
87.5 CD None
% NN None
) ) None
treatment NN None
group NN None
participants NNS None
16 CD Size
( ( None
6.25 CD None
% NN None
) ) None
of IN None
control NN None
group NN None
participants NNS None
-DOCSTART- -X- N

students NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
. . None
Forty-two JJ None
students NNS None
with IN None
autism NN None
, , None
varying VBG None
in IN None
age NN None
and CC None
expressive JJ None
communication NN None
ability NN None
, , None
were VBD None
randomly RB None
assigned VBN None
to TO None
the DT None
experimental JJ None
conditions NNS None
. . None
-DOCSTART- -X- N

iron-deficient JJ None
patients NNS None
undergoing VBG None
bilateral JJ None
total JJ None
knee NN None
replacement NN None
arthroplasty NN None
. . None
iron-deficient JJ None
patients NNS None
. . None
METHODS NNP None
A NNP None
total NN None
of IN None
108 CD None
iron-deficient JJ None
patients NNS None
were VBD None
requirements NNS None
in IN None
iron-deficient JJ None
patients NNS None
. . None
-DOCSTART- -X- N

optic JJ Condition
neuritis NN Condition
: : None
optic JJ Condition
neuritis NN Condition
Subjects NNPS None
in IN None
the DT None
Optic NNP None
Neuritis NNP None
Treatment NNP None
Trial NNP None
, , None
who WP None
were VBD None
enrolled VBN None
between IN None
July NNP None
1 CD None
, , None
1988 CD None
, , None
and CC None
June NNP None
30 CD None
, , None
1991 CD None
, , None
were VBD None
followed VBN None
up RP None
prospectively RB None
for IN None
15 CD None
years NNS None
, , None
with IN None
the DT None
final JJ None
examination NN None
in IN None
2006 CD None
. . None
Neurologic NNP None
and CC None
ophthalmologic JJ None
examinations NNS None
at IN None
13 CD None
clinical JJ None
sites NNS None
. . None
Three CD Size
hundred VBD Size
eighty-nine JJ Size
subjects NNS None
with IN None
acute JJ Condition
optic JJ Condition
neuritis NN Condition
. . None
-DOCSTART- -X- N

oncologic JJ None
patients NNS None
cancer NN None
patients NNS None
. . None
cancer NN None
patients NNS None
with IN None
pain NN None
. . None
240 CD None
patients NNS None
with IN None
diagnosed JJ None
malignancy NN None
and CC None
pain NN None
> VBP None
3 CD None
days NNS None
and CC None
average JJ None
pain NN None
> JJ None
or= NN None
3/10 CD None
will MD None
participate VB None
in IN None
a DT None
cluster NN None
randomized VBN None
trial NN None
on IN None
18 CD None
wards NNS None
in IN None
2 CD None
German JJ None
university NN None
hospitals NNS None
. . None
-DOCSTART- -X- N

southern JJ None
Ghana NNP None
. . None
acellular JJ None
diphtheria/pertussis/tetanus NN Condition
( ( None
ADPT NNP None
) ) None
in IN None
infants NNS Age
was VBD None
conducted VBN None
in IN None
a DT None
peri-urban JJ None
community NN None
( ( None
Ashaiman NNP None
) ) None
in IN None
southern JJ None
Ghana NNP None
. . None
pertussis NN Condition
in IN None
children NNS Age
under IN None
5 CD Age
years NNS None
of IN None
age NN None
in IN None
the DT None
study NN None
area NN None
were VBD None
also RB None
determined VBN None
. . None
2 CD Size
% NN Size
( ( None
8/399 CD None
) ) None
to TO None
2.3 CD Size
% NN Size
( ( None
9/385 CD None
) ) None
of IN None
the DT None
acellular JJ None
vaccine NN None
recipients NNS None
as IN None
against IN None
31 CD Size
% NN Size
( ( None
122/394 CD None
) ) None
in IN None
the DT None
whole-cell JJ None
vaccine NN None
group NN None
. . None
-DOCSTART- -X- N

gastrointestinal JJ Condition
cancer NN Condition
: : Condition
Southeastern NNP None
Cancer NNP None
Study NNP None
Group NNP None
experience NN None
, , None
1979 CD None
to TO None
1983 CD None
. . None
gastrointestinal JJ None
cancer NN None
from IN None
1979 CD None
to TO None
1983 CD None
at IN None
30 CD None
member NN None
institutions NNS None
of IN None
the DT None
Southeastern NNP None
Cancer NNP None
Study NNP None
Group NNP None
( ( None
SECSG NNP None
) ) None
. . None
1,087 CD None
patients NNS None
. . None
America NNP None
. . None
-DOCSTART- -X- N

acute JJ Condition
myocardial JJ Condition
infarction NN Condition
: : Condition
A DT None
total NN None
of IN None
269 CD Size
patients NNS None
, , None
who WP None
presented VBD None
with IN None
symptoms NNS None
and CC None
electrocardiographic JJ None
signs NNS None
suggesting VBG None
acute JJ Condition
myocardial JJ Condition
infarction NN Condition
were VBD None
randomized VBN None
to TO None
acute VB None
intravenous JJ None
and CC None
subsequent JJ None
oral JJ None
therapy NN None
with IN None
propranolol NN None
( ( None
n JJ None
= NNP None
134 CD None
) ) None
or CC None
placebo NN None
( ( None
n JJ None
= NNP None
135 CD None
) ) None
. . None
patients NNS None
with IN None
acute JJ Condition
myocardial JJ Condition
infarction NN Condition
-DOCSTART- -X- N

population NN None
based VBN None
Swedish JJ None
sample NN None
. . None
postpartum NN None
41 CD None
women NNS None
identified VBN None
as IN None
depressed JJ None
-DOCSTART- -X- N

patients NNS None
with IN None
normal-tension JJ Condition
glaucoma NN Condition
with IN None
low-normal JJ Condition
intraocular JJ Condition
pressure NN Condition
. . None
patients NNS None
with IN None
normal-tension JJ Condition
glaucoma NN Condition
( ( None
NTG NNP None
) ) None
with IN None
low-normal JJ None
intraocular JJ None
pressure NN None
( ( None
IOP NNP None
) ) None
. . None
Fifty-two JJ Size
patients NNS None
with IN None
NTG NNP Condition
( ( None
average JJ None
age NN None
57.7 CD Age
years NNS None
) ) None
with IN None
an DT None
IOP NNP None
that WDT None
was VBD None
consistently RB None
less JJR None
than IN None
15 CD None
mmHg NNS None
were VBD None
randomly RB None
assigned VBN None
to TO None
patients NNS None
with IN None
NTG NNP Condition
who WP None
have VBP None
low-normal JJ None
IOP NNP None
. . None
-DOCSTART- -X- N

for IN None
teens NNS None
with IN None
ASD NNP None
. . None
parent-assisted JJ None
social JJ None
skills NNS None
training VBG None
for IN None
teens NNS None
with IN None
ASD NNP None
. . None
Korean NNP None
and CC None
reviewed VBN None
by IN None
21 CD None
child JJ None
mental JJ None
health NN None
professionals NNS None
. . None
Items NNP None
surveyed VBN None
by IN None
447 CD None
middle JJ None
school NN None
students NNS None
, , None
and CC None
accordingly RB None
. . None
Participants NNS None
included VBD None
47 CD None
teens NNS None
between IN None
12 CD None
and CC None
18 CD None
years NNS None
of IN None
age NN None
with IN None
a DT None
diagnosis NN None
of IN None
ASD NNP None
and CC None
a DT None
verbal JJ None
intelligence NN None
quotient NN None
( ( None
IQ NNP None
) ) None
? . None
65 CD None
efficacious JJ None
for IN None
teens NNS None
with IN None
ASD NNP None
in IN None
Korea NNP None
adolescents NNS None
with IN None
ASD NNP None
. . None
-DOCSTART- -X- N

100 CD None
patients NNS None
. . None
patients NNS None
with IN None
a DT None
laryngoscope NN None
. . None
-DOCSTART- -X- N

metastatic JJ Condition
breast NN Condition
cancer NN Condition
. . None
first-line JJ Condition
treatment NN Condition
of IN Condition
women NNS Condition
with IN Condition
metastatic JJ Condition
breast NN Condition
cancer NN Condition
( ( Condition
MBC NNP Condition
) ) Condition
. . Condition
Women NNP None
( ( None
n=509 JJ None
) ) None
with IN None
MBC NNP Condition
and CC Condition
normal JJ Condition
cardiac JJ Condition
function NN Condition
were VBD None
randomized VBN None
-DOCSTART- -X- N

children NNS Condition
undergoing VBG Condition
laparoscopy NN Condition
. . Condition
50 CD Condition
children NNS Condition
undergoing JJ Condition
laparoscopy NN Condition
for IN Condition
diagnostic JJ Condition
and CC Condition
therapeutic JJ Condition
purposes NNS Condition
. . Condition
Their PRP$ None
ages NNS None
ranged VBN None
from IN None
3 CD None
to TO None
13 CD None
years NNS None
, , None
and CC None
all DT None
belonged VBD None
to TO None
American NNP None
Society NNP None
of IN None
Anesthesiologists NNP None
( ( None
ASA NNP None
) ) None
class NN None
I PRP None
or CC None
II NNP None
. . None
-DOCSTART- -X- N

oxidation NN None
in IN None
subjects NNS None
with IN None
impaired JJ Condition
glucose JJ Condition
tolerance NN Condition
. . None
29 CD Size
subjects NNS None
with IN None
impaired JJ None
glucose JJ None
tolerance NN None
. . None
subjects NNS None
with IN None
impaired JJ None
glucose JJ None
tolerance NN None
-DOCSTART- -X- N

endosseous JJ None
implants NNS None
up IN None
to TO None
and CC None
including VBG None
stage NN None
II NNP None
surgery NN None
: : None
a DT None
study NN None
of IN None
2,641 CD Size
implants NNS None
. . None
endosseous JJ None
implants NNS None
-DOCSTART- -X- N

IHD NNP None
. . None
Ischemic NNP None
Heart NNP None
disease NN None
. . None
Ischemic NNP None
Heart NNP None
Disease NNP None
patients NNS None
with IN None
a DT None
previous JJ None
myocardial JJ None
infarction NN None
or CC None
unstable JJ None
angina-ischemic JJ None
heart NN None
disease NN None
( ( None
IHD NNP None
) ) None
. . None
9014 CD None
patients NNS None
from IN None
85 CD None
centers NNS None
in IN None
Australia NNP None
and CC None
New NNP None
Zealand NNP None
. . None
-DOCSTART- -X- N

Thirty-four JJ Size
patients NNS None
undergoing VBG None
elective JJ Condition
shoulder NN Condition
surgery NN Condition
were VBD None
randomized VBN None
-DOCSTART- -X- N

Economic JJ None
evaluation NN None
of IN None
a DT None
nursing-led JJ None
inpatient JJ None
unit NN None
: : None
transfer NN None
to TO None
a DT None
nursing-led JJ None
inpatient NN None
unit NN None
for IN None
intermediate JJ None
care NN None
nursing-led JJ None
inpatient JJ None
units NNS None
sample JJ None
size NN None
of IN None
175 CD None
, , None
of IN None
which WDT None
89 CD None
were VBD None
in IN None
the DT None
nursing-led JJ None
inpatient NN None
unit NN None
arm NN None
and CC None
86 CD None
in IN None
the DT None
control NN None
arm NN None
. . None
-DOCSTART- -X- N

ischemic JJ None
stroke NN None
: : None
acute JJ None
ischemic JJ None
stroke NN None
patients NNS None
. . None
From IN None
215 CD None
patients NNS None
admitted VBD None
within IN None
24 CD None
hours NNS None
of IN None
a DT None
hemispheric JJ None
ischemic JJ None
stroke NN None
, , None
89 CD None
patients NNS None
on IN None
chronic JJ None
statin NN None
treatment NN None
were VBD None
randomly RB None
assigned VBN None
Patients NNS None
with IN None
statin NN None
withdrawal NN None
patients NNS None
without IN None
previous JJ None
treatment NN None
with IN None
statins NNS None
-DOCSTART- -X- N

children NNS Age
with IN None
autistic JJ Condition
spectrum NN Condition
disorders NNS Condition
. . None
31 CD None
children NNS None
with IN None
autistic JJ None
spectrum NN None
disorders NNS None
in IN None
an DT None
8-week JJ None
, , None
double-blinded JJ None
study NN None
-DOCSTART- -X- N

men NNS None
aged VBN None
?40 CD None
years NNS None
with IN None
erectile JJ None
dysfunction NN None
? . None
men NNS None
aged VBN None
?40 CD None
years NNS None
with IN None
erectile JJ None
dysfunction NN None
( ( None
ED NNP None
) ) None
. . None
PATIENTS NNP None
partners NNS None
. . None
Men NNP Sex
aged VBD None
?40 CD None
years NNS None
who WP None
were VBD None
not RB None
receiving VBG None
lipid JJ None
lowering NN None
or CC None
anti-hypertensive JJ Condition
medication NN None
and CC None
not RB None
at IN None
high JJ None
cardiovascular JJ None
risk NN None
were VBD None
recruited VBN None
from IN None
10 CD None
general JJ None
practices NNS None
in IN None
the DT None
East NNP None
of IN None
England NNP None
, , None
173 CD Size
eligible JJ None
men NNS Sex
with IN None
untreated JJ Condition
ED NNP Condition
were VBD None
randomized VBN None
to TO None
double-blind VB None
treatment NN None
with IN None
40 CD None
Identifying VBG None
men NNS None
with IN None
ED NNP None
provides VBZ None
-DOCSTART- -X- N

men NNS Sex
receiving VBG Condition
finasteride NN Condition
for IN Condition
2 CD Condition
years NNS Condition
. . None
men NNS None
with IN None
urodynamically RB None
documented VBN None
bladder NN None
outflow JJ None
obstruction NN None
( ( None
BOO NNP None
) ) None
. . None
One CD Size
hundred VBD Size
twenty-one NN Size
men NNS Sex
with IN None
benign JJ Condition
prostatic JJ Condition
enlargement NN Condition
( ( None
BPE NNP None
) ) None
and CC None
lower JJR Condition
urinary JJ Condition
tract NN Condition
symptoms NNS Condition
( ( None
LUTS NNP None
) ) None
Patients NNS None
who WP None
were VBD None
obstructed VBN None
according VBG None
to TO None
a DT None
modified VBN None
Abrams-Griffiths JJ None
nomogram NNS None
men NNS None
with IN None
BPE NNP None
and CC None
LUTS NNP None
-DOCSTART- -X- N

UK NNP None
registered JJ None
population NN None
aged VBD None
over IN Age
65 CD Age
years NNS Age
in IN None
east JJ None
London NNP None
practices NNS None
. . None
East NNP None
London NNP None
and CC None
Essex NNP None
network NN None
of IN None
researchers NNS None
( ( None
ELENoR NNP None
) ) None
. . None
Participants NNS None
were VBD None
1,820 CD Size
low-risk JJ None
patients NNS None
aged VBD None
65 CD Age
to TO Age
74 CD Age
years NNS None
who WP None
had VBD None
not RB None
previously RB None
been VBN None
in IN None
a DT None
recall NN None
system NN None
for IN None
influenza JJ None
immunisation NN None
at IN None
their PRP$ None
general JJ None
practice NN None
. . None
patients NNS None
making VBG None
a DT None
telephone NN None
appointment NN None
low-risk JJ None
older JJR None
population NN None
in IN None
inner-city JJ None
areas NNS None
-DOCSTART- -X- N

sweating NN None
threshold NN None
gain NN None
of IN None
sweating VBG None
. . None
Six NNP None
healthy JJ None
male NN None
volunteers NNS None
were VBD None
evaluated VBN None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
disseminated JJ Condition
testicular JJ Condition
tumors NNS Condition
] VBP Condition
patients NNS None
with IN None
disseminated JJ None
testicular JJ None
tumors NNS None
. . None
Of IN None
34 CD None
patients NNS None
registered VBD None
, , None
10 CD None
patients NNS None
were VBD None
with IN None
minimal JJ None
disease NN None
in IN None
stages NNS None
IIA NNP None
, , None
IIIO NNP None
and CC None
IIIA NNP None
and CC None
24 CD None
with IN None
extensive JJ None
disease NN None
in IN None
IIB NNP None
, , None
IIIB2 NNP None
and CC None
IIIC NNP None
. . None
Seminomas NNP None
were VBD None
found VBN None
in IN None
10 CD None
patients NNS None
, , None
while IN None
non-seminomatous JJ None
tumors NNS None
in IN None
24 CD None
. . None
-DOCSTART- -X- N

healthy JJ Condition
volunteers NNS Condition
. . Condition
-DOCSTART- -X- N

aortic JJ Condition
valve NN Condition
replacement NN Condition
. . None
Stentless NNP None
( ( None
Freestyle NNP None
, , None
Toronto NNP None
, , None
n RB None
= VBZ None
106 CD Size
) ) None
or CC None
conventional JJ None
biological JJ None
aortic JJ None
valves NNS None
( ( None
Carpentier-Edwards NNP None
, , None
n JJ None
= NNP None
74 CD Size
) ) None
were VBD None
evaluated VBN None
patients NNS None
after IN None
aortic JJ Condition
valve NN Condition
replacement NN Condition
. . None
-DOCSTART- -X- N

influenza NN None
type NN None
A DT None
or CC None
B NNP None
infection NN None
in IN None
25 CD None
patients NNS None
. . None
patients NNS None
with IN None
influenza NN None
A NNP None
or CC None
B NNP None
infection NN None
-DOCSTART- -X- N

management NN None
of IN None
unresectable JJ None
malignant JJ None
mesothelioma NN None
Malignant NNP None
mesothelioma NN None
patients NNS None
with IN None
unresectable JJ None
disease NN None
. . None
mesothelioma NN None
. . None
-DOCSTART- -X- N

chronic JJ Condition
alcoholic JJ Condition
patients NNS None
. . None
32 CD Size
randomly RB None
selected VBN None
hospitalized VBN None
male JJ Sex
alcoholic JJ Condition
patients NNS None
with IN None
clinical JJ None
, , None
biochemical JJ None
and CC None
histological JJ None
evidence NN None
of IN None
hepatic JJ Condition
damage NN Condition
. . None
ethanol-induced JJ Condition
liver NN Condition
damage NN Condition
patients NNS None
with IN None
alcoholic JJ Condition
liver NN Condition
disease NN Condition
( ( Condition
ALD NNP Condition
) ) Condition
. . None
-DOCSTART- -X- N

104 CD Size
patients NNS None
with IN None
H. NNP None
pylori FW None
infection NN None
and CC None
recurrent JJ Condition
duodenal JJ Condition
ulcer NN Condition
52 CD Size
patients NNS None
given VBN None
antibiotics NNS None
patients NNS None
with IN None
recurrent JJ Condition
duodenal JJ Condition
ulcer NN Condition
-DOCSTART- -X- N

autism NN None
preschool NN Age
children NNS Age
with IN Age
autism NN Age
Participants NNS None
were VBD None
58 CD None
children NNS None
( ( None
46 CD None
boys NNS None
) ) None
with IN None
autism NN None
between IN None
3 CD None
and CC None
4 CD None
years NNS None
of IN None
age NN None
. . None
young JJ None
children NNS None
with IN None
autism NN None
-DOCSTART- -X- N

COPD NNP None
patients NNS None
. . None
Participants NNS None
can MD None
use VB None
any DT None
background NN None
treatment NN None
for IN None
COPD NNP None
except IN None
inhaled JJ None
anticholinergic JJ None
agents NNS None
. . None
The DT None
study NN None
encompasses VBZ None
a DT None
wide JJ None
range NN None
of IN None
COPD NNP None
patients NNS None
, , None
e.g FW None
. . None
patients NNS None
with IN None
stable JJ None
cardiac JJ None
diseases NNS None
including VBG None
arrhythmia NN None
can MD None
be VB None
included VBN None
. . None
Clinical JJ None
sites NNS None
are VBP None
international JJ None
and CC None
include VBP None
both DT None
primary JJ None
care NN None
as RB None
well RB None
as IN None
specialists NNS None
. . None
RESULTS NNP None
To TO None
date NN None
, , None
over IN None
17,000 CD None
participants NNS None
have VBP None
been VBN None
randomized VBN None
from IN None
over IN None
1200 CD None
sites NNS None
in IN None
50 CD None
countries NNS None
with IN None
-DOCSTART- -X- N

Fifteen JJ Condition
males NNS Condition
with IN Condition
angiographic JJ Condition
evidence NN Condition
of IN Condition
coronary JJ Condition
heart NN Condition
disease NN Condition
and CC Condition
stable JJ Condition
, , Condition
exercise-induced JJ Condition
angina NN Condition
pectoris NN Condition
-DOCSTART- -X- N

prethreshold JJ Condition
retinopathy NN Condition
of IN Condition
prematurity NN Condition
. . None
prethreshold JJ Condition
retinopathy NN Condition
of IN Condition
prematurity NN Condition
( ( Condition
ROP NNP Condition
) ) Condition
Thirty-six JJ None
eyes NNS None
of IN None
18 CD Size
premature NN Size
infants NNS Size
less RBR None
than IN None
34 CD None
weeks NNS None
gestational JJ None
age NN None
and/or NN None
less JJR None
than IN None
1600 CD None
g JJ None
birth NN None
weight NN None
with IN None
prethreshold JJ Condition
ROP NNP Condition
Regression NNP Condition
of IN Condition
ROP NNP Condition
36 CD None
eyes NNS None
-DOCSTART- -X- N

partial JJ Condition
thickness NN Condition
burns NNS Condition
thermal JJ Condition
2nd CD Condition
degree NN Condition
burns NNS Condition
partial JJ Condition
thickness NN Condition
burns NNS Condition
. . None
40 CD Size
patients NNS None
received VBD None
either RB None
topical JJ None
treatment NN None
with IN None
Moist NNP None
Exposed VBD None
Burn NNP None
Ointment NNP None
( ( None
MEBO NNP None
) ) None
or CC None
standard JJ None
Flammazine NNP None
treatment NN None
. . None
All DT None
patients NNS None
suffered VBD None
from IN None
partial-thickness JJ None
burn NN None
injuries NNS None
( ( None
< VB None
20 CD None
% NN None
TBSA NNP None
) ) None
. . None
limited JJ Condition
partial JJ Condition
thickness NN Condition
thermal JJ Condition
burns NNS Condition
. . None
-DOCSTART- -X- N

PTSD NNP Condition
patients NNS Condition
with IN Condition
Posttraumatic NNP Condition
stress NN Condition
disorder NN Condition
( ( Condition
PTSD NNP Condition
) ) Condition
PTSD JJ None
patients NNS None
were VBD None
recruited VBN None
from IN None
five CD None
primary JJ None
care NN None
clinics NNS None
at IN None
four CD None
Veterans NNS None
Affairs NNP None
healthcare NN None
facilities NNS None
Participants NNS None
were VBD None
195 CD Size
Veterans NNPS None
Their PRP$ None
average JJ None
age NN None
was VBD None
45 CD Age
years NNS Age
, , None
91 CD None
% NN None
were VBD None
male JJ None
, , None
58 CD None
% NN None
were VBD None
white JJ None
, , None
40 CD None
% NN None
served VBN None
in IN None
Iraq NNP None
or CC None
Afghanistan NNP None
, , None
and CC None
42 CD None
% NN None
served VBD None
in IN None
Vietnam NNP None
-DOCSTART- -X- N

adolescents NNS Age
with IN None
autism NN Condition
spectrum NN Condition
disorder NN Condition
. . None
Anxiety NN None
is VBZ None
common JJ None
among IN None
adolescents NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
( ( None
ASD NNP Condition
) ) None
in IN None
a DT None
sample NN None
of IN None
30 CD Size
adolescents NNS Age
with IN None
ASD NNP Condition
and CC Condition
anxiety NN Condition
symptoms NNS Condition
of IN None
moderate JJ None
or CC None
greater JJR None
severity NN None
. . None
-DOCSTART- -X- N

tracheal JJ None
intubating NN None
conditions NNS None
60 CD Size
patients NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
acute JJ Condition
migraine NN Condition
. . None
patients NNS None
acute JJ Condition
migraine NN Condition
attack NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
acute JJ Condition
respiratory NN Condition
distress NN Condition
syndrome NN Condition
. . None
patients NNS None
with IN None
acute JJ None
respiratory NN None
distress NN None
syndrome NN None
( ( None
ARDS NNP Condition
) ) None
patients NNS None
with IN None
ARDS NNP None
. . None
12 CD Size
patients NNS None
with IN None
ARDS NNP None
-DOCSTART- -X- N

Parkinson NNP Condition
's POS Condition
disease NN Condition
. . None
Parkinson NNP Condition
's POS Condition
disease NN Condition
Parkinson NNP Condition
's POS Condition
disease NN Condition
subjects NNS None
and CC None
age-matched JJ None
controls NNS None
. . None
Parkinson NNP Condition
's POS Condition
disease NN Condition
patients NNS None
-DOCSTART- -X- N

nasal JJ Condition
congestion NN Condition
. . None
patients NNS None
with IN None
nasal JJ None
congestion NN None
. . None
Twenty-four JJ Size
patients NNS None
with IN None
perennial JJ Condition
rhinitis NN Condition
due JJ None
to TO None
house-dust-mite JJ Condition
( ( Condition
HDM NNP Condition
) ) Condition
allergy NN Condition
were VBD None
recruited VBN None
-DOCSTART- -X- N

children NNS None
with IN None
autism NN None
children NNS None
with IN None
autism NN None
47 CD None
teachers NNS None
and CC None
children NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
unresectable JJ None
pancreatic JJ None
adenocarcinoma NN None
. . None
Advanced NNP None
pancreatic JJ None
cancer NN None
Patients NNS None
with IN None
histological/cytological JJ None
proven NN None
inoperable JJ None
adenocarcinoma NN None
of IN None
the DT None
head NN None
of IN None
pancreas NNS None
were VBD None
randomised VBN None
to TO None
receive VB None
KAb NNP None
201 CD None
Between NNP None
February NNP None
2003 CD None
and CC None
July NNP None
2005 CD None
, , None
25 CD None
patients NNS None
were VBD None
enrolled VBN None
. . None
Nineteen JJ None
patients NNS None
were VBD None
randomised VBN None
, , None
9 CD None
to TO None
the DT None
intravenous JJ None
and CC None
10 CD None
to TO None
the DT None
intra-arterial JJ None
arms NNS None
. . None
-DOCSTART- -X- N

CAPD NNP Condition
peritonitis NN Condition
. . None
Fifty-one CD Size
patients NNS Size
were VBD None
included VBN None
CAPD NNP Condition
peritonitis NN Condition
. . None
-DOCSTART- -X- N

high-risk JJ Condition
head NN Condition
and CC Condition
neck NN Condition
surgery NN Condition
: : None
Patients NNS None
who WP None
undergo VBP None
major JJ None
contaminated VBN None
surgery NN None
of IN None
the DT None
head NN None
and CC None
neck NN None
Patients NNS None
who WP None
were VBD None
identified VBN None
as IN None
requiring VBG None
pedicled VBD None
flap JJ None
reconstruction NN None
were VBD None
potential JJ None
candidates NNS None
for IN None
the DT None
study NN None
. . None
One CD Size
hundred VBD Size
nine CD Size
patients NNS None
were VBD None
evaluable JJ None
. . None
-DOCSTART- -X- N

obesity NN Condition
treatment NN None
140 CD Condition
patients NNS Condition
( ( None
36 CD Condition
men NNS Condition
, , None
104 CD Condition
women NNS Condition
) ) None
, , None
aged VBN None
18-60 CD Age
years NNS None
and CC None
body NN None
mass NN None
index NN None
> VBD None
30 CD None
kg/m NN None
( ( None
2 CD None
) ) None
were VBD None
randomized VBN None
and CC None
93 CD Condition
patients NNS Condition
( ( None
27 CD Condition
men NNS Condition
, , None
66 CD Condition
women NNS Condition
) ) None
completed VBD None
the DT None
study NN None
. . None
-DOCSTART- -X- N

squamous JJ Condition
cell NN Condition
carcinomas NN Condition
of IN Condition
the DT Condition
head NN Condition
and CC Condition
neck NN Condition
squamous JJ Condition
cell NN Condition
carcinomas NN Condition
of IN Condition
the DT Condition
head NN Condition
and CC Condition
neck NN Condition
( ( Condition
HNSCC NNP Condition
) ) None
Eight NNP Size
hundred VBD Size
and CC Size
three CD Size
patients NNS Size
with IN None
representative JJ None
pretreatment NN None
tissue NN None
samples NNS None
from IN None
the DT None
randomized VBN None
DAHANCA NNP None
6 CD None
and CC None
7 CD None
study NN None
of IN None
5 CD None
vs. FW None
6 CD None
fx/wk NN None
of IN None
radiotherapy NN None
. . None
-DOCSTART- -X- N

sensory JJ Condition
problems NNS Condition
for IN None
children NNS None
with IN None
autism NN Condition
. . None
children NNS None
with IN None
autism NN Condition
. . None
Trakya NNP None
University NNP None
Training NNP None
and CC None
Research NNP None
Center NNP None
for IN None
Mentally NNP None
and CC None
Physically NNP None
Handicapped NNP None
Children NNP None
in IN None
Turkey NNP None
. . None
comprising VBG None
15 CD Size
children NNS None
between IN None
7 CD None
and CC None
11 CD None
years NNS None
of IN None
age NN None
with IN None
autism NN Condition
, , None
according VBG None
to TO None
DSM-IV NNP None
criteria NNS None
. . None
-DOCSTART- -X- N

multiple JJ Condition
sclerosis NN Condition
: : None
MS NNP Condition
patients NNS None
-DOCSTART- -X- N

Seventy-three JJ Size
patients NNS None
undergoing VBG None
elective JJ Condition
perianal JJ Condition
surgery NN Condition
-DOCSTART- -X- N

autistic JJ None
children NNS None
: : None
20 CD None
autistic JJ None
children NNS None
received VBD None
40 CD None
mg/day NN None
of IN None
the DT None
neuropeptide NN None
ORG NNP None
2766 CD None
, , None
a DT None
synthetic JJ None
analog NN None
of IN None
ACTH NNP None
( ( None
4-9 JJ None
) ) None
, , None
for IN None
8 CD None
weeks NNS None
. . None
-DOCSTART- -X- N

urogenital JJ Condition
atrophy NN Condition
in IN None
postmenopausal JJ Condition
women NNS Size
on IN Condition
hormone NN Condition
therapy NN Condition
. . None
27 CD Size
women NNS Size
with IN None
climacteric JJ Condition
symptoms NNS Condition
and CC None
atrophic JJ Condition
vaginitis NN Condition
receive VB None
HT NNP None
plus CC None
local JJ None
estriol NN None
or CC None
placebo NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
IBS NNP Condition
and CC None
a DT None
study NN None
conducted VBN None
in IN None
healthy JJ Condition
male JJ Sex
subjects NNS None
. . None
2516 CD Size
IBS NNP Condition
patients NNS None
with IN None
symptoms NNS None
of IN None
abdominal JJ Condition
pain NN Condition
and CC None
constipation NN Condition
tegaserod JJ None
In IN None
an DT None
additional JJ None
study NN None
, , None
36 CD Size
healthy JJ Condition
male NN Sex
subjects NNS None
received VBD None
iv NN None
. . None
single JJ None
doses NNS None
of IN None
tegaserod NN None
( ( None
0.8 CD None
mg NN None
to TO None
20 CD None
mg NN None
) ) None
or CC None
placebo NN None
. . None
healthy JJ Condition
volunteers NNS None
-DOCSTART- -X- N

adolescent JJ None
girls NNS None
: : None
adolescent JJ None
girls NNS None
33 CD None
sexually-active JJ None
, , None
single JJ None
girls NNS None
. . None
62 CD None
sexually-active JJ None
, , None
single JJ None
girls NNS None
. . None
girls NNS None
-DOCSTART- -X- N

kala-azar NN Condition
. . None
288 CD Size
parasitologically RB Condition
proved JJ Condition
patients NNS Condition
of IN Condition
kala-azar NNS Condition
Indian JJ Condition
kala-azar JJ Condition
patients NNS Condition
-DOCSTART- -X- N

early JJ None
haemorrhoids NNS None
. . None
early JJ None
hemorrhoids NNS None
102 CD Size
patients NNS Size
were VBD None
included VBN None
at IN None
the DT None
POF NNP None
Hospital NNP None
, , None
Wah NNP None
Cantt NNP None
from IN None
October NNP None
2004 CD None
to TO None
June NNP None
2005 CD None
. . None
The DT Age
mean JJ Age
age NN Age
of IN Age
the DT Age
patients NNS Age
was VBD Age
44 CD Age
years NNS Age
, , None
86 CD None
were VBD None
males NNS Sex
and CC None
16 CD None
were VBD None
females NNS None
. . None
24.5 CD None
% NN None
of IN None
the DT None
patients NNS None
had VBD None
a DT None
positive JJ Condition
family NN Condition
history NN Condition
of IN Condition
haemorrhoids NNS Condition
. . None
-DOCSTART- -X- N

on IN None
clinical JJ None
outcome NN None
after IN None
balloon NN None
coronary JJ None
angioplasty NN None
. . None
Between NNP None
September NNP None
1985 CD None
and CC None
April NNP None
1987 CD None
, , None
110 CD None
consecutive JJ None
patients NNS None
who WP None
had VBD None
successful JJ None
coronary JJ None
angioplasty NN None
One CD None
hundred CD None
and CC None
eight CD None
( ( None
98 CD None
% NN None
) ) None
of IN None
patients NNS None
were VBD None
followed VBN None
up RP None
clinically RB None
after IN None
a DT None
median NN None
of IN None
five CD None
months NNS None
( ( None
range VB None
1-20 CD None
) ) None
. . None
Eighty NNP None
five CD None
( ( None
77 CD None
% NN None
) ) None
had VBD None
follow VBN None
up RP None
angiography NN None
at IN None
five CD None
months NNS None
. . None
-DOCSTART- -X- N

children NNS Age
of IN None
non-severe JJ Condition
pneumonia NN Condition
with IN None
wheeze NN Condition
: : None
developing NN None
countries NNS None
. . None
children NNS Age
presenting VBG None
with IN None
non-severe JJ Condition
pneumonia NN Condition
with IN None
wheeze NN Condition
, , None
who WP None
have VBP None
persistent VBN None
fast RB None
breathing NN None
after IN None
nebulisation NN None
with IN None
salbutamol NN None
, , None
and CC None
have VBP None
normal JJ None
chest NN None
radiograph NN None
. . None
eight CD None
government NN None
hospitals NNS None
in IN None
India NNP None
. . None
Participants NNS None
were VBD None
children NNS Age
aged VBN None
2-59 JJ Age
months NNS None
of IN None
age NN None
836 CD Size
cases NNS None
in IN None
placebo NN None
and CC None
835 CD Size
in IN None
amoxycillin NN None
group NN None
. . None
children NNS Age
with IN None
non-severe JJ Condition
pneumonia NN Condition
and CC None
wheeze NN Condition
-DOCSTART- -X- N

children NNS Age
with IN None
acute JJ Condition
lymphoblastic JJ Condition
leukemia NN Condition
in IN None
first JJ None
bone NN None
marrow NN None
relapse NN None
. . None
relapsed JJ None
acute NN Condition
lymphoblastic JJ Condition
leukemia NN Condition
( ( None
ALL DT Condition
) ) None
. . None
45 CD Size
patients NNS None
with IN None
ALL NNP None
in IN None
first JJ None
bone NN None
marrow NN None
relapse NN None
enrolled VBD None
-DOCSTART- -X- N

55 CD None
premature NN None
infants NNS None
weighing VBG None
less JJR None
than IN None
1501 CD None
g NN None
at IN None
birth NN None
were VBD None
selected VBN None
randomly RB None
at IN None
their PRP$ None
initial JJ None
eye NN None
examination NN None
. . None
42 CD None
patients NNS None
. . None
premature JJ None
infants NNS None
. . None
-DOCSTART- -X- N

acute JJ Condition
bacterial JJ Condition
maxillary JJ Condition
sinusitis NN Condition
in IN None
adults NNS Age
. . Age
outpatients NNS None
with IN None
both DT None
clinical JJ None
signs NNS None
and CC None
symptoms NNS None
and CC None
radiographic JJ None
evidence NN None
of IN None
acute JJ Condition
sinusitis NN Condition
452 CD Size
patients NNS None
considered VBN None
valid JJ None
for IN None
clinical JJ None
efficacy NN None
-DOCSTART- -X- N

asthmatics NNS Condition
8 CD Size
asthmatics NNS Condition
. . None
Subjects NNS None
-DOCSTART- -X- N

subject NN Condition
's POS Condition
fist NN Condition
clenching NN Condition
20 CD None
female JJ None
and CC None
20 CD None
male JJ None
students NNS None
( ( None
ages NNS None
: : None
17-34 CD None
years NNS None
) ) None
-DOCSTART- -X- N

acute JJ None
contrast NN None
nephropathy NN Condition
. . None
after IN None
exposure NN None
to TO None
radiocontrast VB Condition
media NNS None
. . None
98 CD Size
subjects NNS None
who WP None
underwent VBP None
cardiac JJ Condition
catheterization NN Condition
The DT None
mean JJ None
age NN None
, , None
baseline NN None
serum NN None
Cr NNP None
, , None
and CC None
Cr NNP None
clearance NN None
( ( None
CrCl NNP None
) ) None
were VBD None
69.3 CD Age
+/- JJ Age
10.8 CD Age
years NNS Age
, , None
2.5 CD None
+/- JJ None
0.9 CD None
mg/dL NN None
, , None
and CC None
31.4 CD None
+/- JJ None
12.1 CD None
mL/min NN None
, , None
respectively RB None
. . None
-DOCSTART- -X- N

IPPB NNP None
for IN None
the DT None
treatment NN None
of IN None
croup NN None
: : None
Twenty CD None
patients NNS None
( ( None
aged VBN None
4 CD None
months NNS None
to TO None
5 CD None
years NNS None
) ) None
hospitalized VBD None
with IN None
acute JJ None
croup NN None
and CC None
persistent JJ None
inspiratory NN None
stridor NN None
at IN None
rest NN None
acute JJ None
signs NNS None
of IN None
croup NN None
. . None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
severe JJ Condition
aplastic JJ Condition
anemia NN Condition
( ( Condition
SAA NNP Condition
) ) Condition
treated VBD Condition
with IN Condition
anti-lymphocyte JJ Condition
globulin NN Condition
( ( Condition
ALG NNP Condition
) ) Condition
, , Condition
cyclosporin NN Condition
( ( Condition
CyA NNP Condition
) ) Condition
and CC Condition
granulocyte JJ Condition
colony-stimulating JJ Condition
factor NN Condition
( ( Condition
G-CSF NNP Condition
) ) Condition
multicenter NN None
prospective JJ None
trial NN None
in IN None
77 CD None
SAA NNP None
patients NNS None
treated VBD None
with IN None
horse NN None
ALG NNP None
( ( None
15 CD None
mg/kg/day RB None
day1-5 NN None
) ) None
and CC None
CyA NNP None
( ( None
5 CD None
mg/kg/day RB None
day NN None
1-180 JJ None
) ) None
. . None
Patients NNS None
were VBD None
randomized VBN None
Thirteen JJ None
patients NNS None
( ( None
5 CD None
in IN None
group NN None
A NNP None
and CC None
8 CD None
in IN None
group NN None
B NNP None
) ) None
patients NNS None
with IN None
SAA NNP None
receiving VBG None
ALG NNP None
and CC None
CyA NNP None
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
Asperger NNP Condition
syndrome NN Condition
children NNS Age
with IN None
Asperger NNP Condition
syndrome NN Condition
( ( Condition
AS IN Condition
) ) Condition
Forty-nine JJ Size
children NNS Age
with IN None
AS NNP Condition
children NNS Age
with IN None
AS NNP Condition
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
: : None
Children NNP Age
who WP None
have VBP None
a DT None
combination NN None
of IN None
language NN Condition
and CC Condition
developmental JJ Condition
disabilities NNS Condition
with IN None
autism NN Condition
Participants NNS None
were VBD None
two CD None
groups NNS None
of IN None
children NNS Age
with IN None
autism NN Condition
, , None
aged VBD None
between IN None
3 CD Age
and CC None
7 CD Age
years NNS None
. . None
-DOCSTART- -X- N

in IN None
Canadian JJ None
Cree NNP None
infants NNS None
. . None
studied VBD None
184 CD None
Cree NNP None
Indian JJ None
infants NNS None
from IN None
26 CD None
infants NNS None
without IN None
BCG NNP None
vaccination NN None
rose VBD None
for IN None
66 CD None
infants NNS None
who WP None
received VBD None
BCG NNP None
in IN None
the DT None
first JJ None
7 CD None
days NNS None
of IN None
life NN None
, , None
-DOCSTART- -X- N

Nine NNP None
healthy JJ Condition
volunteers NNS None
( ( None
age NN Age
, , Age
23.4 CD Age
+/- JJ Age
0.2 CD Age
years NNS Age
; : None
body NN None
mas VBZ None
index NN None
[ NNP None
BMI NNP None
] NNP None
, , None
23.5 CD None
+/- JJ None
1.6 CD None
kg/m NN None
( ( None
2 CD None
) ) None
) ) None
-DOCSTART- -X- N

cervical JJ Condition
carcinoma NN Condition
: : None
patients NNS None
affected VBN None
by IN None
cervical JJ None
cancer NN None
undergoing VBG None
radical JJ None
hysterectomy NN None
. . None
Consecutive JJ None
patients NNS None
affected VBN None
by IN None
stage NN None
IB-IIB JJ None
cervical JJ None
carcinoma NN None
scheduled VBN None
for IN None
radical JJ None
surgery NN None
All DT None
patients NNS None
underwent JJ None
classical JJ None
radical JJ None
hysterectomy NN None
. . None
168 CD Size
patients NNS None
entered VBD None
the DT None
study NN None
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
: : None
Forty NNP Size
outpatients NNS None
aged VBD None
4 CD Age
to12 NN Age
years NNS None
, , None
who WP None
were VBD None
diagnosed VBN None
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
based VBN None
on IN None
the DT None
Diagnostic NNP None
and CC None
Statistical NNP None
Manual NNP None
of IN None
Mental NNP None
Disorders NNP None
, , None
Fourth NNP None
Edition NNP None
, , None
Text NNP None
Revision NNP None
criteria NNS None
-DOCSTART- -X- N

human JJ None
immune NN None
response NN None
to TO None
hepatitis VB None
B NNP None
surface NN None
antigen NN None
50 CD Size
subjects NNS None
receiving VBG Condition
four CD Condition
doses NNS Condition
of IN Condition
hepatitis NN Condition
B NNP Condition
vaccine NN Condition
according VBG None
to TO None
a DT None
0 CD None
, , None
1 CD None
, , None
2 CD None
, , None
12 CD None
month NN None
vaccination NN None
scheme NN None
. . None
Twenty-three JJ None
subjects NNS None
were VBD None
given VBN None
a DT None
plasma-derived JJ None
vaccine NN None
( ( None
Hevac NNP None
B NNP None
) ) None
and CC None
27 CD None
received VBD None
a DT None
recombinant JJ None
HBsAg NNP None
vaccine NN None
( ( None
yeast-derived JJ None
; : None
Engerix-B NNP None
) ) None
. . None
-DOCSTART- -X- N

coronary-prone NN None
( ( None
Type NNP None
A NNP None
) ) None
managers NNS None
. . None
type NN None
A DT None
intervention NN None
project NN None
for IN None
healthy JJ None
managers NNS None
manifestations NNS None
of IN None
clinical JJ None
CHD NNP None
) ) None
all DT None
three CD None
groups NNS None
-DOCSTART- -X- N

hypertensive JJ Condition
patients NNS None
with IN None
type JJ Condition
2 CD Condition
diabetes NNS Condition
. . None
hypertensive JJ Condition
type-2 JJ Condition
diabetic JJ Condition
patients NNS None
hypertensive JJ Condition
type-2 JJ Condition
diabetic JJ Condition
patients NNS None
. . None
Forty NNP Size
type-2 JJ Condition
diabetic JJ Condition
patients NNS None
with IN None
never-treated JJ None
hypertension NN Condition
-DOCSTART- -X- N

non-hyperlipidaemic JJ Condition
primary JJ Condition
hypertension NN Condition
. . None
hypercholesterolaemic JJ None
hypertensive JJ None
subjects NNS None
hypertensive JJ Condition
subjects NNS Condition
with IN Condition
lower JJR Condition
plasma NN Condition
cholesterol NN Condition
Fourteen JJ None
non-hyperlipidaemic JJ None
primary JJ None
hypertensive JJ None
subjects NNS None
( ( None
10 CD None
men NNS None
; : None
overall JJ None
mean?SD NN None
age NN None
58?12 CD None
years NNS None
) ) None
. . None
non-hyperlipidaemic JJ None
subjects NNS None
with IN None
primary JJ None
hypertension NN None
, , None
simvastatin JJ None
-DOCSTART- -X- N

Eskimo NNP Condition
diet NN Condition
. . None
Healthy JJ None
men NNS Sex
and CC Sex
women NNS Sex
( ( None
134 CD None
) ) None
-DOCSTART- -X- N

young JJ None
children NNS None
with IN None
autism NN None
. . None
young JJ None
children NNS None
with IN None
autism NN None
. . None
Four CD None
young JJ None
boys NNS None
( ( None
ages IN None
4-5 CD None
years NNS None
) ) None
diagnosed VBD None
with IN None
autism NN None
participated VBN None
. . None
The DT None
children NNS None
were VBD None
participants NNS None
in IN None
an DT None
early JJ None
intensive JJ None
behavioural JJ None
intervention NN None
clinic NN None
children NNS None
-DOCSTART- -X- N

healthy JJ Condition
volunteers NNS None
. . None
Twenty-four JJ Size
Helicobacter NNP Condition
pylori-negative JJ Condition
subjects NNS None
-DOCSTART- -X- N

clinical JJ None
responses NNS None
in IN None
man NN Sex
. . None
177 CD Size
volunteers NNS None
. . None
-DOCSTART- -X- N

cognitive JJ None
functioning NN None
patients NNS None
with IN None
MS NNP None
. . None
A NNP None
total NN None
of IN None
45 CD None
ambulatory JJ None
patients NNS None
with IN None
MS NNP None
and CC None
severe JJ None
fatigue NN None
-DOCSTART- -X- N

osteoarthritis NN Condition
of IN None
the DT None
ankle NN Condition
. . None
patients NNS None
with IN None
osteoarthritis NN None
( ( None
OA NNP Condition
) ) None
of IN None
the DT None
ankle NN None
. . None
43 CD None
ankles NNS None
( ( None
30 CD Size
patients NNS None
) ) None
with IN None
radiographic JJ None
Kellgren NNP None
Lawrence NNP None
grade VBD None
III NNP None
OA NNP None
-DOCSTART- -X- N

anemic JJ None
cancer NN None
surgery NN None
patients NNS None
. . None
cancer NN None
patients NNS None
. . None
Twenty NNP Size
anemic JJ None
sideropenic JJ None
patients NNS None
( ( None
hemoglobin JJ None
< NNP None
/=110 NNP None
g/l NN None
; : None
serum CC None
iron VB None
< JJ None
600 CD None
microg/l NN None
) ) None
with IN None
cancer NN None
of IN None
the DT None
gastrointestinal JJ None
tract NN None
two CD None
groups NNS None
: : None
the DT None
first JJ None
( ( None
n JJ None
= NNP None
10 CD Size
) ) None
received VBD None
400 CD None
U/kg NNP None
of IN None
r-Hu JJ None
EPO NNP None
divided VBD None
in IN None
4 CD None
doses NNS None
( ( None
100 CD None
U/kg NNP None
each DT None
, , None
every DT None
4 CD None
days NNS None
) ) None
; : None
the DT None
second JJ None
( ( None
n JJ None
= NNP None
10 CD Size
) ) None
received VBD None
200 CD None
U/kg NNP None
of IN None
r-HuEPO NN None
( ( None
50 CD None
U/kg NNP None
each DT None
, , None
every DT None
4 CD None
days NNS None
) ) None
. . None
anemic JJ None
sideropenic JJ None
cancer NN None
patients NNS None
. . None
-DOCSTART- -X- N

AIDS NNP Condition
: : Condition
10 CD None
patients NNS None
with IN None
AIDS NNP None
and CC None
cryptosporidiosis NN None
-DOCSTART- -X- N

antiretroviral-naive JJ Condition
HIV-infected JJ Condition
adults NNS Age
: : None
antiretroviral-naive JJ Condition
patients NNS None
over IN None
48 CD None
weeks NNS None
. . None
-DOCSTART- -X- N

nurse JJ None
run NN None
clinics NNS None
for IN None
patients NNS None
with IN None
epilepsy NN Condition
in IN None
general JJ None
practice NN None
: : None
nurse JJ None
run NN None
epilepsy NN Condition
clinics NNS None
in IN None
primary JJ None
care NN None
. . None
nurse JJ None
run NN None
clinics NNS None
versus VBP None
usual JJ None
care NN None
. . None
Six NNP None
general JJ None
practices NNS None
in IN None
the DT None
South NNP None
Thames NNPS None
region NN None
. . None
251 CD Size
patients NNS None
aged VBN None
over IN None
15 CD None
years NNS None
who WP None
were VBD None
taking VBG None
anti-epileptic JJ None
drugs NNS None
or CC None
had VBD None
a DT None
diagnosis NN None
of IN None
epilepsy NN Condition
and CC None
an DT None
attack NN None
in IN None
the DT None
past JJ None
two CD None
years NNS None
who WP None
met VBD None
specified VBN None
inclusion NN None
criteria NNS None
and CC None
had VBD None
responded VBN None
to TO None
a DT None
questionnaire NN None
. . None
127 CD Size
patients NNS None
Nurse NNP None
run VBP None
clinics NNS None
for IN None
patients NNS None
with IN None
epilepsy NN Condition
-DOCSTART- -X- N

40 CD Condition
open-angle JJ Condition
patients NNS Condition
treated VBN Condition
with IN Condition
the DT Condition
long JJ Condition
acting JJ Condition
pilocarpine-complex NN Condition
for IN Condition
120 CD Condition
days NNS Condition
. . Condition
-DOCSTART- -X- N

bacteriuria NN Condition
in IN Condition
elderly JJ Condition
women NNS Condition
. . Condition
bacteriuria NN None
in IN None
a DT None
group NN None
of IN None
non-catheterized JJ None
elderly JJ None
women NNS None
Thirty-one JJ None
women NNS None
received VBD None
single-dose JJ None
treatment NN None
and CC None
22 CD None
conventional-dose JJ None
treatment NN None
. . None
selected VBN None
elderly JJ None
women NNS None
with IN None
bacteriuria NN None
-DOCSTART- -X- N

postmenopausal JJ Condition
bone NN Condition
loss NN Condition
. . None
postmenopausal JJ Condition
osteoporosis NN Condition
. . None
groups NNS None
of IN None
20 CD Size
, , None
60 CD Size
women NNS Sex
Patients NNPS None
who WP None
received VBD Condition
calcium NN Condition
alone RB None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
coronary JJ Condition
artery NN Condition
disease NN Condition
. . Condition
patients NNS None
with IN None
coronary JJ None
artery NN None
disease NN None
( ( None
CAD NNP None
) ) None
CAD NNP None
patients NNS None
with IN None
average JJ None
cholesterol NN None
levels NNS None
. . None
Twenty-eight NNP None
sedentary JJ None
male NN None
patients NNS None
with IN None
angiographically RB None
documented VBN None
CAD NNP None
and CC None
average JJ None
pretreatment JJ None
total NN None
plasma NN None
cholesterol NN None
levels NNS None
( ( None
5.1+/-0.9 JJ None
mmol/l NN None
) ) None
aged VBD None
42-75 CD None
years NNS None
were VBD None
included VBN None
. . None
patients NNS None
with IN None
CAD NNP None
and CC None
average JJ None
cholesterol NN None
levels NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
diffuse NN None
peritonitis NN None
at IN None
the DT None
postoperative JJ None
period NN None
] NNP None
64 CD None
patients NNS None
that IN None
inclusion NN None
of IN None
complex JJ None
antioxidant NN None
cytoflavin NN None
in IN None
intensive JJ None
therapy NN None
at IN None
the DT None
postoperative JJ None
period NN None
of IN None
diffuse NN None
peritonitis NN None
-DOCSTART- -X- N

Thirty-seven NNP None
healthy JJ None
volunteers NNS None
, , None
19 CD None
of IN None
whom WP None
had VBD None
consistently RB None
elevated VBN None
total JJ None
serum NN None
bilirubin NN None
( ( None
TSB NNP None
) ) None
concentrations NNS None
, , None
took VBD None
part NN None
volunteers NNS None
volunteers NNS None
volunteers NNS None
volunteers NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
knee JJ None
osteoarthritis NN None
. . None
patients NNS None
with IN None
knee JJ None
joint JJ None
OA NNP None
. . None
Fifty NNP None
patients NNS None
( ( None
19 CD None
males NNS None
and CC None
31 CD None
females NNS None
) ) None
with IN None
a DT None
mean JJ None
age NN None
of IN None
53.6 CD None
+/- JJ None
8.9 CD None
years NNS None
patients NNS None
with IN None
OA NNP None
of IN None
the DT None
knee NN None
. . None
-DOCSTART- -X- N

advanced JJ None
laryngeal NN None
and CC None
hypopharyngeal NN None
squamous JJ None
carcinoma NN None
. . None
Two CD None
hundred VBD None
and CC None
twelve JJ None
patients NNS None
with IN None
previously RB Condition
untreated VBN Condition
advanced JJ Condition
squamous JJ Condition
carcinoma NN Condition
of IN Condition
the DT Condition
larynx NN Condition
or CC Condition
hypopharynx NN Condition
Two CD None
hundred VBD None
and CC None
nine CD None
of IN None
the DT None
212 CD None
patients NNS None
randomized VBN None
were VBD None
included VBN None
in IN None
the DT None
analyses NNS None
. . None
-DOCSTART- -X- N

exposure NN Condition
to TO Condition
acid VB Condition
fog NN Condition
: : Condition
seven CD None
healthy JJ None
young JJ None
men NNS None
-DOCSTART- -X- N

elderly JJ Age
adults NNS Age
with IN None
newly RB None
diagnosed VBN None
acute RB Condition
myelogenous JJ Condition
leukemia NN Condition
. . None
elderly JJ Age
adults NNS Age
with IN None
newly RB None
diagnosed VBN None
acute RB None
myelogenous JJ None
leukemia NN None
( ( None
AML NNP Condition
) ) None
. . None
84 CD Size
adults NNS Age
( ( None
age NN None
range NN None
, , None
70-90 JJ Age
years NNS Age
; : None
median JJ Age
, , Age
76 CD Age
years NNS Age
) ) None
who WP None
were VBD None
not RB None
candidates NNS None
for IN None
conventional JJ None
chemotherapy NN None
. . None
40 CD None
patients NNS None
treated VBN None
-DOCSTART- -X- N

40 CD None
children NNS None
with IN None
severe JJ None
and CC None
persistent JJ None
soiling NN None
and CC None
often RB None
with IN None
a DT None
history NN None
of IN None
faecal JJ None
retention NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
alcoholic JJ None
cirrhosis NN None
and CC None
massive JJ None
ascites NNS None
. . None
patients NNS None
with IN None
alcoholic JJ None
cirrhosis NN None
299 CD None
men NNS None
with IN None
alcoholic JJ None
cirrhosis NN None
, , None
who WP None
had VBD None
persistent NN None
or CC None
recurrent NN None
severe JJ None
ascites VBZ None
despite IN None
a DT None
standard JJ None
medical JJ None
regimen NNS None
, , None
to TO None
receive VB None
either RB None
intensive JJ None
medical JJ None
treatment NN None
or CC None
peritoneovenous JJ None
( ( None
LeVeen NNP None
) ) None
shunting VBG None
. . None
Group NNP None
1 CD None
had VBD None
normal JJ None
or CC None
mildly RB None
abnormal JJ None
results NNS None
on IN None
liver-function NN None
tests NNS None
, , None
Group NNP None
2 CD None
had VBD None
more RBR None
severe JJ None
liver NN None
dysfunction NN None
or CC None
previous JJ None
complications NNS None
, , None
and CC None
Group NNP None
3 CD None
had VBD None
severe JJ None
prerenal JJ None
azotemia NN None
without IN None
kidney NN None
disease NN None
. . None
medical JJ None
patients NNS None
surgical JJ None
patients NNS None
medical JJ None
and CC None
surgical JJ None
patients NNS None
. . None
-DOCSTART- -X- N

Prospective NNP None
study NN None
of IN None
104 CD None
consecutive JJ None
patients NNS None
undergoing VBG None
coronary JJ None
angiography NN None
who WP None
were VBD None
randomized VBN None
-DOCSTART- -X- N

gastric JJ Condition
cancer NN Condition
patients NNS None
: : None
cancer NN Condition
patients NNS None
gastric JJ None
cancer NN None
patients NNS None
. . None
121 CD Size
gastric JJ Condition
cancer NN Condition
patients NNS None
attending VBG None
inpatient JJ None
rehabilitation NN None
after IN None
surgical JJ None
treatment NN None
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ Condition
coronary JJ Condition
artery NN Condition
disease NN Condition
: : None
100 CD Size
patients NNS None
with IN None
chronic JJ Condition
CAD NNP Condition
, , None
60 CD Size
of IN None
whom WP None
were VBD None
chronic JJ Condition
smokers NNS Condition
. . None
60 CD Size
of IN None
100 CD None
patients NNS None
( ( None
30 CD None
of IN None
whom WP None
were VBD None
smokers NNS Condition
) ) None
and CC None
in IN None
24 CD Size
healthy JJ None
controls NNS None
. . None
Smokers NNS Condition
( ( None
n JJ None
= NNP None
20 CD Size
) ) None
matched VBN None
for IN None
age NN None
, , None
myocardial JJ None
ischemia NN None
, , None
and CC None
other JJ None
risk NN None
factors NNS None
with IN None
20 CD Size
nonsmokers NNS Condition
patients NNS None
with IN None
chronic JJ Condition
CAD NNP Condition
. . None
-DOCSTART- -X- N

pterygium NN Condition
pterygium NN Condition
208 CD Size
patients NNS Size
( ( None
229 CD None
eyes NNS None
) ) None
with IN None
initial JJ None
pterygium NN Condition
-DOCSTART- -X- N

participants NNS None
performed VBD None
a DT None
self-timed JJ None
30 CD None
minute NN None
brisk NN Condition
walk VBP Condition
in IN None
two CD None
different JJ None
environments NNS None
, , None
park NN None
and CC None
urban JJ None
sample NN None
of IN None
40 CD None
healthy JJ None
adults NNS None
was VBD None
recruited VBN None
: : None
16 CD None
males NNS None
, , None
24 CD None
females NNS None
, , None
mean JJ None
age NN None
22.9 CD None
( ( None
5.5 CD None
) ) None
years NNS None
. . None
The DT None
steps/min NN None
. . None
Participants NNS None
accumulated VBD None
-DOCSTART- -X- N

mental JJ Condition
rotation NN Condition
task NN Condition
. . None
Forty-six JJ Size
females NNS None
and CC None
46 CD Size
males NNS None
-DOCSTART- -X- N

Wuchereria NNP Condition
bancrofti JJ Condition
infection NN Condition
in IN None
human JJ None
beings NNS None
and CC None
mosquitoes NNS None
. . None
14 CD None
communities NNS None
in IN None
matched JJ None
pairs NNS None
. . None
People NNS None
aged VBD None
5 CD Age
years NNS None
or CC None
older JJR None
in IN None
seven CD None
communities NNS None
received VBD None
randomly RB None
assigned VBN None
diethylcarbamazine NN None
6 CD None
mg/kg NN None
and CC None
people NNS None
in IN None
the DT None
other JJ None
seven CD None
communities NNS None
five CD None
communities NNS None
2219 CD Size
( ( None
87.6 CD None
% NN None
) ) None
of IN None
2534 CD Size
eligible JJ None
people NNS None
received VBD None
treatment NN None
. . None
-DOCSTART- -X- N

thrombotic JJ Condition
disorders NNS Condition
. . Condition
venous JJ Condition
thromboembolism NN Condition
( ( Condition
VTE NNP Condition
) ) Condition
in IN None
the DT None
orthopedic JJ None
surgical JJ None
setting NN None
. . None
acute JJ Condition
coronary JJ Condition
syndromes NNS Condition
-DOCSTART- -X- N

Leukocyte-depleted JJ None
reperfusion NN None
of IN None
transplanted JJ None
human JJ None
hearts NNS None
: : None
20 CD None
patients NNS None
were VBD None
enrolled VBN None
in IN None
a DT None
randomized JJ None
, , None
double-blind JJ None
clinical JJ None
trial NN None
to TO None
be VB None
treated VBN None
with IN None
either DT None
warm JJ None
whole NN None
blood NN None
reperfusion NN None
( ( None
group NN None
I PRP None
; : None
n CC None
= VB None
9 CD None
) ) None
( ( None
group NN None
II NNP None
; : None
n CC None
= VB None
11 CD None
) ) None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
bulimia JJ Condition
nervosa NN Condition
. . None
patients NNS None
with IN None
bulimia JJ Condition
nervosa NNS Condition
The DT None
study NN None
included VBD None
93 CD Size
patients NNS None
. . None
-DOCSTART- -X- N

surgery NN None
of IN None
the DT None
abdominal JJ None
aorta NN None
] NNP None
Twenty-five JJ None
patients NNS None
undergoing VBG None
excision NN None
of IN None
an DT None
aortic JJ None
abdominal JJ None
aneurysm NN None
-DOCSTART- -X- N

young JJ Age
children NNS Age
with IN None
autism NN Condition
. . None
Children NNP None
with IN None
autism NN None
three CD Size
young JJ None
children NNS None
with IN None
autism NN None
and CC None
their PRP$ None
mothers NNS None
. . None
young JJ None
children NNS None
with IN None
autism NN None
parents NNS None
. . None
-DOCSTART- -X- N

pregnant JJ None
women NNS None
infected VBN None
with IN None
HIV NNP None
. . None
Pregnant NNP None
women NNS None
with IN None
WHO NNP None
stage VBP None
1 CD None
, , None
2 CD None
, , None
or CC None
3 CD None
HIV-1 JJ None
infection NN None
who WP None
had VBD None
CD4 NNP None
cell NN None
counts NNS None
of IN None
200-500 JJ None
cells NNS None
per IN None
?L NN None
in IN None
Burkina NNP None
Faso NNP None
, , None
Kenya NNP None
, , None
and CC None
South NNP None
Africa NNP None
to TO None
start VB None
study VB None
treatment NN None
at IN None
28-36 JJ None
weeks NNS None
' POS None
gestation NN None
. . None
All DT None
infants NNS None
received VBD None
FINDINGS NNP None
From IN None
June NNP None
, , None
2005 CD None
, , None
to TO None
August NNP None
, , None
2008 CD None
, , None
882 CD None
women NNS None
were VBD None
enrolled VBN None
, , None
824 CD None
805 CD None
singleton NN None
or CC None
first JJ None
, , None
liveborn JJ None
infants NNS None
. . None
The DT None
-DOCSTART- -X- N

after IN None
anal JJ None
fissure NN None
surgery NN None
. . None
patients NNS None
. . None
Between NNP None
July NNP None
1999 CD None
and CC None
December NNP None
2000 CD None
, , None
140 CD None
patients NNS None
undergoing JJ None
anal JJ None
sphincterotomy NN None
patients NNS None
who WP None
had VBD None
polyp NN None
and CC None
papilla NN None
removal NN None
-DOCSTART- -X- N

asthma NN Condition
. . None
bronchial JJ Condition
asthma NN Condition
a DT None
group NN None
of IN None
asthmatic JJ Condition
subjects NNS None
. . None
asthmatic JJ Condition
patients NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
ischemic JJ Condition
heart NN Condition
disease NN Condition
. . None
14 CD Size
randomized JJ None
patients NNS None
with IN None
stable JJ None
ischemic JJ None
heart NN None
disease NN None
-DOCSTART- -X- N

Effects NNS None
of IN None
a DT None
common JJ None
variant NN None
in IN None
the DT None
CD38 NNP None
gene NN None
on IN None
social JJ None
processing NN None
One CD None
potential JJ None
candidate NN None
could MD None
be VB None
the DT None
CD38 NNP None
gene NN None
autism NN None
spectrum NN None
disorders NNS None
( ( None
ASD NNP None
) ) None
. . None
55 CD None
healthy JJ None
young JJ None
men NNS None
depending VBG None
on IN None
their PRP$ None
CD38 NNP None
gene NN None
variant NN None
Homozygotic JJ None
risk NN None
allele NN None
carriers NNS None
homozygotic JJ None
risk NN None
allele NN None
carriers NNS None
. . None
allele JJ None
groups NNS None
-DOCSTART- -X- N

non-small JJ None
cell NN None
lung NN None
cancer NN None
: : None
patients NNS None
with IN None
or CC None
without IN None
nodal JJ None
micrometastases NNS None
patients NNS None
with IN None
non-small JJ None
cell NN None
lung NN None
cancer NN None
. . None
Lymph NNP None
nodes NNS None
from IN None
patients NNS None
( ( None
n=94 NN None
) ) None
patients NNS None
without IN None
an DT None
early JJ None
locoregional JJ None
spread NN None
of IN None
cancer NN None
cells NNS None
. . None
-DOCSTART- -X- N

Maternal NNP None
erythropoietin NN None
in IN None
singleton NN Condition
pregnancies NNS Condition
: : None
97 CD Size
patients NNS None
with IN None
a DT None
first-trimester JJ None
hemoglobin NN None
level NN None
> NN None
or CC None
= $ None
14.0 CD None
gm/dl NN None
( ( None
hematinic JJ None
group NN None
, , None
n RB None
= VBZ None
53 CD Size
) ) None
or CC None
a DT None
placebo NN None
( ( None
n JJ None
= NNP None
44 CD Size
) ) None
. . None
-DOCSTART- -X- N

toothbrushes NNS None
periodontal JJ Condition
diseases NNS Condition
. . None
Twenty NNP Size
patients NNS None
had VBD None
one CD None
side NN None
of IN None
their PRP$ None
mouths NNS None
brushed VBN None
with IN None
a DT None
toothbrush NN None
containing VBG None
the DT None
antimicrobial JJ None
agent NN None
( ( None
experimental JJ None
side NN None
) ) None
, , None
and CC None
the DT None
other JJ None
side NN None
with IN None
a DT None
toothbrush NN None
containing VBG None
no DT None
agent NN None
( ( None
control NN None
) ) None
. . None
-DOCSTART- -X- N

recovery NN None
enhancement NN None
after IN None
stroke VBD Condition
2 CD None
to TO None
60 CD None
patients NNS None
3 CD None
to TO None
30 CD None
days NNS None
after IN None
ischemic JJ None
or CC None
hemorrhagic JJ None
stroke NN None
. . None
RESULTS NNP None
Sixty NNP None
patients NNS None
were VBD None
recruited VBN None
at IN None
mean NN None
of IN None
8 CD None
days NNS None
( ( None
SD NNP None
? . None
5 CD None
) ) None
post NN None
ictus NN None
, , None
with IN None
mean JJ None
age NN None
71 CD None
years NNS None
( ( None
? . None
12 CD None
years NNS None
) ) None
and CC None
53 CD None
% NN None
men NNS None
. . None
The DT None
were VBD None
no DT None
significant JJ None
differences NNS None
between IN None
groups NNS None
in IN None
baseline NN None
in IN None
G-CSF-treated JJ None
patients NNS None
( ( None
P=0.06 NNP None
in IN None
patients NNS None
with IN None
ischemic JJ None
stroke NN None
. . None
CLINICAL NNP None
-DOCSTART- -X- N

Eighty-four JJ Size
cases NNS None
were VBD None
randomly RB None
divided VBN None
into IN None
3 CD None
groups NNS None
, , None
28 CD Size
cases NNS None
in IN None
each DT None
group NN None
. . None
-DOCSTART- -X- N

premature JJ Condition
ejaculation NN Condition
. . None
premature JJ None
ejaculation NN None
. . None
Forty-three JJ Size
patients NNS None
suffering VBG None
from IN None
premature JJ None
ejaculation NN None
The DT None
exclusion NN None
criteria NNS None
were VBD None
erectile JJ None
dysfunction NN None
, , None
loss NN None
of IN None
libido NN None
, , None
alcohol NN None
and CC None
substance NN None
abuse NN None
, , None
mental JJ None
retardation NN None
, , None
diabetes VBZ None
mellitus NN None
, , None
thyroid JJ None
disease NN None
, , None
hypotension NN None
, , None
previous JJ None
use NN None
of IN None
these DT None
drugs NNS None
and CC None
urogenital JJ None
infections NNS None
. . None
The DT None
patients NNS None
' POS None
ages NNS None
ranged VBD None
from IN None
19 CD Age
to TO Age
48 CD Age
years NNS Age
( ( None
mean JJ None
age NN None
28 CD Age
+/- JJ Age
1.6 CD Age
) ) None
. . None
They PRP None
had VBD None
regular JJ None
sexual JJ None
lives NNS None
. . None
They PRP None
had VBD None
normal JJ None
psychiatric JJ None
consultation NN None
and CC None
the DT None
Glombock NNP None
Rast NNP None
Sexual NNP None
Satisfactory NNP None
Test NNP None
( ( None
GRISS NNP None
) ) None
psychiatric JJ None
test NN None
were VBD None
in IN None
accordance NN None
with IN None
premature JJ None
ejaculation NN None
. . None
No UH None
patients NNS None
were VBD None
excluded VBN None
from IN None
the DT None
study NN None
due JJ None
to TO None
side VB None
effects NNS None
. . None
premature JJ None
ejaculation NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
type JJ Condition
2 CD Condition
diabetes NNS Condition
. . None
Forty-two NNP Size
diabetic JJ Condition
patients NNS None
-DOCSTART- -X- N

infertile JJ Condition
patients NNS None
: : None
One CD Size
hundred VBN Size
eighty-nine JJ Size
infertile JJ Condition
women NNS Sex
undergoing VBG None
outpatient JJ None
hysteroscopy NN None
. . None
group NN None
B NNP None
group NN None
A NNP None
. . None
patients NNS None
. . None
-DOCSTART- -X- N

major JJ Condition
abdominal JJ Condition
trauma NN Condition
-- : None
reduced VBD None
septic JJ Condition
morbidity NN Condition
. . None
the DT None
critically RB Condition
injured VBN Condition
. . None
Seventy-five JJ Size
patients NNS None
with IN None
an DT None
abdominal JJ Condition
trauma NN Condition
index NN None
( ( None
ATI NNP None
) ) None
greater JJR None
than IN None
15 CD None
and CC None
less JJR None
than IN None
40 CD None
were VBD None
randomized VBN None
at IN None
initial JJ None
laparotomy NN Condition
to TO None
receive VB None
either RB None
TEN NNP None
( ( None
Vivonex NNP None
TEN NNP None
) ) None
or CC None
TPN NNP None
( ( None
Freamine NNP None
HBC NNP None
6.9 CD None
% NN None
and CC None
Trophamine NNP None
6 CD None
% NN None
) ) None
; : None
both DT None
regimens NNS None
contained VBD None
2.5 CD None
% NN None
fat NN None
, , None
33 CD None
% NN None
branched VBD None
chain NN None
amino NN None
acids NNS None
, , None
and CC None
had VBD None
a DT None
calorie NN None
to TO None
nitrogen VB None
ratio NN None
of IN None
150:1 CD None
. . None
severely RB Condition
injured JJ Condition
-DOCSTART- -X- N

upper JJ None
lobectomy NN None
-- : None
randomized VBD None
Sixty NNP None
patients NNS None
who WP None
underwent VBP None
upper JJ None
lobectomy NN None
30 CD None
patients NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
locally RB None
advanced JJ None
gastric JJ Condition
cancer NN Condition
. . Condition
gastric JJ Condition
cancer NN Condition
patients NNS None
advanced JJ None
gastric JJ Condition
cancer NN Condition
. . Condition
patients NNS None
with IN None
locally RB None
advanced VBN None
resectable JJ Condition
gastric JJ Condition
cancer NN Condition
. . Condition
156 CD Size
patients NNS None
with IN None
stage NN Condition
III NNP Condition
or CC Condition
IV NNP Condition
gastric JJ Condition
cancer NN Condition
who WP None
had VBD None
undergone JJ None
curative JJ Condition
resection NN Condition
patients NNS None
with IN None
pT2/T3 JJ Condition
primary JJ Condition
tumors NNS Condition
patients NNS None
with IN None
intestinal-type JJ Condition
but CC Condition
not RB Condition
diffuse-type JJ Condition
cancer NN Condition
. . Condition
limited JJ None
number NN None
of IN None
patients NNS None
gastric JJ Condition
cancer NN Condition
patients NNS None
after IN None
curative JJ Condition
gastrectomy NN Condition
; : None
in IN None
particular JJ None
, , None
in IN None
patients NNS None
with IN None
pT2/T3 JJ Condition
tumors NNS Condition
and CC Condition
intestinal-type JJ Condition
primary JJ Condition
tumors NNS Condition
. . Condition
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ None
proximal JJ None
plantar NN None
fasciitis NN None
: : None
chronically RB None
painful JJ None
proximal JJ None
plantar NN None
fasciitis NN None
Forty-seven JJ None
patients NNS None
( ( None
49 CD None
feet NNS None
) ) None
with IN None
a DT None
previously RB None
unsuccessful JJ None
nonsurgical JJ None
treatment NN None
of IN None
at IN None
least JJS None
6 CD None
months NNS None
were VBD None
randomized VBN None
to TO None
two CD None
groups NNS None
. . None
Group NNP None
1 CD None
( ( None
25 CD None
heels NNS None
) ) None
group NN None
2 CD None
( ( None
24 CD None
heels NNS None
) ) None
-DOCSTART- -X- N

adults NNS None
with IN None
autism NN None
spectrum NN None
disorder NN None
individuals NNS None
with IN None
autism NN None
spectrum NN None
disorder NN None
( ( None
ASD NNP None
) ) None
( ( None
a DT None
) ) None
215 CD None
supported VBN None
employees NNS None
who WP None
were VBD None
in IN None
sheltered JJ None
workshops NNS None
prior RB None
to TO None
entering VBG None
supported JJ None
employment NN None
and CC None
( ( None
b NN None
) ) None
215 CD None
supported VBN None
employees NNS None
who WP None
were VBD None
not RB None
in IN None
sheltered JJ None
workshops NNS None
. . None
individuals NNS None
with IN None
ASD NNP None
-DOCSTART- -X- N

adult NN None
normotensive JJ None
or CC None
hypertensive JJ None
hydrocephalus NN None
. . None
new JJ None
hydrostatic JJ None
dual-switch NN None
valve NN None
( ( None
DSV NNP None
) ) None
was VBD None
implanted VBN None
in IN None
35 CD None
adult NN None
patients NNS None
with IN None
hydrocephalus NN None
of IN None
different JJ None
etiology NN None
. . None
26 CD None
patients NNS None
suffered VBD None
from IN None
normotensive JJ None
hydrocephalus NN None
( ( None
10 CD None
idiopathic NN None
and CC None
16 CD None
symptomatic JJ None
) ) None
, , None
and CC None
9 CD None
patients NNS None
from IN None
hypertensive JJ None
hydrocephalus NN None
of IN None
various JJ None
origin NN None
. . None
21 CD None
patients NNS None
35 CD None
patients NNS None
-DOCSTART- -X- N

participants NNS None
undertook VBP None
an DT None
active JJ None
object NN Condition
location NN Condition
memory NN Condition
task NN Condition
within IN None
a DT None
virtual JJ None
house NN None
in IN None
which WDT None
each DT None
room NN None
was VBD None
associated VBN None
with IN None
a DT None
different JJ None
schedule NN None
of IN None
task-irrelevant JJ None
emotional JJ None
events NNS None
. . None
participants NNS None
participants NNS None
-DOCSTART- -X- N

retinopathy NN None
of IN None
prematurity NN None
: : None
one CD None
randomly NN None
selected VBN None
eye NN None
172 CD None
infants NNS None
had VBD None
been VBN None
examined VBN None
3 CD None
months NNS None
after IN None
randomization NN None
. . None
-DOCSTART- -X- N

lung NN None
adenocarcinoma NN None
patients NNS None
with IN None
lung NN None
adenocarcinoma NN None
prospective JJ None
study NN None
on IN None
30 CD None
patients NNS None
with IN None
lung NN None
adenocarcinoma NN None
, , None
divided VBN None
into IN None
two CD None
groups NNS None
of IN None
15 CD None
patients NNS None
each DT None
. . None
-DOCSTART- -X- N

men NNS None
with IN None
localized JJ Condition
prostate NN Condition
cancer NN Condition
. . None
A NNP None
total NN None
of IN None
101 CD None
patients NNS None
radical JJ Condition
external-beam NN Condition
radiation NN Condition
therapy NN Condition
( ( Condition
RT NNP Condition
) ) None
for IN None
localized JJ Condition
cancer NN Condition
of IN Condition
the DT Condition
prostate NN Condition
. . None
-DOCSTART- -X- N

ischaemic JJ Condition
ulcers NNS Condition
of IN None
the DT None
lower JJR None
limb NN None
. . None
Scandinavian-Polish JJ None
placebo NN None
controlled VBN None
, , None
randomised VBN None
multicenter NN None
study NN None
. . None
103 CD Size
patients NNS None
with IN None
ischaemic JJ None
ulcers NNS None
who WP None
were VBD None
randomised VBN None
to TO None
receive VB None
active JJ None
treatment NN None
or CC None
placebo NN None
. . None
-DOCSTART- -X- N

patients NNS None
undergoing VBG None
high-risk JJ Condition
coronary JJ Condition
artery NN Condition
bypass NN Condition
graft NN Condition
surgery NN Condition
: : None
patients NNS None
with IN None
obstructive JJ Condition
coronary JJ Condition
artery NN Condition
disease NN Condition
; : None
high-risk JJ None
patients NNS None
High-risk JJ Condition
patients NNS Condition
undergoing VBG Condition
CABG NNP Condition
surgery NN Condition
3023 CD Size
patients NNS None
were VBD None
enrolled VBN None
at IN None
130 CD None
sites NNS None
in IN None
Canada NNP None
, , None
the DT None
United NNP None
States NNPS None
, , None
and CC None
Germany NNP None
between IN None
October NNP None
2006 CD None
and CC None
September NNP None
2007 CD None
, , None
with IN None
results NNS None
anticipated VBN None
shortly RB None
after IN None
completion NN None
of IN None
90-day JJ None
follow-up NN None
in IN None
March NNP None
2008 CD None
. . None
-DOCSTART- -X- N

septic JJ Condition
shock NN Condition
: : Condition
adrenal JJ Condition
insufficiency NN Condition
in IN None
septic JJ Condition
shock NN Condition
40 CD Size
patients NNS None
with IN None
septic JJ Condition
shock NN Condition
-DOCSTART- -X- N

children NNS None
vaccinated VBN None
with IN None
live JJ None
attenuated VBN None
influenza JJ None
vaccine NN None
. . None
children NNS None
vaccinated VBN None
with IN None
live JJ None
attenuated VBN None
influenza JJ None
vaccine NN None
( ( None
LAIV NNP None
) ) None
children NNS None
6-36 JJ None
months NNS None
of IN None
age NN None
. . None
-DOCSTART- -X- N

Supervisor NNP None
tolerance-responsiveness NN None
Supervisor NNP None
tolerance-responsiveness JJ None
troubled JJ None
employees NNS None
supervisor NN None
responsiveness NN None
to TO None
employee NN None
substance NN None
abuse NN None
. . None
supervisor NN None
response NN None
to TO None
and CC None
tolerance NN None
of IN None
coworker NN None
substance NN None
use NN None
Employee NNP None
Assistance NNP None
Program NNP None
( ( None
EAP NNP None
) ) None
in IN None
two CD None
workplaces NNS None
( ( None
n JJ None
= NN None
244 CD None
and CC None
107 CD None
) ) None
. . None
Supervisors NNS None
receiving VBG None
this DT None
training NN None
( ( None
n JJ None
= NNP None
29 CD None
) ) None
supervisors NNS None
who WP None
received VBD None
a DT None
more RBR None
didactic JJ None
, , None
informational JJ None
training NN None
( ( None
n JJ None
= NNP None
23 CD None
) ) None
or CC None
a DT None
no-training JJ None
control NN None
group NN None
( ( None
n JJ None
= NNP None
17 CD None
) ) None
. . None
Trained VBN None
supervisors NNS None
-DOCSTART- -X- N

female JJ Sex
stress NN Condition
urinary JJ Condition
incontinence NN Condition
: : None
female JJ Sex
stress NN Condition
urinary JJ Condition
incontinence NN Condition
( ( Condition
SUI NNP Condition
) ) Condition
. . None
Women NNP Sex
with IN None
urodynamic JJ Condition
SUI NNP Condition
were VBD None
enrolled VBN None
Subjects NNPS None
Of IN None
285 CD Size
women NNS Sex
, , None
144 CD Size
had VBD None
the DT None
U-type JJ None
method NN None
and CC None
141 CD Size
had VBD None
the DT None
H-type JJ None
method NN None
. . None
female JJ None
SUI NNP Condition
. . None
-DOCSTART- -X- N

130 CD Condition
patients NNS Condition
with IN Condition
inferior JJ Condition
alveolar JJ Condition
nerve NN Condition
( ( Condition
IAN NNP Condition
) ) Condition
and CC Condition
lingual JJ Condition
nerve NN Condition
( ( Condition
LN NNP Condition
) ) Condition
injuries NNS Condition
. . Condition
IAN NNP None
patients NNS None
the DT None
IAN NNP None
and CC None
LN NNP None
patient JJ None
populations NNS None
. . None
patients NNS None
with IN None
IAN NNP None
injuries NNS None
. . None
-DOCSTART- -X- N

invasive JJ None
aspergillosis NN None
in IN None
high-risk JJ None
haematology NN None
patients NNS None
: : None
haematology NN None
patients NNS None
at IN None
high JJ None
risk NN None
of IN None
invasive JJ None
aspergillosis NN None
. . None
eligible JJ None
patients NNS None
were VBD None
adults NNS None
undergoing VBG None
allogeneic JJ None
stem-cell JJ None
transplantation NN None
or CC None
chemotherapy NN None
for IN None
acute JJ None
leukaemia NN None
, , None
with IN None
no DT None
history NN None
of IN None
invasive JJ None
fungal JJ None
disease NN None
. . None
240 CD None
eligible JJ None
patients NNS None
were VBD None
recruited VBN None
from IN None
six CD None
Australian JJ None
centres NNS None
between IN None
Sept NNP None
30 CD None
, , None
2005 CD None
, , None
and CC None
Nov NNP None
19 CD None
, , None
2009 CD None
. . None
high-risk JJ None
haematology NN None
patients NNS None
. . None
FUNDING NNP None
-DOCSTART- -X- N

Twenty-six JJ None
postmenopausal JJ None
women NNS None
-DOCSTART- -X- N

men NNS Sex
with IN None
signs NNS None
and CC None
symptoms NNS None
of IN None
benign JJ Condition
prostatic JJ Condition
hyperplasia NN Condition
: : None
Men NNP Sex
50 CD Age
years NNS Age
or CC Age
older JJR Age
with IN None
an DT None
International NNP None
Prostate NNP Condition
Symptom NNP None
Score NNP None
of IN None
13 CD None
or CC None
greater JJR None
and CC None
peak JJ None
urinary JJ None
flow NN None
rate NN None
of IN None
4 CD None
to TO None
15 CD None
ml NNS None
per IN None
second JJ None
received VBN None
placebo NN None
or CC None
8 CD None
mg NNS None
silodosin JJ None
daily JJ None
with IN None
breakfast NN None
for IN None
12 CD None
weeks NNS None
. . None
923 CD Size
patients NNS None
( ( None
mean JJ None
age NN None
65 CD Age
years NNS None
) ) None
466 CD Size
received VBN None
silodosin NN None
and CC None
457 CD Size
placebo NN None
. . None
-DOCSTART- -X- N

70 CD None
patients NNS None
( ( None
without IN None
previous JJ None
history NN None
of IN None
cerebral JJ None
or CC None
systemic JJ None
embolus NN None
) ) None
undergoing VBG None
cardiac JJ None
catheterization NN None
. . None
-DOCSTART- -X- N

adults NNS Age
with IN None
high-functioning JJ Condition
autism NN Condition
spectrum NN Condition
disorders NNS Condition
: : None
Adults NNP Age
with IN None
high-functioning JJ Condition
autism NN Condition
spectrum NN Condition
disorders NNS Condition
( ( Condition
ASD NNP Condition
) ) Condition
have VBP None
difficulties NNS None
in IN None
social JJ None
communication NN None
; : None
adults NNS Age
with IN None
ASD NNP Condition
children NNS Age
with IN None
ASD NNP Condition
. . None
adults NNS Age
with IN None
ASD NNP Condition
. . None
The DT None
participants NNS None
will MD None
be VB None
60 CD None
adults NNS None
with IN None
ASD NNP Condition
; : None
30 CD None
will MD None
be VB None
assigned VBN None
to TO None
a DT None
CBT NNP None
group NN None
and CC None
30 CD None
to TO None
a DT None
waitlist NN None
control NN None
group NN None
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
spectrum NN None
disorders NNS None
and CC None
developmental JJ None
disabilities NNS None
in IN None
a DT None
population-based JJ None
study NN None
. . None
preschoolers NNS Age
with IN None
autism NN None
spectrum NN None
disorders NNS None
( ( None
ASD NNP None
) ) None
and CC None
other JJ None
developmental JJ None
disabilities NNS None
( ( None
DD NNP None
) ) None
. . None
Participants NNS None
were VBD None
578 CD Size
children NNS Age
who WP None
were VBD None
part NN None
of IN None
an DT None
ongoing JJ None
population-based JJ None
, , None
case-control JJ None
study NN None
of IN None
2- JJ Age
to TO Age
5-year JJ Age
olds NNS Age
with IN None
ASD NNP None
, , None
DD NNP None
, , None
and CC None
the DT None
general JJ None
population NN None
. . None
Four CD Size
hundred VBD Size
fifty-three JJ Size
children NNS None
with IN None
ASD NNP None
and CC None
125 CD Size
DD NNP None
children NNS Age
were VBD None
included VBN None
. . None
Hispanic JJ None
families NNS None
non-Hispanic JJ None
families NNS None
. . None
Families NNS None
Underimmunized VBN None
children NNS Age
families NNS None
of IN None
young JJ Age
children NNS Age
with IN None
neurodevelopmental JJ None
disorders NNS None
-DOCSTART- -X- N

methadone NN None
maintenance NN None
heroin VB Condition
addicts NNS Condition
waiting VBG None
for IN None
treatment NN None
in IN None
standard JJ None
comprehensive JJ None
methadone NN None
maintenance NN None
programs NNS None
. . None
New NNP None
York NNP None
City NNP None
. . None
A NNP None
sample NN None
of IN None
301 CD Size
volunteer NN None
subjects NNS None
recruited VBN None
from IN None
the DT None
waiting VBG None
list NN None
for IN None
treatment NN None
in IN None
the DT None
Beth NNP None
Israel NNP None
methadone NN None
program NN None
persons NNS None
awaiting VBG None
entry NN None
into IN None
comprehensive JJ None
treatment NN None
-DOCSTART- -X- N

provisional JJ Condition
restorations NNS Condition
: : Condition
polymethyl NN None
methacrylate NN None
( ( None
PMMA NNP None
) ) None
self-cured VBD None
acrylic JJ None
resin NN None
provisional JJ None
crowns NNS None
. . None
Three NNP None
types NNS None
of IN None
PMMA NNP None
surfaces NNS None
were VBD None
tested VBN None
: : None
( ( None
1 CD None
) ) None
polished VBN None
, , None
( ( None
2 CD None
) ) None
polished VBN None
and CC None
coated VBN None
with IN None
bonding NN None
agent NN None
, , None
and CC None
( ( None
3 CD None
) ) None
polished VBN None
and CC None
coated VBN None
with IN None
light-cured JJ None
liquid JJ None
polish NN None
. . None
-DOCSTART- -X- N

larger JJR None
patient JJ None
population NN None
. . None
Nine NNP None
hundred VBD None
patient JJ None
aged VBN None
< NN None
80 CD None
, , None
with IN None
diabetes NNS None
of IN None
> NN None
or CC None
=1 JJ None
year NN None
known VBN None
duration NN None
, , None
treated VBN None
by IN None
either DT None
diet JJ None
alone NN None
or CC None
diet JJ None
and CC None
oral JJ None
agents NNS None
, , None
will MD None
be VB None
recruited VBN None
in IN None
15 CD None
centres NNS None
and CC None
followed VBD None
for IN None
4 CD None
years NNS None
. . None
-DOCSTART- -X- N

geriatric JJ Condition
depression NN Condition
Thirty-eight JJ Size
patients NNS None
treatment NN None
of IN None
late-life JJ Condition
depression NN Condition
. . None
small JJ None
and CC None
predominantly RB None
White NNP None
sample NN None
. . None
-DOCSTART- -X- N

two CD None
intensive JJ None
care NN None
units NNS None
in IN None
two CD None
adult NN None
acute NN None
care NN None
hospitals NNS None
. . None
Thirty NNP Size
patients NNS None
admitted VBD None
to TO None
the DT None
intensive JJ None
care NN None
unit NN None
who WP None
had VBD None
a DT None
thermodilution NN None
pulmonary JJ None
artery NN None
catheter NN None
in IN None
place NN None
. . None
Ages NNS None
ranged VBD None
from IN None
39 CD Age
to TO Age
80 CD Age
years NNS None
( ( None
mean NN None
of IN None
66.4 CD None
+/- JJ None
11.3 CD None
years NNS None
) ) None
. . None
-DOCSTART- -X- N

metabolically RB None
obese JJ None
, , None
normal-weight JJ None
individuals NNS None
: : None
metabolically RB None
obese JJ None
, , None
normal-weight JJ None
( ( None
MONW NNP None
) ) None
individuals NNS None
. . None
A NNP None
total NN None
of IN None
47 CD None
MONW NNP None
individuals NNS None
with IN None
hypomagnesemia NN None
were VBD None
enrolled VBN None
of IN None
MONW NNP None
individuals NNS None
. . None
-DOCSTART- -X- N

subarachnoid NN Condition
and CC None
intraventricular JJ Condition
cysticercosis NN Condition
. . None
Thirty-six JJ Size
patients NNS None
with IN None
subarachnoid JJ Condition
and CC None
intraventricular JJ Condition
cysticercosis NN Condition
-DOCSTART- -X- N

children NNS Age
with IN None
pervasive JJ Condition
developmental JJ Condition
disorder NN Condition
Young NNP Age
children NNS Age
with IN None
pervasive JJ Condition
developmental JJ Condition
disorder NN Condition
7 CD Size
with IN None
autism NN Condition
, , None
8 CD Size
with IN None
pervasive JJ None
developmental JJ None
disorder NN None
not RB None
otherwise RB None
specified VBN None
-- : None
NOS NNP None
7 CD Size
with IN None
autism NN None
, , None
6 CD Size
with IN None
pervasive JJ Condition
developmental JJ Condition
disorder NN Condition
NOS NNP None
Children NNP Age
with IN None
pervasive JJ Condition
developmental JJ Condition
disorder NN Condition
-DOCSTART- -X- N

advanced JJ Condition
breast NN Condition
cancer NN Condition
: : None
From IN None
January NNP None
1985 CD None
to TO None
September NNP None
1988 CD None
, , None
60 CD Size
women NNS Sex
with IN None
advanced JJ Condition
breast NN Condition
cancer NN Condition
were VBD None
randomized VBN None
in IN None
two CD None
arms NNS None
All DT None
patients NNS None
were VBD None
post-menopausal JJ Condition
, , None
previously RB None
untreated VBN None
with IN None
hormone NN None
therapy NN None
, , None
and CC None
with IN None
tumor NN None
receptor NN None
status NN None
determined VBD None
immediately RB None
before IN None
randomization NN None
; : None
all DT None
had VBD None
objectively RB None
evaluable JJ Condition
lesions NNS Condition
. . None
Thirty-one NN Size
and CC None
29 CD Size
patients NNS None
were VBD None
included VBN None
respectively RB None
in IN None
arms NNS None
A NNP None
and CC None
B NNP None
. . None
-DOCSTART- -X- N

metastatic JJ None
breast NN None
cancer NN None
patients NNS None
with IN None
metastatic JJ None
breast NN None
cancer NN None
( ( None
MBC NNP None
) ) None
patients NNS None
-DOCSTART- -X- N

adults NNS None
with IN None
high JJ None
functioning VBG None
autism NN None
spectrum NN None
disorders NNS None
. . None
adults NNS None
with IN None
ASD NNP None
who WP None
showed VBD None
initial JJ None
impairment NN None
in IN None
face NN None
recognition NN None
. . None
individuals NNS None
with IN None
ASD NNP None
-DOCSTART- -X- N

rheumatic JJ None
arthropathies NNS None
( ( None
inflammatory NN None
and CC None
degenerative NN None
) ) None
] NN None
patients NNS None
suffering VBG None
from IN None
inflammatory NN None
and CC None
degenerative JJ None
rheumatic JJ None
arthropathies NNS None
. . None
30 CD None
subjects NNS None
using VBG None
the DT None
controlled JJ None
experiment NN None
technique NN None
according VBG None
to TO None
the DT None
between IN None
patient NN None
pattern NN None
, , None
attributing VBG None
parsalmide NN None
and CC None
indomethacin NN None
at IN None
random NN None
to TO None
two CD None
groups NNS None
. . None
-DOCSTART- -X- N

participants NNS None
in IN None
the DT None
Appropriate NNP None
Blood NNP None
Pressure NNP None
Control NNP None
in IN None
Diabetes NNP None
trial NN None
. . None
two CD None
study NN None
populations NNS None
: : None
a DT None
hypertensive JJ None
one NN None
( ( None
diastolic JJ None
blood NN None
pressure NN None
of IN None
> NN None
or CC None
= $ None
90.0 CD None
mm NN None
Hg NNP None
at IN None
the DT None
time NN None
of IN None
randomization NN None
) ) None
and CC None
a DT None
normotensive JJ None
one NN None
( ( None
diastolic JJ None
blood NN None
pressure NN None
of IN None
80.0-89.0 JJ None
mm NN None
Hg NNP None
at IN None
the DT None
time NN None
of IN None
randomization NN None
) ) None
. . None
950 CD None
men NNS None
and CC None
women NNS None
aged VBN None
40-74 JJ None
years NNS None
There EX None
were VBD None
470 CD None
randomized JJ None
participants NNS None
in IN None
the DT None
hypertensive JJ None
population NN None
and CC None
480 CD None
randomized JJ None
participants NNS None
in IN None
the DT None
normotensive JJ None
population NN None
. . None
randomized JJ None
patients NNS None
-DOCSTART- -X- N

hypertensive JJ None
and CC None
hypercholesterolaemic JJ None
patients NNS None
patients NNS None
who WP None
were VBD None
also RB None
encouraged VBN None
to TO None
improve VB None
their PRP$ None
lifestyle NN None
. . None
Fifty-four JJ None
general JJ None
practice NN None
surgeries NNS None
in IN None
Norway NNP None
. . None
Hypertensive JJ None
patients NNS None
, , None
210 CD None
females NNS None
and CC None
160 CD None
males NNS None
, , None
treated VBD None
or CC None
untreated JJ None
with IN None
antihypertensive JJ None
drugs NNS None
with IN None
a DT None
sitting VBG None
diastolic JJ None
blood NN None
pressure NN None
between IN None
95 CD None
and CC None
115 CD None
mmHg NN None
and CC None
a DT None
serum JJ None
total NN None
cholesterol NN None
between IN None
6.5 CD None
mmol/l NNS None
( ( None
7.0 CD None
for IN None
those DT None
age NN None
60-67 JJ None
years NNS None
) ) None
and CC None
9.0 CD None
mmol/l NN None
. . None
hypertensive JJ None
and CC None
hypercholesterolaemic JJ None
patients NNS None
. . None
-DOCSTART- -X- N

after IN None
lumbar JJ Condition
disk NN Condition
surgery NN Condition
: : None
patient JJ None
outcome NN None
after IN Condition
lumbar NN Condition
disk NN Condition
surgery NN Condition
. . None
Departments NNS None
of IN None
physical JJ None
medicine NN None
and CC None
rehabilitation NN None
and CC None
orthopedics NNS None
at IN None
a DT None
Finnish JJ None
hospital NN None
. . None
Patients NNPS None
( ( None
N=126 NNP Size
) ) None
were VBD None
randomized VBN None
-DOCSTART- -X- N

superficial JJ None
bladder NN None
cancer NN None
superficial JJ None
bladder NN None
cancer NN None
. . None
total NN None
of IN None
99 CD None
subjects NNS None
with IN None
resected JJ None
superficial JJ None
bladder NN None
cancer NN None
( ( None
pTa NN None
, , None
pT1 NN None
) ) None
bladder NN None
cancer NN None
. . None
-DOCSTART- -X- N

patients NNS None
treated VBN None
with IN None
CDDP NNP None
( ( None
80 CD None
mg/m2 NN None
) ) None
-DOCSTART- -X- N

20 CD Size
male JJ Sex
subjects NNS None
-DOCSTART- -X- N

children NNS None
with IN None
autistic JJ Condition
spectrum NN Condition
disorders NNS Condition
: : None
children NNS None
with IN None
autistic JJ Condition
spectrum NN Condition
disorders NNS Condition
. . None
9 CD Size
Caucasian JJ Size
boys NNS None
, , None
3.8-8.1 CD Age
years NNS Age
old JJ None
, , None
with IN None
a DT None
DSM-IV JJ Condition
diagnosis NN Condition
of IN Condition
a DT Condition
pervasive JJ Condition
developmental NN Condition
disorder NN Condition
, , None
living VBG None
with IN None
their PRP$ None
families NNS None
, , None
receiving VBG None
no DT None
chronic JJ None
medications NNS None
, , None
and CC None
without IN None
significant JJ None
gastrointestinal JJ None
symptoms NNS None
. . None
Children NNP Age
with IN None
marked VBN None
stereotypy NN None
( ( None
meaningless NN None
, , None
repetitive JJ None
behaviors NNS None
) ) None
Our PRP$ None
subjects NNS None
did VBD None
not RB None
have VB None
prominent JJ None
gastrointestinal JJ None
symptoms NNS None
children NNS Age
with IN None
autistic JJ None
spectrum NN None
disorders NNS None
-DOCSTART- -X- N

eyes NNS None
with IN None
functioning VBG None
filtering VBG None
blebs NN None
: : None
eyes NNS None
with IN None
filtering VBG None
blebs NN None
. . None
36 CD Size
eyes NNS Size
of IN Size
34 CD Size
patients NNS Size
with IN None
functioning VBG None
filtering VBG None
blebs NNS None
who WP None
were VBD None
to TO None
undergo VB None
cataract NN None
surgery NN None
. . None
-DOCSTART- -X- N

knee NN Condition
osteoarthritis NN Condition
( ( Condition
KOA NNP Condition
, , Condition
Bi NNP Condition
syndrome NN Condition
of IN Condition
knee NN Condition
) ) Condition
Totally RB None
61 CD Size
patients NNS None
with IN None
grade NN Condition
I PRP Condition
to TO Condition
III NNP Condition
KOA NNP Condition
-DOCSTART- -X- N

International NNP None
Czech NNP None
and CC None
Slovak NNP None
patients NNS None
with IN None
differentiated JJ Condition
thyroid NN Condition
cancer NN Condition
. . None
Slovak NNP None
patients NNS None
with IN None
differentiated JJ None
thyroid NN None
cancer NN None
in IN None
Slovak NNP None
and CC None
Czech NNP None
hospitals NNS None
. . None
From NNP None
September NNP None
1991 CD None
to TO None
October NNP None
2005 CD None
in IN None
the DT None
Department NNP None
of IN None
Nuclear NNP None
Medicine NNP None
in IN None
Ostrava NNP None
357 CD Size
patients NNS None
from IN None
the DT None
Slovak NNP None
Republic NNP None
with IN None
differentiated VBN Condition
thyroid NN Condition
cancers NNS Condition
( ( None
follicular JJ Condition
and CC Condition
papillary JJ Condition
) ) None
underwent NN None
complex JJ None
therapy NN None
. . None
They PRP None
were VBD None
diagnosed VBN None
and CC None
operated VBN None
due JJ None
to TO None
the DT None
cancer NN None
( ( None
near-total JJ Condition
thyroidectomy NN Condition
and CC None
removal NN Condition
of IN Condition
lymph JJ Condition
node JJ Condition
metastases NNS Condition
) ) None
in IN None
Slovak NNP None
hospitals NNS None
. . None
Then RB None
they PRP None
were VBD None
sent VBN None
to TO None
the DT None
Department NNP None
of IN None
Nuclear NNP None
Medicine NNP None
in IN None
Ostrava NNP None
in IN None
the DT None
Czech NNP None
Republic NNP None
. . None
Slovak NNP None
Republic NNP None
, , None
in IN None
the DT None
University NNP None
Hospital NNP None
in IN None
Martin NNP None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
metastatic JJ Condition
breast NN Condition
cancer NN Condition
: : None
Three NNP Size
hundred VBD Size
two CD Size
patients NNS None
with IN Condition
no DT Condition
previous JJ Condition
chemotherapy NN Condition
for IN None
MBC NNP Condition
patients NNS None
with IN None
no DT None
previous JJ None
chemotherapy NN None
for IN None
MBC NNP None
. . None
-DOCSTART- -X- N

children NNS Age
, , Age
adolescents NNS Age
, , Age
and CC Age
adults NNS Age
with IN Age
mental JJ Age
retardation NN Age
and CC Age
pervasive JJ Age
developmental NN Age
disorders NNS Age
. . Age
children NNS Age
, , Age
adolescents NNS Age
, , Age
and CC Age
adults NNS Age
with IN Age
mental JJ Age
retardation NN Age
( ( Age
MR NNP Age
) ) Age
and CC Age
pervasive JJ Age
developmental NN Age
disorders NNS Age
( ( Age
PDD NNP Age
) ) Age
. . Age
children NNS Condition
, , Condition
adolescents NNS Condition
, , Condition
and CC Condition
adults NNS Condition
with IN Condition
MR NNP Condition
and CC Condition
PDDs NNP Condition
21-subject JJ None
subset NN None
during IN None
the DT None
course NN None
of IN None
a DT None
double-blind JJ None
, , None
placebo-controlled JJ None
trial NN None
. . None
children NNS Age
and CC Age
adolescents NNS Age
( ( Age
n=10 NN Age
) ) Age
, , Age
mean JJ Age
age NN Age
of IN Age
12.5 CD Age
years NNS Age
adults NNS Age
, , Age
mean JJ Age
age NN Age
of IN Age
35.3 CD Age
years NNS Age
-DOCSTART- -X- N

patients NNS None
with IN None
congestive JJ None
heart NN None
failure NN None
. . None
patients NNS None
with IN None
congestive JJ None
heart NN None
failure NN None
97 CD None
patients NNS None
( ( None
aged VBN None
31-83 CD None
years NNS None
) ) None
belonging VBG None
to TO None
NYHA NNP None
class NN None
II NNP None
and CC None
III NNP None
with IN None
congestive JJ None
heart NN None
failure NN None
of IN None
different JJ None
aetiology NN None
, , None
but CC None
without IN None
any DT None
complex JJ None
ventricular NN None
arrhythmias NN None
in IN None
basal NN None
conditions NNS None
( ( None
couplets NNS None
with IN None
R'-R NNP None
less JJR None
than IN None
or CC None
equal JJ None
to TO None
400 CD None
msec NNS None
, , None
ventricular JJ None
tachycardia NN None
, , None
R NNP None
on IN None
T NNP None
phenomena NN None
) ) None
. . None
-DOCSTART- -X- N

head NN Condition
and CC Condition
neck NN Condition
cancer NN Condition
patients NNS None
. . None
head NN Condition
and CC Condition
neck NN Condition
cancer NN Condition
patients NNS None
undergoing VBG None
treatment NN None
for IN None
head NN Condition
and CC Condition
neck NN Condition
cancers NNS Condition
. . None
patients NNS None
undergoing VBG None
treatment NN None
for IN None
head NN Condition
and CC Condition
neck NN Condition
cancers NNS Condition
. . None
-DOCSTART- -X- N

chronic JJ None
hemodialysis NN Condition
patients NNS None
. . None
14 CD Size
chronic JJ Condition
uremic JJ Condition
patients NNS Condition
on IN Condition
regular JJ Condition
hemodialysis NN Condition
treatment NN None
. . None
Nine JJ Size
patients NNS None
with IN None
chronic JJ Condition
renal JJ Condition
anemia NN Condition
on IN Condition
maintenance NN Condition
hemodialysis NN Condition
patients NNS None
had VBD None
chronic JJ None
hemodialysis NN None
patients NNS None
-DOCSTART- -X- N

Endometrial JJ None
cytodiagnosis NN None
cytological JJ None
screening NN None
for IN None
endometrial JJ None
cancer NN None
315 CD Size
women NNS Size
( ( None
premenopause IN None
251 CD Size
, , None
postmenopause RB None
64 CD Size
) ) None
were VBD None
randomly RB None
assigned VBN None
to TO None
two CD None
groups NNS None
who WP None
underwent VBP None
the DT None
endometrial JJ None
cytological JJ None
screening NN None
with IN None
either CC None
the DT None
softcyte NN None
or CC None
the DT None
endocyte NN None
. . None
screening VBG None
for IN None
endometrial JJ None
cancer NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
hepatocellular JJ None
carcinoma NN None
Group NNP None
A NNP None
( ( None
19 CD None
patients NNS None
) ) None
group NN None
B NNP None
( ( None
18 CD None
patients NNS None
) ) None
-DOCSTART- -X- N

Consecutive JJ Condition
procedural JJ Condition
angiograms NNS Condition
of IN Condition
patients NNS Condition
randomly RB Condition
assigned VBN Condition
to TO Condition
EES NNP Condition
( ( Condition
n=669 NN Condition
) ) Condition
or CC Condition
PES NNP Condition
( ( Condition
n=333 RB Condition
) ) Condition
were VBD Condition
analysed VBN Condition
by IN Condition
an DT Condition
independent JJ Condition
angiographic JJ Condition
core NN Condition
laboratory NN Condition
. . Condition
patients NNS None
receiving VBG None
EES NNP None
compared VBN None
to TO None
PES NNP None
Patients NNS None
treated VBD None
with IN None
EES NNP None
rather RB None
than IN None
PES NNP None
-DOCSTART- -X- N

pigs NNS None
with IN Condition
and CC Condition
without IN Condition
passively RB Condition
acquired VBN Condition
maternal JJ Condition
antibody NN Condition
Pigs NNS None
pigs NNS None
inoculated VBD None
with IN None
strain NN None
Bartha NNP None
or CC None
with IN None
the DT None
inactivated JJ None
vaccine NN None
-DOCSTART- -X- N

uncomplicated JJ Condition
falciparum NN Condition
malaria NN Condition
. . Condition
multicentre JJ None
study NN None
, , None
conducted VBN None
in IN None
Senegal NNP None
and CC None
in IN None
Cameroon NNP None
in IN None
2005 CD None
any DT None
subject JJ None
weighting NN None
more JJR None
than IN None
10 CD None
kg NNS None
, , None
presenting VBG None
with IN None
a DT None
malaria NN None
paroxysm NN None
confirmed VBN None
by IN None
parasitaemia NN None
> NN None
or CC None
= $ None
1,000/microl CD None
, , None
after IN None
informed JJ None
consent NN None
. . None
Three-hundred JJ Size
and CC Size
sixteen JJ Size
patients NNS None
were VBD None
included VBN None
in IN None
the DT None
study NN None
. . None
-DOCSTART- -X- N

low JJ Condition
back RB Condition
pain NN Condition
low JJ None
back RB None
pain NN None
( ( None
LBP NNP None
) ) None
and CC None
disability NN None
. . None
Middle-aged JJ None
working VBG None
men NNS None
with IN None
recent JJ None
LBP NNP None
but CC None
without IN None
severe JJ None
disability NN None
training NN None
LBP NNP None
and CC None
disability NN None
among IN None
middle JJ None
aged VBN None
working VBG None
men NNS None
. . None
-DOCSTART- -X- N

subjects NNS Condition
with IN Condition
mild-to-moderate JJ Condition
asthma NN Condition
. . Condition
subjects NNS None
with IN None
mild-to-moderate JJ None
asthma NN None
, , None
three CD None
groups NNS None
of IN None
11 CD None
patients NNS None
-DOCSTART- -X- N

type NN Condition
2 CD Condition
diabetes NNS Condition
. . None
patients NNS None
with IN None
type JJ Condition
2 CD Condition
diabetes NNS Condition
type NN Condition
2 CD Condition
diabetic JJ Condition
patients NNS None
eight CD Size
patients NNS None
with IN None
type JJ Condition
2 CD Condition
diabetes NNS Condition
who WP None
were VBD None
being VBG None
treated VBN None
with IN None
oral JJ None
glucose-lowering JJ None
agents NNS None
. . None
type NN Condition
2 CD Condition
diabetic JJ Condition
patients NNS None
atherosclerosis NN Condition
in IN None
type NN Condition
2 CD Condition
diabetic JJ Condition
patients NNS None
. . None
-DOCSTART- -X- N

robot-assisted JJ None
motor NN None
training NN None
after IN None
chronic JJ Condition
stroke NN Condition
: : None
robot-assisted JJ None
reaching NN None
programs NNS None
robot-assisted JJ None
training VBG None
out IN None
of IN None
the DT None
horizontal JJ None
plane NN None
Adults NNP Age
( ( None
N=62 NNP Size
) ) None
with IN None
chronic JJ Condition
, , Condition
stroke-related JJ Condition
arm NN Condition
weakness NN Condition
stratified VBN None
by IN None
impairment JJ None
severity NN None
using VBG None
baseline JJ None
UE NNP None
motor NN None
assessments NNS None
. . None
1.40-4.47 JJ None
) ) None
. . None
Participants NNS None
with IN None
greater JJR None
motor NN None
impairment NN None
( ( None
n=41 JJ None
) ) None
demonstrated VBD None
-DOCSTART- -X- N

Sixty-one JJ Size
patients NNS None
with IN None
ovarian JJ Condition
cancer NN Condition
or CC None
endometrial JJ Condition
cancer NN Condition
who WP None
underwent JJ None
retroperitoneal NN Condition
lymph NN Condition
node JJ Condition
resection NN Condition
-DOCSTART- -X- N

artery NN Condition
bypass NN Condition
grafting NN Condition
. . Condition
patients NNS Condition
who WP Condition
undergo VBP Condition
off-pump JJ Condition
coronary JJ Condition
artery NN Condition
bypass NN Condition
grafting NN Condition
( ( Condition
CABG NNP Condition
) ) Condition
. . Condition
Thirty-two JJ Condition
patients NNS Condition
with IN Condition
left JJ Condition
anterior JJ Condition
descending VBG Condition
coronary JJ Condition
artery NN Condition
( ( Condition
LAD NNP Condition
) ) Condition
or CC Condition
two-vessel JJ Condition
heart NN Condition
disease NN Condition
( ( Condition
including VBG Condition
LAD NNP Condition
) ) Condition
who WP Condition
were VBD Condition
to TO Condition
undergo VB Condition
off-pump JJ Condition
CABG NNP Condition
patients NNS None
undergoing VBG None
off-pump JJ None
myocardial JJ None
revascularization NN None
-DOCSTART- -X- N

peripheral JJ Condition
pulmonary JJ Condition
lesions NNS Condition
: : Condition
Two CD None
hundred VBD None
two CD None
patients NNS None
with IN None
PPLs NNP None
and CC None
positive JJ None
EBUS NNP None
findings NNS None
were VBD None
enrolled VBN None
. . None
A DT None
total NN None
of IN None
182 CD None
patients NNS None
( ( None
94 CD None
in IN None
the DT None
EBUS NNP None
CDPs NNP None
group NN None
and CC None
88 CD None
in IN None
the DT None
EBUS-TBNA JJ None
plus CC None
CDPs NNP None
group NN None
) ) None
were VBD None
analyzed VBN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
gynecologic JJ Condition
malignancies NNS Condition
. . None
patients NNS None
with IN None
gynecologic JJ Condition
malignancies NNS Condition
. . None
Ninety-three JJ Size
consecutive JJ None
patients NNS None
with IN None
gynecologic JJ Condition
pelvic JJ Condition
malignancies NNS Condition
who WP None
underwent VBP None
surgery NN None
including VBG None
pelvic NN None
or CC None
pelvic NN None
and CC None
paraaortic JJ None
lymphadenectomy NN None
93 CD Size
patients NNS None
-DOCSTART- -X- N

10 CD Size
consecutive JJ None
patients NNS None
with IN None
a DT None
minute NN None
ventilation-sensing NN None
, , None
rate-modulating JJ None
ventricular JJ None
pacemaker NN None
implanted VBN None
for IN None
complete JJ None
heart NN None
block NN None
. . None
All DT None
patients NNS None
had VBD None
paroxysmal JJ Condition
( ( None
seven CD Size
patients NNS None
) ) None
or CC None
chronic JJ None
( ( None
three CD Size
patients NNS None
) ) None
atrial JJ Condition
fibrillation NN Condition
and CC None
were VBD None
referred VBN None
for IN None
catheter JJR None
ablation NN None
of IN None
the DT None
atrioventricular JJ None
junction NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
hip JJ Condition
osteoarthritis NN Condition
: : None
patients NNS None
with IN None
hip NN None
osteoarthritis NN None
( ( None
OA NNP Condition
) ) None
. . None
patients NNS None
from IN None
hospitals NNS None
, , None
primary JJ None
health NN None
care NN None
and CC None
advertisement NN None
, , None
Oslo NNP None
, , None
Norway NNP None
. . None
109 CD Size
patients NNS None
with IN None
radiographic JJ None
and CC None
symptomatic JJ None
hip NN None
OA NNP None
with IN None
mild NN None
to TO None
moderate VB None
symptoms NNS None
. . None
-DOCSTART- -X- N

May NNP None
2008 CD None
to TO None
July NNP None
2010 CD None
, , None
78 CD Condition
patients NNS None
with IN None
knee JJ Condition
osteoarthritis NN Condition
42 CD Size
patients NNS None
in IN None
the DT None
experimental JJ None
group NN None
, , None
including VBG None
16 CD Size
males NNS None
and CC None
26 CD Size
females NNS None
, , None
ranging VBG None
in IN None
age NN None
from IN None
41 CD None
to TO None
63 CD None
years NNS None
, , None
with IN None
an DT None
average NN None
of IN None
( ( None
53.62 CD None
+/- JJ None
6.53 CD None
) ) None
years NNS None
; : None
the DT None
disease NN None
course NN None
ranged VBD None
from IN None
8 CD None
to TO None
24 CD None
months NNS None
, , None
with IN None
an DT None
average NN None
of IN None
( ( None
10.35 CD None
+/- JJ None
6.42 CD None
) ) None
months NNS None
. . None
36 CD Size
patients NNS None
in IN None
the DT None
control NN None
group NN None
, , None
including VBG None
14 CD Size
males NNS None
and CC None
22 CD Size
females NNS None
, , None
ranging VBG None
in IN None
age NN None
from IN None
40 CD None
to TO None
62 CD None
years NNS None
, , None
with IN None
an DT None
average NN None
of IN None
( ( None
54.34 CD None
+/- JJ None
7.67 CD None
) ) None
years NNS None
; : None
the DT None
disease NN None
course NN None
ranged VBD None
from IN None
6 CD None
to TO None
25 CD None
months NNS None
, , None
with IN None
an DT None
average NN None
of IN None
( ( None
11.94 CD None
+/- JJ None
5.13 CD None
) ) None
months NNS None
. . None
with IN None
knee JJ Condition
osteoarthritis NN Condition
-DOCSTART- -X- N

chronic JJ Condition
suppurative JJ Condition
otitis NN Condition
media NNS Condition
. . None
Active NNP Condition
chronic JJ Condition
suppurative NN Condition
otitis NN Condition
media NNS Condition
patients NNS None
are VBP None
being VBG None
considered VBN None
for IN None
surgical JJ None
treatment NN None
. . None
discharging VBG Condition
ears NNS Condition
. . None
Fifty-two JJ Size
patients NNS None
were VBD None
selected VBN None
chronic JJ Condition
suppurative NN Condition
otitis NN Condition
media NNS Condition
. . None
active JJ None
chronic JJ None
suppurative NN None
otitis NN None
media NNS None
-DOCSTART- -X- N

exercise NN None
therapy NN None
in IN None
patients NNS None
with IN None
acute JJ Condition
low JJ Condition
back RB Condition
pain NN Condition
. . None
patients NNS None
with IN None
acute JJ None
low JJ None
back RB None
pain NN None
. . None
Patients NNS None
with IN None
acute JJ Condition
nonspecific NN Condition
low JJ Condition
back RB Condition
pain NN Condition
and CC None
a DT None
paid VBN Condition
job NN Condition
were VBD None
included VBN None
for IN None
analysis NN None
. . None
40 CD None
general JJ None
practices NNS None
363 CD Size
patients NNS None
who WP None
were VBD None
gainfully RB None
employed VBN None
were VBD None
included VBN None
. . None
patients NNS None
with IN None
acute JJ None
low JJ None
back RB None
pain NN None
-DOCSTART- -X- N

informal JJ None
caregivers NNS None
of IN None
heart NN Condition
failure NN Condition
patients NNS Condition
. . None
informal JJ None
caregivers NNS None
of IN None
patients NNS None
with IN None
heart NN None
failure NN None
. . None
60 CD Size
caregiver/patient NN Size
dyads NNS Size
in IN None
a DT None
cross-sectional JJ None
design NN None
. . None
Patients NNS None
with IN None
chronic JJ Condition
stable JJ Condition
heart NN Condition
failure NN Condition
were VBD None
recruited VBN None
from IN None
out-patient JJ None
clinics NNS None
. . None
informal JJ None
caregivers NNS None
of IN None
heart NN None
failure NN None
patients NNS None
. . None
-DOCSTART- -X- N

3-5 JJ Condition
year NN Condition
old JJ Condition
children NNS Condition
attending VBG Condition
long RB Condition
day NN Condition
care NN Condition
services NNS Condition
: : Condition
Young NNP None
children NNS None
young JJ None
children NNS None
children NNS None
attending VBG None
long RB None
day NN None
care NN None
services NNS None
. . None
Three CD None
hundred VBD None
children NNS None
aged VBN None
between IN None
3-5 CD None
years NNS None
from IN None
twenty NN None
randomly RB None
selected VBN None
long RB None
day NN None
care NN None
services NNS None
in IN None
the DT None
Hunter NNP None
Region NNP None
of IN None
New NNP None
South NNP None
Wales NNP None
, , None
Australia NNP None
young JJ None
children NNS None
in IN None
long JJ None
day NN None
care NN None
settings NNS None
. . None
Australian NNP None
New NNP None
Zealand NNP None
Clinical NNP None
Trials NNP None
Registry NNP None
-DOCSTART- -X- N

knee NN Condition
arthroplasty NN Condition
: : None
240 CD Size
patients NNS Size
. . None
five CD None
regimens NNS None
( ( None
four CD None
intravenous NN None
, , None
one CD None
local JJ None
; : None
40 CD None
patients NNS None
each DT None
) ) None
with IN None
a DT None
control NN None
group NN None
-DOCSTART- -X- N

children NNS None
with IN None
sickle NN Condition
cell NN Condition
anemia NN Condition
and CC None
abnormal JJ None
results NNS None
on IN None
transcranial JJ None
Doppler NNP None
ultrasonography NN None
. . None
children NNS None
with IN None
sickle NN Condition
cell NN Condition
anemia NN Condition
children NNS None
with IN None
sickle NN Condition
cell NN Condition
anemia NN Condition
who WP None
were VBD None
at IN None
high JJ None
risk NN None
for IN None
stroke NN Condition
children NNS None
with IN None
sickle NN Condition
cell NN Condition
anemia NN Condition
and CC None
no DT None
history NN None
of IN None
stroke NN Condition
had VBD None
to TO None
have VB None
undergone JJ None
two CD None
transcranial JJ None
Doppler NNP None
studies NNS None
that WDT None
showed VBD None
that IN None
the DT None
time-averaged JJ None
mean JJ None
blood-flow JJ None
velocity NN None
in IN None
the DT None
internal JJ None
carotid NN None
or CC None
middle JJ None
cerebral JJ None
artery NN None
was VBD None
200 CD None
cm JJ None
per IN None
second NN None
or CC None
higher JJR None
. . None
patients NNS None
130 CD Size
children NNS None
( ( None
mean JJ None
[ NNP None
+/-SD NN None
] NNP None
age NN None
, , None
8.3+/-3.3 CD None
years NNS None
) ) None
were VBD None
enrolled VBN None
; : None
63 CD Size
children NNS None
with IN None
sickle NN Condition
cell NN Condition
anemia NN Condition
who WP None
have VBP None
abnormal JJ None
results NNS None
on IN None
transcranial JJ None
Doppler NNP None
ultrasonography NN None
. . None
-DOCSTART- -X- N

SDAT NNP Condition
and CC None
MID NNP Condition
. . None
96 CD Size
mildly RB None
to TO None
moderately RB None
demented JJ None
patients NNS None
( ( None
72 CD Size
women NNS Sex
, , None
24 CD Size
men NNS Sex
) ) None
, , None
aged VBN None
61-96 CD Age
years NNS Age
( ( None
mean VB None
82 CD Age
) ) None
, , None
diagnosed VBD None
according VBG None
to TO None
DSM-III NNP None
criteria NNS None
. . None
Patients NNS None
were VBD None
off RP None
drugs NNS None
for IN None
at IN None
least JJS None
2 CD None
weeks NNS None
and CC None
subdiagnosed VBD None
according VBG None
to TO None
the DT None
modified VBN None
Marshall-Hachinski NNP None
ischemic JJ None
score NN None
and CC None
CT NNP None
in IN None
45 CD Size
senile JJ Condition
dementia NN Condition
of IN None
the DT None
Alzheimer NNP Condition
type NN Condition
( ( Condition
SDAT NNP Condition
) ) Condition
and CC None
51 CD Size
multiinfarct NN Condition
dementia NN Condition
( ( Condition
MID NNP Condition
) ) Condition
patients NNS None
. . None
-DOCSTART- -X- N

children NNS Condition
with IN Condition
autistic JJ Condition
spectrum NN Condition
disorder NN Condition
. . Condition
children NNS None
with IN None
autistic JJ None
spectrum NN None
disorder NN None
. . None
Twenty NNP None
( ( None
20 CD None
) ) None
children NNS None
with IN None
autistic JJ None
spectrum NN None
disorder NN None
, , None
ages VBZ None
3-8 CD None
years NNS None
. . None
autistic JJ None
children NNS None
-DOCSTART- -X- N

treated JJ None
hypertensive JJ Condition
patients NNS None
hypertensive JJ None
patients NNS None
receiving VBG None
drug NN None
treatment NN None
people NNS None
with IN None
one CD None
or CC None
more JJR None
cardiovascular JJ Condition
risk NN Condition
factors NNS Condition
Fifteen NNP None
Italian JJ None
hypertension NN None
units NNS None
studied VBD None
142 CD Size
hypertensive JJ None
patients NNS None
( ( None
76 CD Size
men NNS Sex
, , None
66 CD Size
women NNS Sex
; : None
mean JJ None
age NN None
59 CD Age
+/- JJ Age
5.9 CD Age
years NNS Age
) ) None
treated VBD None
with IN None
different JJ None
antihypertensive JJ None
drugs NNS None
-DOCSTART- -X- N

granulocytopenic JJ None
cancer NN None
patients NNS None
. . None
747 CD None
febrile JJ None
granulocytopenic JJ None
patients NNS None
with IN None
cancer NN None
cancer NN None
patients NNS None
with IN None
fever NN None
and CC None
granulocytopenia NN None
. . None
-DOCSTART- -X- N

12 CD None
normal JJ None
subjects NNS None
( ( None
6 CD None
men NNS None
, , None
6 CD None
women NNS None
; : None
ages VBZ None
21 CD None
to TO None
26 CD None
years NNS None
) ) None
before IN None
and CC None
after IN None
ingestion NN None
of IN None
caffeine NN None
normal JJ None
subjects NNS None
-DOCSTART- -X- N

individuals NNS None
in IN None
an DT None
RCT NNP None
of IN None
pharmacotherapy NN None
and CC None
counseling VBG None
for IN None
smoking VBG None
cessation NN None
individuals NNS None
enrolled VBN None
in IN None
a DT None
comparative JJ None
effectiveness NN None
trial NN None
of IN None
cessation NN None
therapies NNS None
between IN None
October NNP None
2005 CD None
and CC None
May NNP None
2007 CD None
( ( None
1346 CD None
total NN None
participants NNS None
; : None
1338 CD None
with IN None
requisite JJ None
data NNS None
for IN None
further JJ None
analysis NN None
) ) None
. . None
-DOCSTART- -X- N

Post-laparoscopic NNP Condition
cholecystectomy NN Condition
pain NN Condition
: : None
Postoperative NNP Condition
pain NN Condition
after IN Condition
laparoscopic NN Condition
cholecystectomy NN Condition
( ( Condition
LC NNP Condition
) ) Condition
Two CD Size
hundred VBD Size
patients NNS None
with IN None
similar JJ None
demographics NNS None
undergoing JJ None
elective JJ None
LC NNP None
four CD None
groups NNS None
of IN None
50 CD Size
patients NNS None
each DT None
patients NNS None
parietal JJ Condition
( ( Condition
somatic JJ Condition
) ) Condition
abdominal JJ Condition
pain NN Condition
. . None
Patients NNS None
in IN None
each DT None
group NN None
all DT None
patients NNS None
-DOCSTART- -X- N

12 CD Size
healthy JJ None
young JJ None
volunteers NNS None
. . None
-DOCSTART- -X- N

early-stage JJ None
non-small-cell JJ None
lung NN None
cancer NN None
( ( None
IFCT NNP None
0002 CD None
trial NN None
) ) None
. . None
resectable JJ None
StageI-II JJ None
non-small-cell JJ None
lung NN None
cancer NN None
( ( None
NSCLC NNP None
) ) None
. . None
RESULTS VB None
A DT None
total NN None
of IN None
528 CD None
patients NNS None
in IN None
early-stage JJ None
NSCLC NNP None
. . None
-DOCSTART- -X- N

healthy JJ Condition
male JJ Condition
subjects NNS Condition
. . Condition
12 CD None
healthy JJ None
male NN None
volunteers NNS None
. . None
-DOCSTART- -X- N

young JJ None
autistic JJ None
children NNS None
: : None
young JJ None
autistic JJ None
children NNS None
Eleven NNP None
children NNS None
with IN None
autistic JJ None
disorder NN None
, , None
aged VBD None
3.0 CD None
to TO None
8.3 CD None
years NNS None
24 CD None
children NNS None
-DOCSTART- -X- N

cytomegalovirus NN Condition
retinitis NN Condition
in IN None
patients NNS None
with IN None
acquired JJ None
immunodeficiency NN None
syndrome NN None
: : None
The DT None
Studies NNPS None
of IN None
Ocular JJ Condition
Complications NNS Condition
of IN None
AIDS NNP None
Research NNP None
Group NNP None
. . None
AIDS NNP None
Clinical JJ None
Trials NNP None
Group NNP None
. . None
Two CD Size
hundred VBD Size
nine CD Size
patients NNS None
with IN None
acquired JJ Condition
immunodeficiency NN Condition
syndrome NN Condition
and CC None
active JJ None
CMV NNP Condition
retinitis NN Condition
were VBD None
enrolled VBN None
in IN None
a DT None
multicenter NN None
, , None
phase NN None
2/3 CD None
, , None
randomized VBN None
, , None
placebo-controlled JJ None
clinical JJ None
trial NN None
. . None
Among IN None
patients NNS None
with IN None
newly RB None
diagnosed VBN Condition
retinitis NN Condition
-DOCSTART- -X- N

children NNS Age
with IN None
autistic JJ Condition
spectrum NN Condition
disorders NNS Condition
. . None
children NNS Age
with IN None
Autistic NNP None
Spectrum NNP None
Disorders NNP None
( ( None
ASD NNP Condition
) ) None
. . None
Thirty-two JJ Size
children NNS Age
with IN None
ASD NNP Condition
treatment NN None
group NN None
control NN None
group NN None
children NNS Age
with IN None
ASD NNP Condition
. . None
-DOCSTART- -X- N

high JJ Condition
risk NN Condition
trauma NN Condition
patients NNS None
: : None
A DT None
group NN None
of IN None
48 CD Size
critically RB Condition
injured JJ Condition
patients NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
amyotrophic JJ Condition
lateral JJ Condition
sclerosis NN Condition
. . None
Fifty-seven CD Size
patients NNS None
with IN None
amyotrophic JJ Condition
lateral JJ Condition
sclerosis NN Condition
( ( Condition
ALS NNP Condition
) ) Condition
patients NNS None
with IN None
ALS NNP Condition
-DOCSTART- -X- N

humans NNS None
in IN None
vivo NN None
: : None
20 CD Size
healthy JJ None
women NNS Sex
( ( None
median JJ Age
age NN Age
33 CD Age
years NNS Age
, , None
range VBP Age
21-47 JJ Age
; : None
phototype JJ None
I/II NNP None
) ) None
-DOCSTART- -X- N

manic JJ None
patients NNS None
who WP None
did VBD None
not RB None
respond VB None
to TO None
an DT None
initial JJ None
adequate JJ None
trial NN None
of IN None
lithium NN None
. . None
( ( None
n JJ None
= NNP None
45 CD None
) ) None
-DOCSTART- -X- N

primary JJ Condition
coronary JJ Condition
intervention NN Condition
: : Condition
Fifty NNP Size
consecutive JJ None
patients NNS None
entered VBD None
the DT None
myocardial JJ None
contrast NN None
echocardiography NN None
( ( None
MCE NNP None
) ) None
substudy NN None
of IN None
the DT None
REMEDIA NNP None
( ( None
Randomized NNP None
Evaluation NNP None
of IN None
the DT None
Effect NNP None
of IN None
Mechanical NNP None
Reduction NNP None
of IN None
Distal NNP None
Embolization NNP None
by IN None
Thrombus NNP None
Aspiration NNP None
in IN None
Primary NNP None
and CC None
Rescue NNP None
Angioplasty NNP None
) ) None
trial NN None
total NN None
of IN None
25 CD Size
patients NNS None
were VBD None
randomized VBN None
to TO None
be VB None
pretreated VBN None
with IN None
thrombus JJ None
aspiration NN None
before IN None
PCI NNP None
of IN None
the DT None
culprit NN None
lesion NN None
and CC None
25 CD Size
received JJ None
standard JJ None
PCI NNP None
. . None
-DOCSTART- -X- N

multiple-dose JJ Condition
bioequivalence NN Condition
studies NNS Condition
-DOCSTART- -X- N

very RB None
preterm JJ Condition
infants NNS Age
to TO None
term NN None
equivalent JJ None
age NN None
. . None
neuromotor NN None
function NN None
in IN None
very RB None
preterm JJ None
infants NNS Age
123 CD Size
very RB None
preterm JJ Condition
infants NNS Age
was VBD None
conducted VBN None
in IN None
the DT None
neonatal JJ None
intensive JJ None
care NN None
unit NN None
of IN None
the DT None
sole JJ None
tertiary JJ None
referral JJ None
centre NN None
in IN None
Western JJ None
Australia NNP None
. . None
Infants NNS Age
were VBD None
stratified VBN None
by IN None
gestational JJ None
age NN None
( ( None
< JJ None
29 CD Age
weeks NNS Age
or CC Age
29-30 JJ Age
weeks NNS Age
) ) None
-DOCSTART- -X- N

people NNS None
with IN None
autism NN Condition
or CC None
Asperger NNP Condition
syndrome VBP Condition
people NNS None
with IN None
autistic JJ Condition
spectrum NN Condition
disorders NNS Condition
Two CD None
groups NNS None
of IN None
11 CD Size
children NNS Age
( ( None
age NN Age
12-18 CD Age
) ) None
with IN None
autism NN None
or CC None
Asperger NNP None
syndrome VBP None
at IN None
two CD None
special JJ None
schools NNS None
participated VBD None
: : None
-DOCSTART- -X- N

older JJR Age
, , None
undernourished JJ Condition
, , None
community-dwelling JJ None
individuals NNS None
in IN None
primary JJ None
care NN None
: : None
older JJR None
, , None
community-dwelling JJ None
individuals NNS None
. . None
older JJR None
, , None
undernourished JJ Condition
, , None
community-dwelling JJ None
individuals NNS None
. . None
146 CD Size
non-institutionalized JJ Condition
, , Condition
undernourished JJ Condition
individuals NNS None
aged VBN None
?65 CD None
years NNS None
in IN None
primary JJ None
care NN None
. . None
functioning NN None
in IN None
older JJR None
, , None
undernourished JJ None
, , None
community-dwelling JJ None
individuals NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
acute JJ Condition
myocardial JJ Condition
infarction NN Condition
. . None
40 CD Size
patients NNS None
with IN None
AMI NNP Condition
within IN None
12 CD None
hours NNS None
after IN None
the DT None
onset NN None
of IN None
the DT None
symptom NN None
and CC None
who WP None
randomly VBP None
received VBN None
early JJ None
treatment NN None
with IN None
either CC None
the DT None
ACE NNP None
inhibitor NN None
imidapril NN None
or CC None
a DT None
placebo NN None
( ( None
20 CD Size
patients NNS None
in IN None
the DT None
imidapril NN None
group NN None
and CC None
20 CD Size
in IN None
the DT None
placebo NN None
group NN None
) ) None
. . None
-DOCSTART- -X- N

post NN None
thrombotic JJ None
syndrome NN None
. . None
acute JJ None
deep JJ None
venous JJ None
thrombosis NN None
( ( None
DVT NNP None
) ) None
Sixty-nine JJ None
consecutive JJ None
patients NNS None
with IN None
acute JJ None
DVT NNP None
documented VBN None
by IN None
duplex JJ None
ultrasonography NN None
Patients NNS None
were VBD None
followed VBN None
clinically RB None
at IN None
months NNS None
1 CD None
, , None
3 CD None
, , None
6 CD None
, , None
12 CD None
, , None
18 CD None
, , None
and CC None
24 CD None
after IN None
the DT None
diagnosis NN None
of IN None
DVT NNP None
. . None
-DOCSTART- -X- N

individuals NNS None
with IN None
chronic JJ Condition
ankle NN Condition
instability NN Condition
. . None
chronic JJ Condition
ankle NN Condition
instability NN Condition
( ( Condition
CAI NNP Condition
) ) Condition
. . None
individuals NNS None
with IN None
CAI NNP Condition
. . None
Forty-three JJ Size
subjects NNS None
-DOCSTART- -X- N

advanced-stage JJ Condition
idiopathic JJ Condition
Parkinson NNP Condition
disease NN Condition
: : None
2 CD None
groups NNS None
of IN None
patients NNS None
with IN None
advanced JJ Condition
stage NN Condition
Parkinson NNP Condition
Disease NNP Condition
. . None
-DOCSTART- -X- N

during IN None
labor NN None
. . None
Eighty NNP None
healthy JJ None
women NNS None
beginning VBG None
active JJ None
labor NN None
( ( None
cervical JJ None
dilation NN None
4 CD None
cm NN None
) ) None
at IN None
term NN None
were VBD None
assigned VBN None
to TO None
receive VB None
fentanyl NN None
intravenously RB None
by IN None
either CC None
patient-controlled JJ None
administration NN None
( ( None
n=37 JJ None
) ) None
or CC None
nurse JJ None
administration NN None
on IN None
demand NN None
( ( None
n=43 JJ None
) ) None
-DOCSTART- -X- N

Bovine NNP Condition
carotid NN Condition
artery NN Condition
heterografts NNS Condition
versus VBP None
polytetrafluoroethylene JJ Condition
grafts NNS None
. . None
diabetic JJ Condition
patients NNS None
nondiabetic JJ Condition
patients NNS None
. . None
-DOCSTART- -X- N

middle-aged JJ Age
adults NNS Age
with IN None
cardiovascular JJ Condition
risk NN Condition
factors NNS Condition
. . None
The DT None
Stages NNPS None
to TO None
Healthy NNP None
Eating NNP None
Patterns NNP None
Study NNP None
( ( None
STEPs NNP None
) ) None
middle-aged JJ Age
adults NNS Age
with IN None
cardiovascular JJ Condition
risk NN Condition
factors NNS Condition
middle-aged JJ Age
adults NNS Age
with IN None
cardiovascular JJ Condition
risk NN Condition
factors NNS Condition
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
human JJ Condition
immunodeficiency NN Condition
virus NN Condition
infection NN Condition
. . None
human JJ Condition
immunodeficiency NN Condition
virus NN Condition
type NN Condition
1 CD Condition
( ( Condition
HIV-1 NNP Condition
) ) Condition
12 CD Condition
HIV-infected JJ None
patients NNS None
( ( None
mean JJ None
[ NNP None
+/- JJ None
standard NN None
deviation NN None
] NNP None
CD4+ NNP None
cell NN None
count NN None
, , None
304 CD None
+/- JJ None
213/mm3 CD None
) ) None
were VBD None
enrolled VBN None
-DOCSTART- -X- N

480 CD None
subjects NNS None
with IN None
a DT None
history NN None
of IN None
repeated VBN None
parasuicide NN None
Most JJS None
patients NNS None
had VBD None
significant JJ None
anxiety NN None
and CC None
depressive JJ None
disturbance NN None
with IN None
42 CD None
% NN None
having VBG None
a DT None
personality NN None
disorder NN None
. . None
-DOCSTART- -X- N

patients NNS Condition
treated VBN Condition
with IN Condition
oral JJ Condition
hypoglycaemic JJ Condition
agents NNS Condition
. . None
Twenty-two JJ Size
maturity-onset JJ None
type NN None
diabetics NNS Condition
treated VBD None
with IN None
oral JJ None
hypoglycaemic JJ None
agents NNS None
thirteen JJ Size
patients NNS None
, , None
under IN None
reasonably RB None
good JJ None
control NN None
maturity-onset JJ None
diabetics NNS None
not RB None
adequately RB None
controlled VBN None
by IN None
diet NN None
combined VBN None
with IN None
oral JJ None
hypoglycaemic JJ None
agents NNS None
. . None
-DOCSTART- -X- N

Three CD None
hundred VBD None
forty-one NN None
Tanzanian JJ None
preschool NN None
children NNS None
children NNS None
-DOCSTART- -X- N

Japanese JJ None
adult NN Age
healthy JJ Condition
subjects NNS None
: : None
Japanese JJ None
healthy JJ Condition
subjects NNS Condition
. . None
Forty-eight JJ Size
Japanese JJ None
healthy JJ Condition
subjects NNS Condition
( ( None
males NNS Sex
24 CD Size
; : None
females NNS Sex
24 CD Size
) ) None
single-center JJ None
, , None
double-blind JJ None
Japanese JJ None
subjects NNS None
; : None
-DOCSTART- -X- N

12 CD None
healthy JJ None
male NN None
volunteers NNS None
Six CD None
participants NNS None
-DOCSTART- -X- N

after IN Condition
Roux-en-Y NNP Condition
gastric JJ Condition
bypass NN Condition
surgery NN Condition
. . Condition
12 CD Condition
healthy JJ Condition
volunteers NNS Condition
who WP Condition
underwent VBP Condition
gastric JJ Condition
bypass NN Condition
surgery NN Condition
. . Condition
in IN None
healthy JJ None
volunteers NNS None
who WP None
underwent VBP None
gastric JJ None
bypass NN None
surgery NN None
. . None
after IN None
gastric JJ None
bypass NN None
. . None
-DOCSTART- -X- N

type NN None
2 CD None
diabetes NNS None
: : None
type VB None
2 CD None
diabetes NNS None
subjects NNS None
8 CD None
patients NNS None
, , None
5 CD None
of IN None
whom WP None
were VBD None
insulin-requiring JJ None
. . None
type NN None
2 CD None
diabetes NNS None
group NN None
normal JJ None
nondiabetic JJ None
subjects NNS None
-DOCSTART- -X- N

parents NNS Condition
of IN Condition
a DT Condition
child NN Condition
diagnosed VBN Condition
with IN Condition
an DT Condition
autism NN Condition
spectrum NN Condition
disorder NN Condition
. . Condition
Fifty-nine JJ None
families NNS None
with IN None
a DT None
child NN None
with IN None
ASD NNP None
aged VBD None
between IN None
2 CD None
and CC None
9 CD None
participated VBN None
parental JJ None
reports NNS None
of IN None
child JJ None
behaviour NN None
and CC None
parenting NN None
styles NNS None
with IN None
the DT None
treatment NN None
effects NNS None
for IN None
child NN None
behaviour NN None
, , None
parental NN None
over IN None
reactivity NN None
and CC None
parental JJ None
verbosity NN None
parents NNS None
of IN None
children NNS None
with IN None
ASD NNP None
. . None
-DOCSTART- -X- N

subacute JJ Condition
poststroke NN Condition
patients NNS None
: : None
poststroke NN Condition
patients NNS None
; : None
poststroke NN None
patients NNS None
Loewenstein NNP None
Rehabilitation NNP None
Hospital NNP None
, , None
Israel NNP None
. . None
Twenty-eight NNP Size
subacute JJ Condition
stroke VBD Condition
patients NNS None
with IN None
arm JJ None
paresis NN None
after IN None
a DT None
first JJ None
ischemic JJ Condition
stroke NN Condition
in IN None
the DT None
middle JJ None
cerebral JJ None
artery NN None
area NN None
CIMT NNP None
group NN None
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ Condition
hepatitis NN Condition
C NNP Condition
treated VBD None
with IN None
interferon-alpha JJ None
and CC None
ribavirin NN None
: : None
patients NNS None
with IN None
chronic JJ None
hepatitis NN None
C NNP None
during IN None
and CC None
after IN None
treatment NN None
with IN None
interferon-alpha JJ None
( ( None
IFN-alpha NNP None
) ) None
and CC None
ribavirin NN None
. . None
previously RB None
untreated JJ None
patients NNS None
with IN None
chronic JJ Condition
hepatitis NN Condition
C NNP Condition
patients NNS None
in IN None
the DT None
control NN None
and CC None
the DT None
amantadine NN None
group NN None
. . None
-DOCSTART- -X- N

couples NNS None
with IN None
unexplained JJ Condition
subfertility NN Condition
and CC None
an DT None
intermediate JJ None
prognosis NN None
: : None
couples NNS None
with IN None
unexplained JJ Condition
subfertility NN Condition
. . None
couples NNS None
with IN None
unexplained JJ Condition
subfertility NN Condition
253 CD Size
couples NNS None
with IN None
unexplained JJ Condition
subfertility NN Condition
and CC None
a DT None
probability NN None
of IN None
a DT None
spontaneous JJ None
ongoing JJ None
pregnancy NN None
of IN None
30 CD None
% NN None
to TO None
40 CD None
% NN None
within IN None
12 CD None
months NNS None
-DOCSTART- -X- N

amnesics VB Condition
memory-impaired JJ Condition
acquired VBD Condition
brain-injured JJ Condition
persons NNS None
Forty NNP Size
individuals NNS None
comprised VBD None
the DT None
simulating NN None
and CC None
control NN None
group NN None
Twenty CD Size
memory-impaired JJ Condition
patients NNS None
, , None
all DT None
of IN None
whom WP None
had VBD None
been VBN None
diagnosed VBN None
as IN None
suffering VBG None
from IN None
a DT None
memory NN Condition
impairment NN Condition
following VBG None
acquired VBD Condition
brain NN Condition
damage NN Condition
, , Condition
participated VBD None
as IN None
the DT None
memory-impaired JJ None
control NN None
group NN None
. . None
-DOCSTART- -X- N

42 CD None
cases NNS None
of IN None
autism NN Condition
] NNP None
autism NN Condition
. . None
Eighty-four JJ Size
children NNS Age
of IN None
autism NN Condition
were VBD None
randomly RB None
divided VBN None
into IN None
a DT None
tongue JJ None
acupuncture NN None
group NN None
( ( None
group NN None
A NNP None
) ) None
and CC None
a DT None
conventional JJ None
training NN None
group NN None
( ( None
group NN None
B NNP None
) ) None
, , None
42 CD None
cases NNS None
in IN None
each DT None
group NN None
. . None
autism NN Condition
. . None
-DOCSTART- -X- N

patients NNS None
entering VBG None
outpatient JJ None
opiate JJ None
detoxification NN None
. . None
Participants NNS None
( ( None
N NNP None
= NNP None
211 CD None
) ) None
-DOCSTART- -X- N

for IN None
advanced JJ None
myeloid NN None
leukemia NN None
and CC None
MDS NNP None
. . None
in IN None
patients NNS None
with IN None
myeloid JJ None
leukemia NN None
undergoing VBG None
allogeneic JJ None
stem NN None
cell NN None
transplantation NN None
( ( None
allo-SCT JJ None
) ) None
. . None
. . None
Fifty-one CD None
patients NNS None
have VBP None
been VBN None
enrolled VBN None
with IN None
days NNS None
. . None
There EX None
were VBD None
32 CD None
males NNS None
and CC None
19 CD None
females NNS None
, , None
with IN None
a DT None
median JJ None
age NN None
of IN None
45 CD None
years NNS None
( ( None
range NN None
: : None
6-59 JJ None
) ) None
. . None
Nine JJ None
patients NNS None
had VBD None
chronic JJ None
myeloid NN None
leukemia NN None
( ( None
CML NNP None
) ) None
( ( None
BC NNP None
: : None
2 CD None
, , None
second JJ None
AP NNP None
: : None
3 CD None
, , None
and CC None
tyrosine-kinase JJ None
inhibitor NN None
refractory NN None
first RB None
chronic JJ None
phase NN None
[ NNP None
CP NNP None
] NN None
: : None
4 CD None
) ) None
. . None
Forty-two JJ None
patients NNS None
had VBD None
AML NNP None
: : None
14 CD None
were VBD None
induction NN None
failures NNS None
, , None
8 CD None
in IN None
first JJ None
chemotherapy-refractory JJ None
relapse NN None
, , None
7 CD None
in IN None
untreated JJ None
relapse NN None
, , None
3 CD None
in IN None
second JJ None
or CC None
subsequent JJ None
relapse NN None
, , None
4 CD None
were VBD None
in IN None
second JJ None
complete JJ None
remission NN None
( ( None
CR NNP None
) ) None
, , None
and CC None
3 CD None
in IN None
second JJ None
CR NNP None
without IN None
platelet NN None
recovery NN None
( ( None
CRp NNP None
) ) None
, , None
2 CD None
were VBD None
in IN None
high-risk JJ None
CR1 NNP None
. . None
Finally NNP None
, , None
1 CD None
patient NN None
was VBD None
in IN None
first JJ None
CRp NNP None
. . None
Graft-versus-host NNP None
engrafted VBN None
. . None
Forty-one CD None
patients NNS None
had VBD None
active JJ None
leukemia NN None
at IN None
the DT None
time NN None
of IN None
transplant NN None
, , None
and CC None
35 CD None
achieved VBN None
CR NNP None
( ( None
. . None
Twenty CD None
in IN None
high-risk JJ None
myeloid JJ None
leukemia NN None
patients NNS None
; : None
( ( None
2 CD None
) ) None
clofarabine NN None
-DOCSTART- -X- N

adults NNS Age
with IN None
asthma NN Condition
. . None
inactive JJ Condition
asthmatic JJ Condition
patients NNS None
Thirty-two JJ Size
adults NNS None
with IN None
asthma NN Condition
Ten CD Size
patients NNS None
, , None
5 CD Size
in IN None
each DT None
group NN None
-DOCSTART- -X- N

infants NNS None
. . None
40 CD None
children NNS None
younger JJR None
than IN None
4 CD None
yr NNS None
having VBG None
elective JJ None
abdominal JJ None
surgery NN None
under IN None
general JJ None
anaesthesia NN None
supplemented VBN None
with IN None
either DT None
systemic JJ None
opioids NNS None
or CC None
extradural JJ None
bupivacaine NN None
. . None
-DOCSTART- -X- N

human JJ Condition
essential JJ Condition
hypertension NN Condition
. . Condition
human JJ Condition
subjects NNS Condition
with IN Condition
essential JJ Condition
hypertension NN Condition
. . Condition
Twenty NNP Condition
male NN Condition
, , Condition
white JJ Condition
patients NNS Condition
( ( Condition
27 CD Condition
+/- JJ Condition
1 CD Condition
years NNS Condition
) ) Condition
with IN Condition
mild JJ Condition
essential JJ Condition
hypertension NN Condition
( ( Condition
143 CD Condition
+/- JJ Condition
11/95 CD Condition
+/- JJ Condition
6 CD Condition
mm NN Condition
Hg NNP Condition
) ) Condition
-DOCSTART- -X- N

healthy JJ Condition
human JJ Condition
volunteers NNS None
: : None
healthy JJ Condition
human JJ Condition
volunteers NNS None
. . None
Forty NNP Size
healthy JJ None
subjects NNS None
healthy JJ Condition
volunteers NNS None
-DOCSTART- -X- N

presyncopal JJ Condition
symptom NN Condition
limited VBD Condition
lower JJR Condition
body NN Condition
negative JJ Condition
pressure NN Condition
exposures NNS None
. . None
11 CD Size
subjects NNS None
were VBD None
exposed VBN None
to TO None
4 CD None
PSL-LBNP JJ Condition
tests NNS None
; : None
nine CD Size
subjects NNS None
-DOCSTART- -X- N

esthesioneuroblastoma NN Condition
poorly RB None
differentiated VBN None
tumors NNS None
arising VBG None
in IN None
the DT None
sinonasal NN None
tract NN None
. . None
high-grade JJ None
esthesioneuroblastomas NN None
other JJ None
poorly RB None
differentiated VBN None
tumors NNS None
arising VBG None
in IN None
the DT None
nasal JJ None
cavity NN None
24 CD None
frozen JJ None
cases NNS None
of IN None
esthesioneuroblastoma NN None
and CC None
poorly RB None
differentiated VBN None
tumors NNS None
. . None
poorly RB None
differentiated VBN None
tumors NNS None
of IN None
the DT None
sinonasal JJ None
region NN None
. . None
-DOCSTART- -X- N

locally RB None
advanced JJ None
prostatic JJ None
cancer NN None
. . None
151 CD Size
patients NNS None
with IN None
locally RB None
advanced JJ None
prostatic JJ None
cancer NN None
( ( None
T3-4 NNP None
M0 NNP None
) ) None
, , None
representing VBG None
38 CD None
% NN None
of IN None
the DT None
404 CD None
cancer NN None
patients NNS None
in IN None
a DT None
Finnish JJ None
multicenter NN None
study NN None
-DOCSTART- -X- N

body NN None
fat JJ None
and CC None
blood NN None
lipid JJ None
profiles NNS None
of IN None
male JJ Sex
hypertriglyceridemic JJ Condition
subjects NNS None
. . None
body NN None
fat JJ None
and CC None
blood NN None
lipid JJ None
profiles NNS None
in IN None
hypertriglyceridemic JJ None
subjects NNS None
. . None
One-hundred-and-twelve JJ Size
subjects NNS None
50 CD Size
subjects NNS None
( ( None
34 CD Size
men NNS Sex
and CC None
16 CD Size
women NNS Sex
) ) None
, , None
while IN None
the DT None
MLCT NNP None
group NN None
consisted VBD None
of IN None
51 CD Size
subjects NNS None
( ( None
33 CD Size
men NNS Sex
and CC None
18 CD Size
women NNS Sex
) ) None
who WP None
completed VBD None
the DT None
study NN None
. . None
male JJ None
hypertriglyceridemic JJ None
subjects NNS None
. . None
-DOCSTART- -X- N

experimental JJ None
human JJ None
influenza NN Condition
: : None
treatment NN None
of IN None
influenza NN None
in IN None
experimentally RB None
infected JJ None
humans NNS None
. . None
2 CD None
large JJ None
US NNP None
university NN None
medical JJ None
schools NNS None
. . None
A DT None
total NN None
of IN None
117 CD Size
healthy JJ Condition
adult NN Age
volunteers NNS Age
( ( None
aged VBN Age
18-40 CD Age
years NNS Age
; : Age
median JJ Age
age NN Age
, , Age
21 CD Age
years NNS Age
) ) None
who WP None
were VBD None
susceptible JJ Condition
( ( Condition
hemagglutination-inhibition NN Condition
antibody NN Condition
titer NN Condition
< NN None
or CC None
=1:8 NN None
) ) None
. . None
experimental JJ None
human JJ None
influenza NN Condition
-DOCSTART- -X- N

Seventy-six JJ Condition
patients NNS Condition
took VBD Condition
part NN Condition
in IN Condition
a DT Condition
randomized JJ Condition
, , Condition
comparative JJ Condition
study NN Condition
of IN Condition
the DT Condition
efficacy NN Condition
of IN Condition
buflomedil NN Condition
hydrochloride NN Condition
and CC Condition
dihydrogenated VBD Condition
ergot JJ Condition
alkaloids NNS Condition
in IN Condition
the DT Condition
treatment NN Condition
of IN Condition
senile JJ Condition
dementia NN Condition
associated VBN Condition
with IN Condition
cerebrovascular JJ Condition
insufficiency NN Condition
. . Condition
senile JJ None
dementia NN None
associated VBN None
with IN None
cerebrovascular JJ None
insufficiency NN None
-DOCSTART- -X- N

insomnia NN Condition
in IN None
children NNS Age
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
. . None
why WRB None
parents NNS None
seek VBP None
medical JJ None
intervention NN None
in IN None
children NNS None
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
( ( Condition
ASDs NNP Condition
) ) None
. . None
Thirty-six JJ Size
children NNS Age
with IN None
ASD NNP Condition
, , None
ages VBZ Age
2 CD Age
to TO Age
10 CD Age
years NNS Age
, , None
were VBD None
enrolled VBN None
. . None
All DT None
had VBD None
prolonged VBN Condition
sleep JJ Condition
latency NN Condition
confirmed VBN None
by IN None
actigraphy NN None
showing VBG None
a DT None
mean JJ None
sleep JJ None
latency NN None
of IN None
30 CD None
minutes NNS None
or CC None
more JJR None
. . None
Parents NNS None
were VBD None
randomly RB None
assigned VBN None
to TO None
receive VB None
the DT None
sleep JJ None
education NN None
pamphlet NN None
or CC None
no DT None
intervention NN None
. . None
sleep JJ Condition
latency NN Condition
in IN None
children NNS None
with IN None
ASDs NNP Condition
. . None
-DOCSTART- -X- N

hypertensive JJ None
patients NNS None
. . None
12 CD None
patients NNS None
with IN None
essential JJ None
hypertension NN None
. . None
-DOCSTART- -X- N

posttransplant JJ None
hypertension NN None
in IN None
kidney NN None
allograft NN None
recipients NNS None
. . None
kidney NN None
recipients NNS None
. . None
Thirty-two JJ None
patients NNS None
on IN None
antihypertensive JJ None
treatment NN None
completed VBD None
the DT None
study NN None
. . None
kidney NN None
allograft NN None
recipients NNS None
-DOCSTART- -X- N

Adjuvant NNP None
subcutaneous JJ None
interleukin-2 NN None
in IN None
patients NNS None
with IN None
resected JJ None
renal JJ None
cell NN None
carcinoma NN None
: : None
patients NNS None
with IN None
resected JJ None
renal JJ None
cell NN None
carcinoma NN None
( ( None
RCC NNP None
) ) None
at IN None
high JJ None
risk NN None
for IN None
recurrent JJ None
disease NN None
( ( None
TNM NNP None
stages VBZ None
III NNP None
and CC None
IV NNP None
resected VBD None
distant JJ None
metastases NNS None
) ) None
. . None
Patients NNPS None
with IN None
surgically RB None
resected VBN None
locally RB None
advanced JJ None
( ( None
T3-4 CD None
or CC None
N1-2 NNP None
) ) None
or CC None
metastatic JJ None
RCC NNP None
Forty-one JJ None
patients NNS None
were VBD None
entered VBN None
in IN None
the DT None
study NN None
and CC None
40 CD None
were VBD None
evaluable JJ None
for IN None
toxicity NN None
. . None
patients NNS None
with IN None
surgically RB None
resected VBN None
RCC NNP None
at IN None
high JJ None
risk NN None
of IN None
recurrence NN None
. . None
-DOCSTART- -X- N

children NNS Age
being VBG None
treated VBN None
for IN None
acute JJ Condition
lymphoblastic JJ Condition
leukaemia NN Condition
. . None
Children NNP Age
were VBD None
investigated VBN None
who WP None
were VBD None
receiving VBG None
glucocorticoid JJ None
treatment NN None
for IN None
acute JJ Condition
lymphoblastic JJ Condition
leukaemia NN Condition
( ( Condition
ALL DT Condition
) ) Condition
. . None
children NNS Age
Nineteen NNP Size
children NNS Age
( ( None
8 CD Size
male NN Sex
, , None
11 CD Size
female NN Sex
) ) None
with IN None
a DT None
median JJ None
age NN None
5.9 CD Age
years NNS Age
( ( None
range VB None
2.6-13 CD Age
years NNS None
) ) None
were VBD None
recruited VBN None
into IN None
the DT None
study NN None
. . None
-DOCSTART- -X- N

older JJR None
patients NNS None
with IN None
diabetes NNS Condition
: : None
elderly JJ Age
patients NNS None
patients NNS None
with IN None
diabetes NNS Condition
. . None
elderly JJ None
patients NNS None
with IN None
type JJ Condition
2 CD Condition
diabetes NNS Condition
. . None
Eleven NNP Size
thousand VBP Size
one CD Size
hundred CD Size
and CC Size
forty JJ Size
patients NNS None
aged VBN None
at IN None
least JJS None
55 CD Age
years NNS None
with IN None
type NN None
2 CD None
diabetes NNS None
( ( None
mean JJ None
66+/-6 CD Age
years NNS None
) ) None
subgroups NNS None
according VBG None
to TO None
age NN None
: : None
below IN Age
65 CD Age
, , None
65-74 JJ Age
and CC None
at IN Age
least JJS Age
75 CD Age
years NNS Age
. . None
patients NNS None
of IN None
at IN None
least JJS None
75 CD None
years NNS None
with IN None
type NN None
2 CD None
diabetes NNS None
. . None
older JJR None
patients NNS None
in IN None
this DT None
age NN None
group NN None
-DOCSTART- -X- N

premolars NNS None
restored VBN None
using VBG None
two CD None
dowel-and-core JJ None
systems NNS None
. . None
endodontically-treated JJ None
teeth NNS None
restored VBN None
with IN None
two CD None
dowel-core JJ None
systems NNS None
. . None
Thirty-two NNP Size
extracted VBD None
mandibular JJ None
first JJ None
premolars NNS None
root NN Condition
fractures NNS Condition
. . None
-DOCSTART- -X- N

familial JJ None
adenomatous JJ None
polyposis NN None
. . None
patients NNS None
with IN None
familial JJ None
adenomatous JJ None
polyposis NN None
( ( None
FAP NNP None
) ) None
. . None
FAP NNP None
patients NNS None
. . None
relevance-M66I NN None
, , None
P153L NNP None
, , None
E158K NNP None
, , None
V257M NNP None
, , None
E305X NNP None
, , None
E308G NNP None
, , None
and CC None
R492W-in NNP None
21 CD None
and CC None
20 CD None
FAP NNP None
patients NNS None
, , None
who WP None
received VBD None
sulindac NN None
and CC None
placebo NN None
, , None
respectively RB None
. . None
41 CD None
patients NNS None
sulindac-treated JJ None
patients NNS None
patients NNS None
on IN None
sulindac NN None
-DOCSTART- -X- N

treatment NN Condition
in IN Condition
an DT Condition
IVF NNP Condition
programme NN Condition
. . Condition
IVF NNP None
programme NN None
HCG NNP None
( ( None
193 CD None
transfers NNS None
) ) None
against IN None
placebo NN None
( ( None
194 CD None
transfers NNS None
) ) None
. . None
IVF NNP Condition
programme NN Condition
. . Condition
-DOCSTART- -X- N

anemic JJ Condition
cancer NN Condition
patients NNS Condition
on IN Condition
combination NN Condition
chemotherapy NN Condition
. . None
Patients NNPS None
with IN None
advanced JJ None
cancer NN None
frequently RB None
experience VBZ None
clinically RB None
significant JJ None
anemia NN None
cancer NN None
patients NNS None
. . None
patients NNS None
with IN None
advanced JJ None
cancer NN None
who WP None
were VBD None
receiving VBG None
myelosuppressive JJ None
chemotherapy NN None
( ( None
excluding VBG None
cisplatin NN None
) ) None
. . None
153 CD Size
anemic JJ None
cancer NN None
patients NNS None
receiving VBG Condition
cyclic JJ Condition
combination NN Condition
chemotherapy NN Condition
patients NNS None
rHuEPO-treated JJ Condition
group NN None
placebo-treated JJ Condition
group NN None
rHuEPO-treated JJ None
patients NNS None
placebo-treated JJ None
patients NNS None
rHuEPO-treated JJ None
patients NNS None
rHuEPO-treated JJ None
group NN None
. . None
-DOCSTART- -X- N

Ten CD None
ceramic JJ None
blocks NNS None
( ( None
6x6x6 CD None
mm NN None
) ) None
were VBD None
fabricated VBN None
and CC None
randomly RB None
assigned VBN None
to TO None
2 CD None
groups NNS None
( ( None
n=5 NN None
) ) None
, , None
according VBG None
to TO None
the DT None
conditioning NN None
method NN None
: : None
G1- JJ None
10 CD None
% NN None
hydrofluoric JJ None
acid NN None
application NN None
for IN None
2 CD None
min NN None
plus CC None
rinsing NN None
and CC None
drying NN None
, , None
followed VBN None
by IN None
silane NN None
application NN None
for IN None
30 CD None
s NNS None
; : None
G2- NNP None
-DOCSTART- -X- N

serum NN Condition
retinol JJ Condition
concentration NN Condition
of IN None
Filipino NNP None
children NNS None
4-7 CD Age
years NNS None
old JJ None
. . None
542 CD Size
Filipino NNP None
children NNS None
aged VBD None
4 CD Age
to TO Age
7 CD Age
years NNS None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
: : None
children NNS Age
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
( ( None
ASD NNP Condition
) ) None
. . None
Children NNP Age
ages VBZ Age
6-12 NN Age
with IN Age
ASD NNP None
children NNS Age
with IN None
ASD NNP Condition
. . None
-DOCSTART- -X- N

Western JJ None
Myanmar NNP None
. . None
Western JJ None
Myanmar NNP None
human JJ None
population NN None
4,824 CD Size
female JJ Sex
anopheline NN None
mosquitoes NNS None
916 CD None
person NN None
nights NNS None
yielded VBD None
3,009 CD None
female JJ None
anopheline NN None
mosquitoes NNS None
between IN None
6 CD None
pm NNS None
and CC None
6 CD None
am VBP None
. . None
A DT None
large JJ None
proportion NN None
of IN None
children NNS Age
Western JJ None
Myanmar NNP None
-DOCSTART- -X- N

patients NNS None
' POS None
well-being NN None
in IN None
a DT None
radiation NN None
therapy NN None
department NN None
. . None
patients NNS None
' POS None
well-being JJ None
. . None
Fifty-five JJ None
subjects NNS None
undergoing VBG None
radiation NN None
therapy NN None
for IN None
cure NN None
and CC None
who WP None
were VBD None
able JJ None
to TO None
communicate VB None
by IN None
telephone NN None
comprised VBD None
the DT None
sample NN None
. . None
control NN None
group NN None
, , None
who WP None
received VBD None
the DT None
usual JJ None
care NN None
or CC None
to TO None
an DT None
experimental JJ None
group NN None
-DOCSTART- -X- N

Mefloquine NNP None
kinetics NNS None
in IN None
cured JJ None
and CC None
recrudescent JJ None
patients NNS None
with IN None
acute JJ None
falciparum NN None
malaria NN None
and CC None
in IN None
healthy JJ None
volunteers NNS None
. . None
clinical JJ None
trial NN None
in IN None
Thailand NNP None
among IN None
patients NNS None
with IN None
malaria NNS None
and CC None
healthy JJ None
volunteers NNS None
. . None
administered VBN None
to TO None
11 CD None
patients NNS None
and CC None
5 CD None
volunteers NNS None
and CC None
750 CD None
mg NN None
was VBD None
given VBN None
to TO None
16 CD None
patients NNS None
and CC None
5 CD None
volunteers NNS None
. . None
cured JJ None
patients NNS None
taking VBG None
750 CD None
mg JJ None
mefloquine NN None
, , None
peak JJ None
plasma JJ None
drug NN None
concentration NN None
( ( None
Cmax NNP None
) ) None
and CC None
area NN None
under IN None
the DT None
plasma JJ None
concentration-time JJ None
curve NN None
( ( None
AUC NNP None
) ) None
patients NNS None
with IN None
malaria NNS None
and CC None
healthy JJ None
volunteers NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ None
idiopathic JJ None
urticaria NN None
( ( None
CIU NNP None
) ) None
AH-resistant NNP None
and CC None
AH NNP None
responder VBP None
CIU NNP None
patients NNS None
. . None
CIU NNP None
patients NNS None
with IN None
treatment NN None
failure NN None
under IN None
fexofenadine NN None
at IN None
180 CD None
mg NN None
q.d NN None
. . None
Those DT None
with IN None
significant JJ None
improvement NN None
of IN None
urticaria JJ None
activity NN None
score NN None
under IN None
fexofenadine NN None
at IN None
180 CD None
mg NNS None
The DT None
control NN None
group NN None
consisted VBD None
of IN None
sex- JJ None
and CC None
age-matched JJ None
patents NNS None
with IN None
allergic JJ None
rhinitis NN None
. . None
Forty-six JJ None
subjects NNS None
were VBD None
included VBN None
in IN None
the DT None
CIU NNP None
group NN None
, , None
21 CD None
were VBD None
in IN None
the DT None
R-CIU NNP None
group NN None
, , None
and CC None
44 CD None
were VBD None
in IN None
the DT None
control NN None
group NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
active JJ None
rheumatoid NN None
arthritis NN None
and CC None
an DT None
inadequate JJ None
response NN None
to TO None
methotrexate VB None
alone RB None
. . None
active JJ None
rheumatoid NN None
arthritis NN None
( ( None
RA NNP None
) ) None
in IN None
patients NNS None
receiving VBG None
a DT None
stable JJ None
background NN None
regimen NNS None
of IN None
methotrexate NN None
( ( None
MTX NNP None
) ) None
who WP None
have VBP None
an DT None
inadequate JJ None
response NN None
to TO None
MTX NNP None
monotherapy NN None
. . None
patients NNS None
with IN None
active JJ None
RA NNP None
( ( None
n JJ None
= NNP None
507 CD None
) ) None
CONCLUSION NNP None
In IN None
patients NNS None
with IN None
active JJ None
RA NNP None
in IN None
whom WP None
the DT None
response NN None
to TO None
MTX NNP None
has VBZ None
been VBN None
inadequate JJ None
, , None
the DT None
-DOCSTART- -X- N

urban JJ None
and CC None
rural JJ None
older JJR None
, , None
long-term JJ Condition
survivors NNS Condition
of IN Condition
breast NN Condition
, , Condition
prostate NN Condition
, , Condition
and CC Condition
colorectal JJ Condition
cancer NN Condition
Older NNP None
adult NN None
cancer NN None
survivors NNS None
urban JJ None
and CC None
rural JJ None
cancer NN None
survivors NNS None
cancer NN None
. . None
Survivors NNS None
in IN None
the DT None
present JJ None
analysis NN None
( ( None
n=729 JJ None
) ) None
underwent JJ None
Among IN None
rural JJ None
survivors NNS None
, , None
-DOCSTART- -X- N

postpartum NN None
Prague NNP None
Prague NNP None
50 CD Size
women NNS Size
with IN None
clinical JJ None
and CC None
lab JJ None
signs NNS None
of IN None
postpartal JJ Condition
anemia NN Condition
. . None
-DOCSTART- -X- N

flexible JJ None
nasendoscopy NN None
98 CD Size
patients NNS None
flexible JJ None
nasendoscopy NN None
flexible JJ None
nasendoscopy NN None
-DOCSTART- -X- N

patients NNS None
with IN None
locally RB Condition
advanced JJ Condition
pancreatic JJ Condition
cancer NN Condition
-- : None
a DT None
multi-centre JJ None
locally RB Condition
advanced JJ Condition
pancreatic JJ Condition
cancer NN Condition
( ( None
LAPC NNP Condition
) ) None
95 CD Size
patients NNS None
with IN None
LAPC NNP Condition
-DOCSTART- -X- N

postmenopausal JJ Condition
women NNS Sex
stratified VBN None
by IN None
Helicobacter NNP Condition
pylori NN Condition
status NN None
. . None
healthy JJ Condition
postmenopausal NN Condition
women NNS Sex
stratified VBN None
by IN None
Helicobacter NNP Condition
pylori NN Condition
status NN None
. . None
-DOCSTART- -X- N

737 CD None
patients NNS None
with IN None
aggressive JJ None
malignant JJ None
lymphoma NN None
. . None
From IN None
July NNP None
1984 CD None
to TO None
September NNP None
1987 CD None
, , None
737 CD None
patients NNS None
with IN None
aggressive JJ None
malignant JJ None
lymphoma NN None
( ( None
ML NNP None
) ) None
Four CD None
hundred VBD None
forty-two JJ None
patients NNS None
-DOCSTART- -X- N

deceased-donor JJ None
kidney NN None
transplant NN None
recipients NNS None
at IN None
specified VBN None
risk NN None
of IN None
delayed JJ None
graft NN None
function NN None
: : None
multicenter NN None
Deceased-donor NNP None
kidney NN None
transplant NN None
patients NNS None
at IN None
protocol-specified JJ None
risk NN None
of IN None
DGF NNP None
in IN None
17 CD None
IE JJ None
patients NNS None
( ( None
in IN None
DGF-risk JJ None
patients NNS None
-DOCSTART- -X- N

severely JJ Age
obese JJ Age
adolescents NNS Age
. . Age
severely RB Age
obese JJ Age
adolescents NNS Age
. . Age
Forty-six JJ Size
subjects NNS None
( ( None
24 CD Size
HPLC NNP None
, , None
22 CD Size
in IN None
low JJ None
fat NN None
) ) None
initiated VBD None
and CC None
33 CD Size
subjects NNS None
completed VBD None
the DT None
intervention NN None
; : None
severely JJ Age
obese JJ Age
adolescents NNS Age
. . Age
-DOCSTART- -X- N

duodenal JJ Condition
ulcer NN Condition
283 CD Size
patients NNS None
with IN None
active JJ None
duodenal JJ Condition
ulcer NN Condition
to TO None
compare VB None
possible JJ None
factors NNS None
that WDT None
may MD None
affect VB None
healing NN None
and CC None
relapse NN None
in IN None
patients NNS None
treated VBN None
with IN None
a DT None
potent JJ None
antisecretory NN None
agent NN None
, , None
cimetidine NN None
, , None
or CC None
a DT None
site-protective JJ None
and CC None
cytoprotective JJ None
agent NN None
, , None
sucralfate NN None
. . None
both DT None
groups NNS None
patients NNS None
with IN None
healed JJ None
ulcers NNS Condition
, , None
238 CD Size
participated VBN None
patients NNS None
-DOCSTART- -X- N

Sixty-two NNP None
( ( None
62 CD None
) ) None
community-recruited JJ None
patients NNS None
with IN None
fibromyalgia NN None
( ( None
FM NNP None
) ) None
Two CD None
homeopaths NNS None
jointly RB None
performed VBD None
case-taking JJ None
interviews NNS None
. . None
A DT None
conventional JJ None
medical JJ None
provider NN None
independently RB None
evaluated VBD None
patients NNS None
with IN None
a DT None
standardized JJ None
history NN None
and CC None
physical JJ None
examination NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
autistic JJ Condition
disorder NN Condition
. . None
About IN None
40 CD Size
children NNS Age
between IN None
the DT None
ages NNS None
three CD Age
and CC Age
11 CD Age
years NNS Age
( ( None
inclusive JJ None
) ) None
with IN None
a DT None
DSM NNP None
IV NNP None
clinical JJ None
diagnosis NN None
of IN None
autism NN Condition
and CC None
who WP None
were VBD None
outpatients NNS None
from IN None
a DT None
specialty NN None
clinic NN None
for IN None
children NNS None
were VBD None
recruited VBN None
. . None
children NNS Age
presented VBN None
with IN None
a DT None
chief JJ None
complaint NN None
of IN None
severely RB None
disruptive JJ None
symptoms NNS None
related VBN None
to TO None
autistic JJ Condition
disorder NN Condition
. . None
-DOCSTART- -X- N

functional JJ Condition
dyspepsia NN Condition
: : None
patients NNS None
with IN None
functional JJ Condition
dyspepsia NN Condition
, , None
supporting VBG None
the DT None
use NN None
of IN None
prokinetic JJ None
drugs NNS None
for IN None
treatment NN None
of IN None
dyspeptic JJ Condition
symptoms NNS Condition
. . None
1298 CD Size
patients NNS None
were VBD None
enrolled VBN None
in IN None
a DT None
double-blind JJ None
multicentric NN None
study NN None
carried VBD None
out IN None
in IN None
45 CD None
Italian JJ None
Gastroenterology NNP None
Departments NNP None
. . None
Patients NNS None
were VBD None
selected VBN None
on IN None
the DT None
basis NN None
of IN None
: : None
a DT None
) ) None
occurrence NN None
in IN None
the DT None
last JJ None
4 CD None
weeks NNS None
of IN None
at IN None
least JJS None
5/10 CD None
selected VBN None
symptoms NNS None
( ( None
anorexia NN Condition
, , None
nausea NN Condition
, , None
vomiting VBG Condition
, , None
upper JJ Condition
abdominal JJ Condition
pain NN Condition
, , None
postprandial JJ Condition
bloating NN Condition
, , None
abdominal JJ Condition
fullness NN Condition
, , None
early JJ Condition
satiety NN Condition
, , None
belching NN Condition
, , None
heartburn NN Condition
, , None
regurgitation NN Condition
) ) None
, , None
severity NN None
of IN None
which WDT None
should MD None
reach/exceed VB None
a DT None
total JJ None
score NN None
of IN None
8 CD None
, , None
as IN None
assessed VBN None
by IN None
a DT None
specific JJ None
scale NN None
ranging VBG None
from IN None
0 CD None
( ( None
absent NN None
) ) None
to TO None
3 CD None
( ( None
severe JJ None
) ) None
; : None
b VBN None
) ) None
normal JJ None
results NNS None
of IN None
routine JJ None
biochemical NN None
, , None
ultrasound NN None
and CC None
endoscopic JJ None
examinations NNS None
. . None
-DOCSTART- -X- N

primary JJ Condition
biliary JJ Condition
cirrhosis NN Condition
: : None
Primary JJ Condition
biliary JJ Condition
cirrhosis NN Condition
( ( Condition
PBC NNP Condition
) ) Condition
is VBZ None
a DT None
chronic JJ None
, , None
progressive JJ None
, , None
cholestatic JJ None
liver NN Condition
disease NN Condition
. . None
from IN None
42 CD Size
patients NNS None
with IN None
PBC NNP Condition
-DOCSTART- -X- N

gastritis NN None
due JJ None
to TO None
Campylobacter NNP None
pylori NN None
. . None
Fifty JJ None
patients NNS None
gastritis NN None
associated VBN None
with IN None
Campylobacter NNP None
pylori NN None
. . None
18 CD None
patients NNS None
-DOCSTART- -X- N

in IN None
HIV-HCV-coinfected JJ None
patients NNS None
: : None
in IN None
HIV-HCV-coinfected JJ None
patients NNS None
. . None
METHODS NNP None
HIV NNP None
and CC None
HCV NNP None
genotype VBP None
1- JJ None
and CC None
4-coinfected JJ None
subjects NNS None
RESULTS VB None
A DT None
total NN None
of IN None
67 CD None
patients NNS None
were VBD None
included VBN None
; : None
33 CD None
in IN None
-DOCSTART- -X- N

South JJ None
African JJ None
population NN None
. . None
women NNS Sex
with IN None
pregnancy-related JJ Condition
low JJ Condition
back RB Condition
pain NN Condition
. . None
Fifty NNP Size
women NNS None
between IN None
16 CD None
and CC None
24 CD None
weeks NNS None
of IN None
pregnancy NN None
were VBD None
recruited VBN None
at IN None
Tygerberg NNP None
and CC None
Paarl NNP None
Hospitals NNP None
, , None
Western NNP None
Cape NNP None
, , None
South NNP None
Africa NNP None
. . None
Twenty-six JJ Size
women NNS None
were VBD None
randomized VBN None
to TO None
a DT None
10-week JJ None
exercise NN None
program NN None
and CC None
24 CD None
were VBD None
randomized VBN None
as IN None
controls NNS None
. . None
pregnancy NN None
in IN None
South JJ None
African JJ None
women NNS None
with IN None
lumbar NN Condition
and CC Condition
pelvic JJ Condition
girdle NN Condition
pain NN Condition
. . None
-DOCSTART- -X- N

adults NNS None
with IN None
common JJ None
variable JJ None
immunodeficiency NN Condition
. . None
The DT None
setting NN None
was VBD None
at IN None
University NNP None
Hospital NNP None
, , None
Out-patient NNP None
Clinic NNP None
. . None
patients NNS None
were VBD None
twenty-one JJ Size
adult NN None
patients NNS None
with IN None
common JJ Condition
variable JJ Condition
immunodeficiency NN Condition
. . None
-DOCSTART- -X- N

chronic JJ Condition
hepatitis NN Condition
B NNP Condition
of IN None
20 CD Size
patients NNS None
] JJ None
chronic JJ Condition
hepatitis NN Condition
B NNP Condition
. . None
42 CD Size
patients NNS None
with IN None
chronic JJ Condition
hepatitis NN Condition
B NNP Condition
patients NNS None
with IN None
chronic JJ Condition
hepatitis NN Condition
B NNP Condition
-DOCSTART- -X- N

autism NN Condition
spectrum NN Condition
disorder NN Condition
. . None
compulsive-like JJ Condition
symptoms NNS Condition
of IN None
autism NN Condition
spectrum NN Condition
disorder NN Condition
( ( Condition
ASD NNP Condition
) ) Condition
. . None
Thirteen JJ Size
individuals NNS None
with IN None
ASD NNP Condition
ASD NNP None
. . None
-DOCSTART- -X- N

acute JJ Condition
myocardial JJ Condition
infarction NN Condition
Patients NNPS None
with IN None
AMI NNP Size
who WP None
were VBD None
admitted VBN None
to TO None
76 CD None
acute NN None
care NN None
hospitals NNS None
in IN None
Quebec NNP None
that WDT None
treated VBD None
at IN None
least JJS None
30 CD None
AMI NNP None
patients NNS None
per IN None
year NN None
between IN None
April NNP None
1 CD None
, , None
1999 CD None
, , None
and CC None
March NNP None
31 CD None
, , None
2003 CD None
. . None
rapid JJ None
( ( None
immediate JJ None
; : None
n CC None
= $ None
38 CD None
hospitals NNS None
and CC None
2533 CD Size
patients NNS None
) ) None
or CC None
delayed VBN None
( ( None
14 CD None
months NNS None
; : None
n CC None
= $ None
38 CD None
hospitals NNS None
and CC None
3142 CD Size
patients NNS None
) ) None
patients NNS None
with IN None
AMI NNP None
. . None
-DOCSTART- -X- N

patients NNS None
undergoing JJ None
transurethral JJ Condition
resection NN Condition
of IN Condition
the DT Condition
prostate NN Condition
( ( None
TURP NNP None
) ) None
. . None
Fifty-six NNP Size
male NN Sex
patients NNS None
( ( None
mean JJ None
age NN None
71.2 CD Age
+/- JJ None
8.2 CD None
years NNS None
) ) None
scheduled VBD None
for IN None
TURP NNP Condition
were VBD None
enrolled VBN None
in IN None
the DT None
study NN None
. . None
27 CD Size
patients NNS None
29 CD Size
patients NNS None
-DOCSTART- -X- N

chronic JJ Condition
nonspecific NN Condition
low JJ Condition
back RB Condition
pain NN Condition
patient NN None
] NN None
chronic JJ Condition
nonspecific NN Condition
low JJ Condition
back RB Condition
pain NN Condition
patient NN None
. . None
Three CD Size
hundred VBD Size
and CC Size
five CD Size
cases NNS None
chronic JJ Condition
nonspecific NN Condition
low JJ Condition
back RB Condition
pain NN Condition
patient NN None
-DOCSTART- -X- N

elderly JJ None
100 CD None
elderly JJ None
patients NNS None
with IN None
signs NNS None
of IN None
cerebro-vascular JJ None
impairment NN None
demonstrated VBN None
by IN None
psychometric JJ None
testing VBG None
-DOCSTART- -X- N

Veterans NNS Age
Affairs VBP None
congestive JJ Condition
heart NN Condition
failure NN Condition
patients NNS None
with IN None
congestive JJ Condition
heart NN Condition
failure NN Condition
and CC None
ventricular JJ Condition
arrhythmia NN Condition
. . None
Eligible JJ None
patients NNS None
include VBP None
those DT None
with IN None
ischemic JJ None
and CC None
nonischemic JJ None
congestive JJ Condition
heart NN Condition
failure NN Condition
and CC None
with IN None
> NNP None
or CC None
= $ None
10 CD None
ventricular JJ Condition
premature NN Condition
beats NNS Condition
per IN None
hour NN None
. . None
All DT None
patients NNS None
must MD None
have VB None
shortness NN Condition
of IN Condition
breath NN Condition
with IN None
minimal JJ None
exertion NN None
or CC None
paroxysmal JJ Condition
nocturnal JJ Condition
dyspnea NN Condition
, , None
a DT None
left JJ None
ventricular JJ None
internal JJ None
dimension NN None
( ( None
LVIDd NNP None
) ) None
by IN None
echocardiogram NN None
of IN None
> NN None
or CC None
= $ None
55 CD None
mm NN None
or CC None
a DT None
cardiothoracic JJ None
ratio NN None
of IN None
> $ None
0.5 CD None
and CC None
an DT None
ejection NN None
fraction NN None
of IN None
< NN None
or CC None
= VB None
40 CD None
% NN None
. . None
Patients NNS None
will MD None
be VB None
entered VBN None
into IN None
the DT None
study NN None
for IN None
2.5 CD None
years NNS None
and CC None
followed VBD None
for IN None
an DT None
additional JJ None
2 CD None
years NNS None
. . None
674 CD None
patients NNS None
will MD None
be VB None
entered VBN None
into IN None
the DT None
study NN None
from IN None
25 CD None
participating VBG None
centers NNS None
. . None
-DOCSTART- -X- N

young JJ Age
children NNS Age
with IN None
autism NN Condition
Forty-seven JJ Size
children NNS Age
were VBD None
randomly RB None
assigned VBN None
to TO None
treatment NN None
and CC None
wait-list JJ None
control NN None
groups NNS None
. . None
-DOCSTART- -X- N

90 CD None
patients NNS None
who WP None
had VBD None
aortic JJ None
, , None
mitral JJ None
, , None
and/or JJ None
tricuspid JJ None
valve FW None
replacement NN None
with IN None
Sorin NNP None
Bicarbon NNP None
or CC None
CarboMedics NNPS None
bileaflet NN None
prostheses NNS None
-DOCSTART- -X- N

rheumatoid JJ Condition
arthritis NN Condition
. . None
( ( None
n JJ None
= NNP None
20 CD Size
) ) None
( ( None
m JJ None
= NNP None
19 CD Size
) ) None
patients NNS None
with IN None
rheumatoid JJ None
arthritis NN None
of IN None
mild-moderate JJ None
activity NN None
. . None
-DOCSTART- -X- N

lipoprotein JJ None
subfractions NNS None
15 CD None
lipoprotein JJ None
subfractions NNS None
( ( None
L1-L15 NNP None
) ) None
in IN None
1791 CD None
samples NNS None
using VBG None
( ( None
1 CD None
) ) None
H-NMR NNP None
( ( None
nuclear JJ None
magnetic JJ None
resonance NN None
) ) None
spectroscopy NN None
. . None
-DOCSTART- -X- N

Fourteen JJ None
patients NNS None
with IN None
paired JJ None
intrabony NN None
periodontal JJ None
defects NNS None
of IN None
? . None
4 CD None
mm NN None
participated VBN None
in IN None
-DOCSTART- -X- N

129 CD None
clinicians NNS None
-DOCSTART- -X- N

preeclampsia NN Condition
. . None
pregnant JJ None
women NNS Sex
with IN None
a DT None
high JJ None
risk NN None
of IN None
preeclampsia NN Condition
Forty NNP Size
pregnant JJ None
women NNS Sex
preeclampsia NN Condition
in IN None
high-risk JJ None
pregnant JJ None
women NNS None
. . None
-DOCSTART- -X- N

Thailand NNP None
Philippines-two JJ None
27 CD Size
healthy JJ None
, , None
Thai NNP None
adults NNS Age
received VBD None
a DT None
40 CD None
IU NNP None
kg NN None
( ( None
-1 NNP None
) ) None
dose NN None
of IN None
either DT None
Erig NNP None
PMC NNP None
( ( None
n JJ None
= NNP None
12 CD None
) ) None
or CC None
PHT-Erig NNP None
( ( None
n JJ None
= NNP None
15 CD None
) ) None
via IN None
the DT None
intramuscular NN None
( ( None
i.m JJ None
. . None
) ) None
route NN None
; : None
71 CD Size
healthy JJ None
volunteers NNS None
